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Abstract 
 
Developing nanoparticulate oligonucleotides as a target-specific antimicrobial for modulation of 
complex gut microbiota  
 
 
The complex human gut microbiota harbours trillions of bacteria that are critical to health. 
Imbalances in the microbiota have been associated with conditions such as inflammatory bowel 
disease and metabolic disorder. Broad spectrum antibiotics that are used as therapy for bacterial 
infections cause major disruption to the diversity and structure of the gut microbiota, leading to 
dysbiosis.    
For the advancement of microbiome-targeting, exploration of technologies that modulate the gut 
microbiota in a specific manner that minimise disruption to the gut microbiota is essential. In this 
thesis we examined a nucleic acid based-antimicrobial called Transcription Factor Decoys (TFDs), 
which are coupled with a proprietary nanoparticle for delivery to modulate the microbiota in a 
targeted manner. A TFD designed to target Enterobacteriaceae and delivered using nanoparticles 
was shown to enter the E. coli cells and inhibit bacterial growth. This system was also shown to 
work in a target-specific manner in an in vitro batch fermentation model of the human colon, and 
analysis by both culturing and 16S rRNA gene based metataxonomic analysis showed no major 
disruption to the rest of the gut microbiota. Metabonomic changes were evaluated to explore 
possible pathways involved for the TFD used to target Enterobacteriaceae. This TFD-specific 
antimicrobial activity against Enterobacteriaceae was also successfully translated to an in vivo 
mouse model with minimal changes to the gut microbiota.   
The design of TFD targeting a phylogenetically diverse group with a similar metabolic function – 
sulphate reducing bacteria (SRB) – was also explored. Human SRB were isolated and a qPCR 
quantification method was designed. The work in this thesis serves as a proof-of-principle that 
TFD technology can specifically-target bacteria of interest and has the capability to selectively 
modulate the gut microbiota. This technology can potentially be developed to target other 
members of the gut microbiota to improve health status.  
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experiment with PMA-treatment with average bacterial populations. a) experiment 1; b) 
experiment 2. (O) indicates an unidentified family in the described order.   
Figure 5.5 Principal coordinates analysis (PCoA) plots from 16S rRNA gene community analysis for 
in vivo mouse model. a) experiment 1; b) experiment 2. 3D PCoA plot was generated from 
weighted UniFrac analysis, where x- and y- axis represents the first and second coordinates 
respectively. 
Figure 5.6 A representative of metabonomic profile from mouse experiment 1, showing the large 
variation within and among mouse faecal samples.  
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treated mouse with signs of illness that was euthanised prior to the end of experiment.  
Figure 6.1 Gram staining of human gut SRB isolates. Representative images of isolates as 
presumptive left) D. piger (Gram negative) bacteria; middle) V. Parvula (Gram positive) and right) 
V. tobetsuensis (Gram positive). 
Figure 6.2 The dsrB gene sequence alignment for the design of qPCR primer sets for Human 
desulfovibrio (using the top 6 gene sequences) and dsrB Human (using all gene sequences). 
Colouring of letters indicates degree of nucleotide conservation between sequences (black, 100%, 
dark grey, 80%; light grey, 60%). Location for alignment used for the design of primers were 
marked (green, forward primer; red, reverse primer) for both primer sets. 
Figure 6.3 The dsrB gene sequence for the design of PCR primers from D. piger UC15 of human 
gut origin. Colouring of letters indicate the location of dsrB primer sequences. Grey, dsrB_F1; 
yellow, dsrB_F2; blue, dsrB_R1. Letters in bold indicate the relative location (but not the sequence 
of) Human_desulfov and dsrB_Human qPCR primers. 
Figure 6.4 Gel electrophoresis of PCR products using gDNA of SRB. Successful amplification was 
achieved with D. piger UC15 and presumptive D. piger isolates 6 and 19. PCR products from 
dsrB_F1 and dsrB_R1 primer sets were preferred and used as DNA template for qPCR standard 
curves. Primer sets a) dsrB_F1 with dsrB_R1; and b) dsrB_F1 with dsrB_R1 were used, showing 
expected band sizes of 911 bp and 719 bp respectively. HyperLadder 1 (Bioline) was used to 
reference DNA band size. 
Figure 6.5 qPCR standard curves for D. piger UC15, presumptive D. piger isolate 6 and isolate 19 
using Human_desulfov qPCR primers sets. Strong linear correlation was obtained for absolute 
quantification of SRB. Means of 3 technical replicates were measured with 3 biological replicates 
in each experiment ± SD. 
Figure 6.6 PCR amplification using left, Human_desulfov primer set; and right, dsrB_Human 
primer set. Isolates identified as D. piger were successfully amplified at 336 bp while isolates 
identified as V. tobetsuensis and V. parvula were not. D. piger UC15 and D. simplex were used as a 
positive control. HyperLadder 1 (Bioline) was used to reference DNA band size. 
Figure 6.7 Alignment of a) nucleotide sequences of Gram negative human gut isolates amplified 
by dsrB_F1 and dsrB_R1 primers. Colouring of letters indicates the degree of nucleotide 
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primers; red, reverse primers. 
Figure 6.8 Alignment of translated amino acid sequence of group 1 and group 2 from PCR 
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dsrB PCR amplicon. Colouring of letters indicates the degree of nucleotide conservation between 
sequences (black: 100%, dark grey, 80%; light grey, 60%). 
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nrfHA orthologs in Desulfovibrio and Bilophila genomes (WebLogo taken from Rajeev et al. 
(2015)); b) RNAP54.1 TFD based on i) RpoN (σ54) for alternative Desulfovibrio sigma factor 54 
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Figure 6.11 Representative confocal scanning microscopy images of Gram negative presumptive 
D. piger isolates. 60 min of LNP incubation of a) isolate 6; and b) isolate 17; c) 120 min of LNP 
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Chapter 1: General Introduction 
1.1 The Human gut microbiota 
1.1.1 Overview of the human gut microbiota 
The human gastrointestinal (GI) tract, which extends from the oral cavity to the anus, is colonised 
by a wide variety of microorganisms that coexist with the human body. This large reservoir of 
microorganisms, including bacteria, archaea, eukarya and viruses (Walker et al. 2014) is 
collectively known as the gut microbiota. They form an organised and complex community that 
colonise in specific regions of the GI tract depending on the most favourable conditions (Aron-
Wisnewsky et al. 2012). Out of all the organs in the human body, the colonic microbiota contains 
the greatest diversity of bacteria (Figure 1.1) that are crucial to human health. 
The microbiome - the collective microbial genomes in the microbiota and the gut microbiota itself 
- encodes unique genes that could impact on the host’s physiology, including the acquirement of 
vitamins, beneficial metabolites (Qin et al. 2010), and the metabolism of indigestible dietary 
compounds by a range of hydrolytic enzymes (Flint et al. 2012). An integrated gene catalogue 
with almost 10 million genes has been identified, which highlights the wide diversity in functions 
of the gut microbiome (Li et al. 2014). The gut microbiota has therefore been widely regarded as a 
hidden metabolic ‘organ’, as the gut commensal bacteria play an influential role in nutrient 
absorption, metabolism (Qin et al. 2010), regulation of fat storage (Samuel et al. 2008), immune 
function (Guinane and Cotter 2013) and protection against intestinal epithelium injury (Rakoff-
Nahoum et al. 2004). 
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Figure 1.1 Bacterial characteristics in different regions of the human GI tract. Diagram showing 
the conditions, bacterial abundance and types of bacteria colonising in each part, taken from 
Aron-Wisnewsky et al. (2012). 
Numerous scientific studies note that bacterial cells in the body outnumber human cells by 10:1 
(Gill et al. 2006, Turnbaugh et al. 2007, Round and Mazmanian 2010). This figure has been found 
to originate from one historic estimate from the 1970s that was based on crude assessments of 
the volume of the whole GI tract (Luckey 1972). However, a recent review has re-evaluated the 
total bacterial numbers against total human cells, a revised human to bacterial cell ratio has been 
proposed to be 1:1, with 1013 bacterial cells mostly dominated by colon bacteria and 1013 human 
cells, when red blood cell numbers are taken into account (Sender et al. 2016). 
1.1.2 The role of human gut microbiota in health  
Physiological functions of the gut microbiota 
In the physiological state, the microbiota establishes a relatively stable ecosystem within the GI 
tract and is one of the most important factors in the maintenance of normal physiological 
function (Rooks et al. 2014). Apart from the minimal bacterial gut genome that allows bacteria to 
survive in the gut, genes that are involved in the homeostasis of the ecosystem which is called the 
minimal gut metagenome have two functional clusters of genes. Those involved in the 
housekeeping of bacteria include functions that contribute to metabolic pathways such as amino-
acid synthesis, central carbon metabolism and essential protein complexes such as DNA and RNA 
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polymerase. Other functions are gut-specific such as sugar harvest and adhesion to host proteins 
i.e. fibrinogen, collagen and fibronectin (Qin et al. 2010). 
One of the main metabolic functions of the gut microbiota includes the fermentation of a range of 
polysaccharides and oligosaccharides including unabsorbed sugars and carbohydrates from mucus 
glycoprotein derived from the host, which will otherwise be lost in the faeces. The predominant 
products from carbohydrate metabolism include hydrogen, carbon dioxide, ethanol and short 
chain fatty acids (SCFA) (Gallo et al. 2016). The gut microbiota also influences the synthesis of 
vitamins and amino acids (LeBlanc et al. 2013), caloric extraction efficiency from food (Turnbaugh 
et al. 2006) and the absorption of iron, calcium and magnesium. SCFA, comprising butyrate, 
propionate and acetate, are a vital energy source for colonocytes and help maintain tissue 
integrity (Conlon and Bird 2015). Gaseous products such as hydrogen sulphide (H2S), carbon 
monoxide and nitric oxide have been regarded as signalling molecules to maintain the mucosal 
integrity. Moreover, in mammalian cells, H2S-driven energy production occurs most efficiently in 
the epithelial cells of the GI tract (Wallace et al. 2017). 
The fermentation products of gut microbiota are responsible for the modulation of gut peptide 
secretion involved in the energy homeostasis, food intake and pancreatic function (Cani and 
Delzenne 2009). The metabolism of fermentable non-digestible dietary fibres also helps the 
development of microvilli and in turn increases nutrient absorption and the anaerobic metabolism 
of peptides and proteins resultant from host energy-conversion (Nicholson et al. 2005). The host 
metabolic status may also be influenced by the GI tract microbiota, as it contributes to the 
metabolism of bile acids, SCFA and breaking down non-digestible polysaccharides and fibres 
(Backhed et al. 2004), as shown in Figure 1.2 a. The gut microbiota exerts a protective function on 
the host by preventing the colonisation of pathogens and modulating the host immune-system 
(Roeselers et al. 2013). The gut microbiota is also responsible for the modulation of hormone 
release in the GI tract and there is increasing interest on how the gut microbiota regulates brain 
behaviour via the gut-brain axis (Carabotti et al. 2015). 
Core microbiota 
It is of great interest to identify whether there is a common core microbiome catalogue that is 
shared among individuals. Using 16S ribosomal RNA (rRNA) gene sequencing methods, it was 
found that there are larger similarities in gut microbiota at phylum level between individuals, as 
the Firmicutes and Bacteroidetes made up over 90% of the distal gut microbiota of known phyla; 
other minor phyla that are shared amongst individuals include Actinobacteria, Fusobacteria, 
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Proteobacteria and Verrucomicrobia (Eckburg et al. 2005, Duncan et al. 2007, Tremaroli and 
Backhed 2012).  
It was proposed that there is a discrete core microbial community with high temporal stability of 
microbiome for each individual, which is dependent on health, age, diet, antibiotic use and other 
environmental factors (Caporaso et al. 2011a, Huttenhower C 2012, Maurice et al. 2013). 
However, the inter-individual variations between adult gut microbiota are huge, as demonstrated 
in an identical-twin study, where participants were found to have less than 50% homology in 
species phylotypes (Turnbaugh et al. 2010). Nonetheless, some species were identified as key 
species in the human gut microbiota, including Bacteroides uniformis, Faecalibacterium prausnitzii 
and Roseburia intestinalis (Qin et al. 2010). 
Metagenomic sequencing has allowed us to analyse the genomes of complex bacterial 
communities. The Metagenomics of the Human Intestinal Tract (MetaHIT) project has 
collaborated with scientists all over Europe to gather metagenomic data from eight countries 
(Ehrlich 2011). One of the studies investigated the gut microbiome of 39 individuals from four 
countries, demonstrating that individuals fall into three distinctive clusters called enterotypes 
(Arumugam et al. 2011), distinguished by the variation in levels of genera in Bacteroides 
(enterotype 1), Prevotella (enterotype 2) and Ruminococcus (enterotype 3), with phylogenetic 
and functional difference in vitamin biosynthesis and the pathways they use to generate energy. 
However, it was shown that the three enterotypes are not a representative sample of microbiota 
classifications (Le Chatelier et al. 2013), as most studies showed only the Bacteroides and 
Prevotella clusters, and Ruminococcus-driven enterotype seemed less evident (Claesson et al. 
2012, Yatsunenko et al. 2012), suggesting that they form part of the Bacteroides enterotype (Wu 
et al. 2011). Furthermore, in a recent study that sequenced more than 1200 adults’ gut 
microbiota, enterotypes were found to lack distinct boundaries of classification. As a continuous 
gradient of bacterial abundance is present within body sites (Koren et al. 2013), this suggests that 
discrete enterotypes may not exist at all. Conflicting opinions on the distinctiveness in 
enterotypes remain debatable (Koren et al. 2013, Ding and Schloss 2014, Moeller and Ochman 
2014). As Bacteroides and Prevotella both belong to Bacteroidales, functional groups were found 
to be continuous and overlapping between the two groups and were clustered in term of 
functions, the lack of distinct metabotypes between the groups may be explained by the 
likelihood that they perform similar functions in the gut (Holmes et al. 2012). 
To better understand the intestinal bacteria that regularly live in the healthy gut, large scale 
studies have since been performed to identify the composition of the gut microbiomes with 110 
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and 1135 participants respectively (Falony et al. 2016, Zhernakova et al. 2016). Out of the 664 
genera present in the gut microbiota, a 14-genera core microbiota composition has been 
identified from the combination of the above studies (Falony et al. 2016). These 14 genera include 
Roseburia, Faecalibacterium, Dorea, Coprococcus, Blautia, Bacteroides, Ruminococcus, Prevotella, 
Parabacteroides, Oscillibacter, Bifidobacterium, Barnesiella, Anaerostipes and Alistipes. Genus 
richness has also been shown to correlate positively to age and negatively to total core 
abundance. Furthermore, markers for the gut microbiota composition and diversity have been 
revealed via population-based metagenomic analyses, of which 110 factors have been associated 
to 125 species (Zhernakova et al. 2016). In particular, faecal chromogranin A (CgA) has been found 
to be negatively correlated to microbiome diversity. It was also suggested that factors such as 
diet, smoking, drugs and disease explains 18.7% of the variations in the gut microbiota 
(Zhernakova et al. 2016). These factors will be further discussed in the next section.  
1.1.2 The role of human gut microbiota in disease 
As the composition of microbial communities plays a major role in maintaining health, minor 
changes of the microbial population could have substantial repercussions, either good or bad, on 
human health. When structural disruption has occurred to the commensal gut microbiota, known 
as dysbiosis (Petersen and Round 2014), the microbiota becomes inefficient at performing their 
main functions such as energy and vitamin production and defending against pathogens, which in 
turn increases the chance of downstream complications including immunological and metabolic 
defects as the host becomes more predisposed to infection (Langdon et al. 2016). 
The disruption of the gut microbiota has been shown to strongly associate with diseases such as 
inflammatory bowel disease (IBD) and metabolic diseases including diabetes, obesity (Zak-Golab 
et al. 2014), cancer (Ohtani et al. 2014) and cardiovascular diseases. Dysbiosis associated with 
these diseases are triggered by low-grade chronic inflammation (Wellen and Hotamisligil 2005); 
the main factors contributing towards the alteration of gut microbiota were established to be 
social- and cultural-dependent, instead of hereditary-dependent. As bacterial colonisation 
happens rapidly after birth, environmental variations from the microbiome have a greater role in 
the pathogenesis of diseases than the variations occurring in the human genome (Madan et al. 
2012) and implies that the microbiota have an important role in the development of disease. To 
identify the underlying gut microbiota variations that characterise various diseases, the change in 
the Firmicutes and Bacteroidetes ratio was frequently highlighted. While there is an increased 
Firmicutes:Bacteroidetes ratio associated with obesity (Turnbaugh et al. 2006), Firmicutes were 
dramatically reduced in Crohn’s disease (Finucane et al. 2014). 
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Diet is one of the biggest factors that rapidly and repeatedly alters the gut microbiome (David et 
al. 2014). It was shown that a strict vegetarian diet reduces the Firmicutes:Bacteroidetes ratio in 
the gut microbiota, whereas the bacterial diversity and enterotypes remains unchanged (Backhed 
et al. 2004). Levels of pathobionts such as Enterobacteriaceae were decreased and commensals 
such as Bacteroides fragilis and Clostridium species in clusters XIVa and IV were increased. These 
collectively lead to a significant reduction of faecal lipocalin-2, a biomarker for intestinal 
inflammation (Chassaing et al. 2012), and short chain fatty acids levels, which are signatures of 
obesity diseased-phenotypes. High-animal based diets contribute to the development of 
inflammatory bowel disease; the overgrowth of the sulphate-reducing pathobiont Bilophila 
wadsworthia increased faecal bile acid concentration and increased sulphite reductase expression 
(David et al. 2014), and is associated with a pro-inflammatory T helper type 1 immune response 
and subsequently increased incidences of colitis in a genetically susceptible mouse model 
(Devkota et al. 2012). The diseased state associated with bile acid and short chain fatty acid 
metabolism is shown in Figure 1.2 b. 
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Figure 1.2 Metabolism of bile acid and SCFA and their mechanism in the a) physiological and b) 
pathophysiological state. Alteration in SCFA production results in increased intestinal permeability 
which leads to worsened metabolic endotoxemia, followed by low-grade inflammation. Figure 
taken from Nieuwdorp et al. (2014). 
 
Dietary fibre or plant-based food intake is important as they are the primary source of 
carbohydrate fermentation in the gut microbiome (Conlon and Bird 2015). Evidence has been 
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shown that the lack of fibre in the diet encourages the degradation of the mucus layer in a 
gnotobiotic mouse model colonised with synthetic human gut microbiota. This leads to 
susceptibility to pathogens and the development of colitis (Desai et al. 2016). The understanding 
of nutritional, biliary and microbial dynamics is therefore crucial to establishing links for diet-
related diseases.  
Conditions such as Crohn’s disease and obesity are both associated with lower bacterial diversity, 
where pro-inflammatory species e.g. Bacteroides and Ruminococcus gnavus that are associated 
with IBD are more frequently found in low bacterial gene count of individuals. It was discovered 
that some metabolic markers correlate with the richness of human gut microbiome and could be 
used to differentiate individuals with high or low bacterial richness (Koren et al. 2013). The 
microbial diversity is reduced both in abundance and biodiversity in Crohn’s disease. The levels of 
Faecalibacterium prausnitzii – an anti-inflammatory commensal bacterium – is reduced in Crohn’s 
disease patients (Sokol et al. 2008). 
Some bacterial genes are enriched in obese individuals (when compared to lean individuals), of 
which 75% of these obesity-associated genes are from Actinobacteria and 25% from Firmicutes. 
Moreover, lean individuals contain 42% of enriched genes from Bacteroidetes (compared to 0% 
for obese individuals) (Turnbaugh et al. 2009). These genes indicate their role in carbohydrate, 
amino acid and lipid metabolism.  Germ free mice receiving a gut microbiota transplant from an 
obese mouse resulted in increased body fat compared to mice receiving a gut microbiota 
transplant from a lean mouse (Turnbaugh et al. 2006). Since the majority of the obese-enriched 
genes derive from Actinobacteria, a more detailed understanding of whether certain bacteria or 
transcripts are causative of obesity would identify these as targets for the development of 
treatments. 
However, there are conflicting results between patient studies and mouse-model data on the role 
of gut microbiome and obesity. A study has analysed publicly available data from the Human 
Microbiome Project (HMP) and MetaHIT and concluded that there is no simple taxonomic 
signature of obesity, as the inter-study variation is much greater than the taxonomic difference 
between lean and obese individuals within each study (Manichanh et al. 2006). This further 
supports the need to understand the function of the microbiota as well as the taxonomic 
structure, as different bacteria or genetic pathways could contribute to the increased 
carbohydrate and lipid functions observed with obese individuals (Turnbaugh et al. 2009). 
Bacterial lipopolysaccharide (LPS) present in Gram-negative bacteria has been shown to be an 
inflammation trigger for high-fat-induced obesity and type 2 diabetes, potentially through a 
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mechanism termed metabolic endotoxaemia (Cani et al. 2007a).  The composition of the 
microbiota clearly affects the concentration of LPS, which was found to be inversely correlated to 
the level of Bifidobacterium spp. (Cani et al. 2007b). Also, increased Escherichia coli (E. coli) levels 
are linked with active ulcerative colitis (UC) (Petersen et al. 2009) and an increased intestinal 
inflammation burden in UC patients (Mirsepasi-Lauridsen et al. 2016), highlighting how 
commensal bacteria could be pathobionts and induce disease progression in an already 
susceptible host.  
1.1.3 Current tools for the study of gut microbiota  
To study the human gut microbiota, an in vitro batch culture model is often utilised as a 
fermentation model of the colon with pH and temperature controls (Mandalari et al. 2007, 
Avendano-Perez et al. 2015). The composition of the gut microbiota is often characterised by 
conventional bacterial culturing techniques and 16S rRNA gene sequencing for metataxonomic 
analysis. Metabonomic analysis can also be incorporated to enhance the understanding of the 
metabolic changes subject to a treatment intervention. 
To evaluate changes in the gut microbiota in an in vivo setting, a murine model is the most 
commonly used model for gut microbiota studies. It has a similar gastrointestinal structure and 
anatomy to humans which allows a better evaluation of the host-microbiota interaction. Both 
human and mouse microbiota are dominated by the Bacteroidetes and Firmicutes phyla, with 
similar abundance in genera such as Clostridium, Bacteroides and Blautia, though genera such as 
Prevotella, Faecalibacterium and Ruminococcus are more abundant in human and Lactobacillus is 
more abundant in mice. The human and mouse microbiota are nonetheless functionally similar 
(Nguyen et al. 2015); the treatment response in mice is often representative of the impact and 
the microbiota shifts in humans by antibiotics (Becattini et al. 2016). Mouse microbiota are 
therefore a comparable model to study the potential impact of human gut microbiota subject to 
antimicrobial treatment. The use of germ free mice transplanted with human gut microbiota is 
also a valuable tool to investigate the direct link between the human gut microbiota within a host. 
However, the lack of a native homeostatic gut microbiota may impact on the evaluation of the 
structural changes in the commensal bacteria following a targeted intervention (Laukens et al. 
2016). 
The composition of the gut microbiota is often characterised by conventional bacterial culturing 
techniques and 16S rRNA gene sequencing for metagenomic analysis (Gallo et al. 2016). The 
technology available for the understanding the gut microbiota has progressively increased in 
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recent years. Whole genome shotgun sequencing is becoming increasingly popular and allows the 
interpretation of functionality of the gut microbiota and increasing taxonomical resolution at 
genus and species level (Jovel et al. 2016). However, in terms of assessing community ecology and 
biodiversity, 16S rRNA gene sequencing is still more robust and allows notably better 
identifications of bacterial communities at different taxonomic scales including the phylum and 
family levels (Tessler et al. 2017). Metabonomic analysis has also been incorporated to study the 
modulation of gut microbiota, which allow the identification of metabolic profiles and help 
explain the possible metabolic pathways involved (Vernocchi et al. 2016).    
1.2. Modulation of the gut microbiota 
1.2.1 Existing agents available for the rebalancing/modulating of the gut 
microbiota 
Non-specific therapeutics 
Antibiotics are the most common treatment readily available to treat microbial infections. Various 
types of antibiotics act by different mechanisms to allow different spectrums of antimicrobial 
activity (Langdon et al. 2016). Broad spectrum antibiotics such as ampicillin and gentamycin, as 
well as the rise in multidrug resistant pathogens, often have a large impact on the microbiota 
including damage to the composition and diversity of the gut microbiota leading to dysbiosis. 
Since antibiotics are readily tested for their safe therapeutic use, modifications of vancomycin 
with the hope of combating and delaying antibiotic resistance are underway. They showed 
increased potency with synergistic action that work via several mechanisms, including different 
ways of interfering with the bacterial cell wall (Okano et al. 2017). However, even though 
vancomycin has narrow-spectrum activity and is designed to target Gram positive bacteria, Gram 
negative bacteria can also be depleted and the commensals perturbed (Ubeda et al. 2010) and 
this can lead to increased susceptibility to secondary infections in both humans and mice (Lewis et 
al. 2015). This is likely due to the great magnitude of interdependence between bacterial taxa 
(Becattini et al. 2016). 
To target the microbiota using transcription as a therapeutic target, rifamycins are a good 
example as they are a successful class of antibiotics. They work by inhibiting bacterial RNA 
polymerase resulting in the prevention of RNA elongation (Campbell et al. 2001). The broad 
spectrum antimicrobial activity spans from staphylococci to Listeria spp. (Thornsberry et al. 1983). 
The results from clinical trials have shown that, by targeting the gut microbiota, the non-systemic 
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antibiotic rifaximin can significantly relieve the general symptoms of irritable bowel syndrome 
(IBS) compared to placebos (Pimentel et al. 2006, Di Stefano et al. 2011, Pimentel et al. 2011, 
Pimentel et al. 2014). This increases our confidence that targeting the bacterial transcription 
mechanism can be used as a drug to treat gastrointestinal conditions. 
Faecal Microbiota Transplantation (FMT) 
To alleviate the impact of dysbiosis, faecal microbiota transplantation has been a popular idea as 
a means of rebalancing the gut microbiota. It has been shown in a randomised clinical trial that 
FMT is effective in treating recurrent C. difficile infection (Cammarota et al. 2015) and is widely 
regarded as an effective treatment option for C. difficile related dysbiosis (Bibbo et al. 2017), with 
a success rate of over 90% (Kelly et al. 2016). 
Some evidence has been shown that it helps with the management of metabolic disorders and 
IBD. To treat IBD, donors with a healthy microbiota were used who could increase protective 
commensals including Clostridia and Bacteroides and decrease pathogenic or opportunistic 
commensals e.g. adherent-invasive E. coli (AIEC) and Mycobacterium in a patient’s microbiota 
(Khajah 2017). Meta-analysis systematic review has indicated that short term use of FMT 
facilitates remission in active UC (Narula et al. 2017). However, more supporting evidence from 
clinical trials are needed in order to review whether or not FMT will be suitable for routine clinical 
use for IBD or metabolic disorder (Bakker and Nieuwdorp 2017). 
Even though successful reversal of gut microbiota by FMT has been reported for multiple 
conditions, the efficacy of FMT treatment is still variable against IBD and dependent on donor and 
also the time of UC (Moayyedi et al. 2015). The long term effects are not fully understood and 
safety is still a major concern. Risks include the transfer of antibiotic resistance genes, the 
transmission of unknown infectious agents, and also possible microbiota-induced diseases that 
may further aggravate the patient’s clinical outcome, as the patient is already a susceptible host 
(van den Elsen et al. 2017). This procedure will require standardisation and needs its safety and 
efficacy to be evaluated to ensure that FMT can be used effectively in regular clinical practice. 
There are also issues concerning donor-recipient compatibility, this indicates that there may be 
significant differences in efficacy of the same faecal transplant between different patients (Li et al. 
2016). Since associated bacterial strains (Lawley et al. 2012, Reeves et al. 2012, Buffie et al. 2015) 
and metabolites (Buffie et al. 2015) have been identified to provide protection against C. difficile, 
FMT may eventually be replaced by selective probiotic strains and effector molecules (Becattini et 
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al. 2016), which allow a more accurate reconstruction of gut microbiota with minimal adverse 
side effects and with reduced safety concerns (Wang et al. 2017). 
Prebiotics, probiotics and polyphenols 
Dietary interventions including probiotics, prebiotics and polyphenols are amongst the most 
accessible ways to modulate gut microbiota composition or to improve metabolic activity. 
Probiotics are microorganisms that can confer health benefits to the host, when adequate 
amounts are administered (Hill et al. 2014). Due to the variability in activity between different 
strains, probiotics are often not well characterised. There is limited comparable strain-matched 
data available for meta-analysis (Marchesi et al. 2016). It was proposed, in a systematic review of 
randomised control trials, that a probiotic does not primarily work by altering the gut microbiota’s 
composition (Kristensen et al. 2016), but instead it was suggested that it may promote health 
benefits by maintaining stability and functionality of the gut microbiome, e.g. by reducing the 
perturbation of the gut microbiota or to confer a quicker recovery following antibiotics and poor 
diet (Sanders 2016).   
Prebiotics are fermented ingredients that selectively stimulate growth and/or activities of 
microbial organisms in the gut microbiota and promote health benefit to the host (Gibson et al. 
2004). In a randomised, double-blind, placebo-controlled cross-over trial, inulin-type fructans 
modulate the gut microbiota including an increase in Bifidobacterium and a decrease in Bilophila 
abundance, which led to improvement in constipation symptoms (Vandeputte et al. 2017). 
Although some evidence has been shown to demonstrate health benefits, more large scale 
human studies will be required to provide the consistent evidence for their long-term health 
effects. 
Polyphenols are another dietary food group that have been generally regarded to have 
modulatory effects on the balance of the gut microbiota, including the increase of Lactobacillus 
spp. and Bifidobacterium spp. and of reducing pathogenic bacteria to maintain intestinal health, 
acting in a way similar to probiotics (Duenas et al. 2015). Researchers have attempted to 
modulate the microbiome and reverse the adverse effects of obesity. One study has examined a 
gastrointestinal microbiome modulator (GIMM), which consists of prebiotics and polyphenols. 
GIMM improved blood glucose tolerance in obese patients but showed insignificant changes in 
the metabolic and gut microbiota markers to indicate successful microbiome modulation (Rebello 
et al. 2015). 
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1.2.2 Target-specific therapeutic agents   
Utilisation of bacterial and bacteriophage systems 
Bacteriophages are capable of infecting and replicating within a selected bacterium and can be 
exploited for target-specific antimicrobials. Bacteriophages have been used to decrease the levels 
of AIEC associated with the intestinal mucosa in Crohn’s disease patients. It was found that AIEC 
were significantly decreased in the faeces and also in the adherent intestinal flora following 
treatments with a bacteriophage cocktail (Galtier et al. 2017). However, such technology is limited 
to finding a bacteriophage that can infect specific bacteria of interest. Also, as large amount of 
bacteriophages will be required to treat an infection, they may trigger an immune response 
leading to secondary health impacts, which may interfere with the treatment (Reardon 2017). 
Clustered Regularly Interspaced Short Palindromic Repeats-associated (CRISPR)-CRISPR-associated 
(Cas) system has been found to have critical roles regulating bacterial physiology during 
environmental stress. The Type II system containing cas9 endonuclease in particular, has been 
exploited for binding nucleic acid sequence or cleaving specific sequence for their targets 
(Barrangou and van Pijkeren 2016). RNA-guided Cas9 has been used in conjugation with 
bacteriophage to kill virulent Staphylococcus aureus, but not non-virulent ones by targeting the 
virulence genes (Bikard et al. 2014), and successful antimicrobial activity against Staphylococcus 
aureus was also observed in vivo. RNA-guided nucleases have allowed specific drug resistant 
bacteria to be killed by targeting drug-resistance genes (Citorik et al. 2014) and showed a 
selective reduction of targeted strains. 
Another approach has discovered the ability to re-sensitise antibiotic resistant E. coli using a 
modified CRISPR-Cas9 mediated system (Kim et al. 2016), suggesting that the CRISPR-cas9 system 
can be used to target bacterial virulence and also reverse drug-resistance with sequence 
specificity. CRISPR-based antibiotics have been commercially pursued by companies in France and 
USA. 
Oligonucleotide-based targeting  
The use of nucleic acid based antimicrobials for narrow-spectrum activity has been described as 
selectively inhibiting the translational initiation of pathogenic bacteria in mixed bacterial cultures 
(Mondhe et al. 2014), suggesting that the use of oligonucleotides as inhibitors may allow a 
tuneable spectrum of activity. The first ribosomal RNA synthesis inhibitor was described in a 
recent study, whereby a small chemical molecule inhibitor was found to bind to NusB and 
prevented the formation of NusB-NusE heterodimer, which regulates the assembly of rRNA 
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transcription antitermination complex to allow transcription of rRNA genes (Yang et al. 2017). 
Such an inhibition in turn reduced the synthesis of rRNA and affected cell viability. Inhibition of 
Staphylococcus aureus was observed when compared to other ESKAPE pathogens whilst showing 
no significant toxicity to mammalian cell lines, though NusB/E are also highly conserved among 
bacteria (Yang et al. 2017). An antivirulence agent of Ebselen targeting major C. difficile virulence 
factor toxin B was shown to reduce disease pathology in host tissues against an in vivo mouse 
model of C. difficile infection (Bender et al. 2015) via multiple mechanisms of action. For the 
above studies, further testing on a native mixed bacterial community is required to evaluate their 
target specificity and their impact on the commensal bacteria. 
A staphylococcus-selective antimicrobial designed to inhibit key components in the fatty acid 
synthesis of Staphylococcus spp. has shown minimal disturbance of the gut microbiota abundance 
and composition compared to an antibiotic control (Yao et al. 2016). This highlights the target-
specific approach that can be utilised as an alternative to broad spectrum antibiotics and thus 
may minimise disruption of the microbiome. 
Other groups have also been studying nanoparticle delivery to target bacteria; magnetic 
nanoparticles encapsulated with broad spectrum antimicrobial peptides have been studied for an 
infection site-targeted approach (Maleki et al. 2016). Furthermore, silver nanoparticles have been 
coupled with siRNA gene silencing to demonstrate siRNA-driven activity against Bacillus subtilis 
targeting bacteraemia (Sun et al. 2016). Though this approach is theoretically target specific, the 
total bacterial profiles were not evaluated in the mouse model. 
Antibiotic resistance is one of the most serious health threats we face as a society. Factors that 
influence successful treatment of microbial infection includes the host, the bacterial target or the 
constituent gut microbiota, and the drug itself (Nemeth et al. 2015). The extensive use of 
antibiotics over the last 80 years has progressively lead to an increased rate of drug resistance and 
also deaths related to drug-resistant pathogens. Taken together with the negligible amount of 
new antibiotic discovery and the rate of bacteria developing antibiotic resistance, we will run out 
of effective antibiotics soon (Langdon et al. 2016). 
The development of bactericidal compounds with higher specificity is needed to minimise 
collateral damage to commensal gut microbiota. The potential to develop DNA-based 
antimicrobials with a narrow spectrum is a novel way to engineer the gut microbiota with 
predictive effects on human health. Specifically targeting a narrowly selected group of the 
bacterial population by blocking transcription of genes, and also to minimise the alteration of 
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bacterial composition and diversity could be an effective approach in the future for selective 
antimicrobial targeting, which will be further discussed in the next section. 
1.3. Antimicrobial system used in this thesis 
1.3.1 Transcription Factor Decoys (TFDs) 
A transcription factor (or sequence-specific DNA-binding factor) is a protein that controls the rate 
of transcription of genetic information from DNA to messenger RNA by binding to a specific DNA 
sequence. In turn, this helps to regulate the expression of genes near that sequence. Transcription 
factors work alone or with other proteins in a complex by promoting (as an activator), or blocking 
(as a repressor) the recruitment of RNA polymerase to specific genes. A defining feature of 
transcription factors is that they contain at least one DNA-binding domain (DBD) which attaches 
to a specific sequence of DNA adjacent to the genes that they regulate. 
Transcription factor decoys (TFDs) are nucleic acids that contain the binding site for a 
transcription factor. When introduced into cells, they act as competitive inhibitors for the binding 
of the transcription factor to its genomic target and so modify the regulation of a targeted gene 
(Mann and Dzau 2000) (Figure 1.3). 
  
Figure 1.3 The mechanism of Transcription factor decoy (TFD) acting on transcription factors of 
interest. TFD competitively inhibits the transcription factor binding sites to block gene expression, 
resulting in the destruction of bacteria cells (McArthur 2009b). 
 
TFDs have distinct advantages over other DNA-based therapeutics including plasmids containing 
transgenes for gene therapy, oligonucleotides for antisense and antigene applications (Crooke 
1998), ribozymes, DNAzymes, aptamers, and small interfering RNAs (siRNAs) (Stull and Szoka 
1995, Patil and Burgess 2003). The mechanism of action for TFDs is simple and predictable - they 
control gene expression by sequestering transcription factors, preventing the latter from binding 
to promoters by flooding the cell with sufficient copies of the specific binding sequences (hence, 
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the term “decoys”). This is in contrast to antisense strategies where targets are difficult to define 
due to the complex secondary structure of mRNA. In comparison to antisense approaches, TFDs 
have the further advantages in that they act rapidly, preventing the expression of genes, whereas 
antisense approaches deal with the consequences of expression. As a result, TFDs are effective at 
much lower concentrations, because a single TFD-transcription factor interaction can block the 
transcription of a single gene that otherwise may have given rise to many thousands of copies of 
mRNA, which constitute the targets for the antisense approach. 
TFDs also have advantages over both traditional antibacterial and other types of biologics, 
including antibodies and antisense molecules, because they act on multiple, novel targets. The 
novelty of the targets ensures that the treatments will not be susceptible to extant resistance 
mechanisms nor can resistance be readily acquired by the pathogen due to horizontal gene 
transfer. They can act on multiple targets (sets of co-ordinately regulated genes) hence they 
greatly reduce the chance of resistance arising as it would require the acquisition of multiple 
mutations at each, or the majority, of targets. 
TFDs have been previously developed to inhibit a number of pathogens, most notably treatment 
of MRSA sepsis infections and also to prevent growth of the Gram-negative Pseudomonas 
aeruginosa in vitro (McArthur 2014). A transcription factor decoy (TFD) is an oligonucleotide 
designed to bind to and sequester targeted transcription factors and to prevent the expression of 
essential genes, ultimately leading to death of the targeted cell or organism. Gram-negative 
bacteria are of particular concern because their outer cell wall protects them against most of the 
antibiotics, detergents and chemicals used as treatments. This outer cell wall consists of a lipid 
bilayer and is a selective permeable barrier that excludes compounds with molecular weights 
above 800. However, many small molecules can pass through the outer membrane via various 
types of pores. As a result, many commonly used antibiotics are not effective against Gram-
negative bacteria. Fortunately, there are a few antibiotics which do work against them, but these 
are a small number of therapies – and the clinical pressure to deliver treatments, in consideration 
of a concomitant danger of misuse – makes the rise of resistance more likely to happen and thus 
it will be more difficult to cope with when it does (Rice 2009).  
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1.3.2 TFD designed against Enterobacteriaceae 
Enterobacteriaceae are a family of Gram-negative bacteria that are of particular relevance to the 
present thesis. Indeed, several Enterobacteriaceae strains have been isolated which are resistant 
to antibiotics including carbapenem, which are often claimed as "the last line of antibiotic 
defence" against resistant organisms. A couple of TFDs with varying antimicrobial spectrum has 
been designed that could exert antimicrobial activity against Enterobacteriaceae. 
The first one being Gram negative sigma factor (GNSig) TFD, which competitively inhibits 
alternative sigma factor 54 in Gram negative bacteria, including Enterobacteriaceae. Alternative 
sigma factor is an RNA polymerase sigma subunit that is highly conserved throughout the 
bacterial genome, which is critical for the initiation of gene expressions. It contributes to virulence 
in Gram negative pathogens (Kazmierczak et al. 2005) and has been found to have an important 
role in regulating stress resistance (Riordan et al. 2010). The inhibition of such transcription 
would, for example, reduce viability during osmotic stress. However, the antimicrobial spectrum 
of the TFD span a variety of Gram negative bacteria (Kazmierczak et al. 2005) and may not show 
Enterobacteriaceae-selective reduction, though this TFD can be used initially for the 
establishment of methods and techniques. 
Another TFD was designed to competitively inhibit the fumarate and nitrate reductase (FNR) 
transcription factor of E. coli, which is a homologue of the cAMP receptor protein (Crp), which 
coordinates the switch between aerobic and anaerobic respiration. An internal hexaethylglycol 
linker is used for this TFD. The FNR transcription factor also coordinates numerous virulence 
factors (Barbieri et al. 2014). The N-terminal sensory domain of the transcription factor binds 
either a [4Fe-4S]2+ or a [2Fe-2S]2+ cluster (Beinert and Kiley 1999). Under anaerobic conditions, 
[4Fe-4S]2+ predominates and this drives the formation of FNR dimers that bind to their genomic 
consensus site 5’- TTGATnnnnATCAA-3’ (Spiro 1994) to control expression of up to 115 operons 
involved in anaerobic respiration (Constantinidou et al. 2006). Expressed in another way, the FNR 
TFD targets facultative anaerobic bacteria (Figure 1.4). This group of bacteria makes adenosine 
triphosphate (ATP) by aerobic respiration if oxygen is present, but is capable of switching to 
anaerobic respiration if oxygen is absent. In contrast, an obligate aerobe cannot make ATP in the 
absence of oxygen and obligate anaerobes die in the presence of oxygen. 
The FNR transcription factor is highly conserved in Enterobacteriaceae and other γ-
proteobacteria. For example, in Pseudomonas aeruginosa two homologues exist, ANR and DNR 
that share the E. coli binding site (Winteler and Haas 1996), and are similarly involved in anaerobic 
respiration, particularly bacterial denitrification as they sense the level of nitrogen oxides directly 
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(Giardina et al. 2008). These homologues are involved in determining the virulent characteristic of 
the pathogen by regulating quorum sensing and biofilm formation (Fink et al. 2007) which are key 
properties. The transcription factor is also involved in the switch of the bacteria to a virulent 
character and is upregulated in infection models of cystic fibrosis (Platt et al. 2008). Homologues 
of the Crp-FNR superfamily occur in most bacterial families, including those containing obligate 
anaerobes, although both the binding site and regulatory function of these transcription factors 
have changed in comparison to the E. coli FNR (Matsui et al. 2013). 
 
Figure 1.4 FNR is involved in the switch between aerobic and anaerobic respiration  
in facultative anaerobic bacteria. Under anaerobic conditions, 4Fe-4S FNR is active and drives the 
fnr modulon. FNR TFD is designed to inhibit the growth of Enterobacteriaceae by blocking the 
transcription of these genes. Figure was adapted from Förster et al. (2014).  
 
1.3.3 Delivery molecule 
While it may be possible to deliver a bacterial TFD to its intended target, the bacterial TFD may be 
part of an antibacterial complex that includes one or more delivery components. Delivery of a TFD 
through the bacterial cell wall is a considerable challenge, although transfection of bacteria with 
oligonucleotides poses notably different and fewer challenges than it does for eukaryotes. In the 
case of Staphylococcus aureus, delivery through a 20-40 nm peptidoglycan layer and a single 
phospholipid bilayer is required (Silhavy et al. 2010), both of which are typically negatively 
charged, whereas for C. difficile the outer capsule consists of a dense proteinaceous shell, termed 
the S-layer, which in Atomic Force Microscopy (AFM) images resembles a closely woven matrix. 
Cationic peptides have previously been used to deliver modified and neutrally charged antisense 
oligonucleotides to various bacteria (Ghosal and Nielsen 2012, Järver et al. 2012). However, 
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because TFDs may be synthesised with an unmodified backbone, they may retain their negative 
charge which is an important component driving DNA-protein interactions. Such molecules will 
readily precipitate if mixed with cationic delivery peptides, making their formulation difficult. An 
appropriate delivery particle for TFDs needs to protect a non-modified oligonucleotide from 
degradation in blood and other fluids, bind the oligonucleotide with high efficiency and selectively 
transfect bacteria. 
Ideally, the delivery moiety is, or is part of a nanoparticulate delivery system consisting of a 
quaternary amine compound or a bis-aminoalkane and unsaturated derivatives. The term 
aminoalkanes refers to amino groups (preferably tertiary amino groups) that form part of a 
heterocyclic ring. The delivery component associates with the phosphate backbone of the TFD to 
shield the TFD’s charge and to protect it from degradation in biological fluids, whilst allowing 
passive transport across bacterial membranes to deliver the TFDs into the cytoplasm of the cell. 
As with all oligonucleotide therapeutics, delivery is a challenge: a large and negatively charged 
molecule must be delivered to the bacterial cytoplasm, through the negatively-charged bacterial 
cell envelope. Previous work has used nanoparticles formed from a bolaamphilic lipid (Fuhrhop 
and Wang 2004), 12-bis-THA. This molecule consists of two tetrahydroacridinium (THA) head 
groups, with delocalized cationic charge, connected by linear aliphatic chain of 12 methylene 
groups (Figure 1.5). THA binds tightly to and condenses DNA, presumably through a combination 
of electrostatic forces and intercalation (Kuruvilla et al. 2005). Additionally THA, and other similar 
compounds, bind to anionic phospholipids typical of prokaryotic membranes, most typically 
cardiolipin (Weissig et al. 2000, Mamusa et al. 2016), as part of the delivery mechanism to the 
bacterial cytoplasm. The poor aqueous solubility of these compounds drives self-assembly to sub-
micromolar particles that bind oligonucleotides with high affinity to protect them against 
degradation (Mamusa et al. 2016, Marín-Menéndez et al. 2017). However, a key property of these 
particles that needs to be improved is their stability, as currently they readily form aggregates. To 
this end a structure activity relationship study was performed to better understand the key parts 
of the molecule driving the formation of the particles. A similar bolaamphiphile, dequalinium, was 
studied; it is a recognised antibacterial agent and also has been investigated as a gene delivery 
agent to mitochondria, which also harbour anionic phospholipids (Weissig et al. 2000, Montis et 
al. 2014). However, the particles formed by dequalinium showed a high polydispersity index (PDI) 
and their colloidal stability was compromised by dilution.  A key improvement was extending the 
polycyclic system of the head group from a 2-ring quinolonium to a 3-ring THA. The resultant 
molecule was found to have approximately a 60-fold higher binding capacity for plasmid DNA and 
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is six-fold better than the commercially available transfection agent Lipofectamine (Weissig et al. 
2001). 
 
Figure 1.5 Chemical structure of bolaamphiphilic lipids, 12,12’-(dodecane-1,12-diyl)bis(9-amino-
1,2,3,4tetrahydroacridinium), referred to as 12-bis-THA, used for the assembly of nanoparticles 
(McArthur 2009b), figure was adapted from Mamusa et al. (2016). 
 
1.3.5 Functional interaction between the delivery particle and Transcription Factor 
Decoy  
To protect TFD from rapid degradation by biological nucleases for successful delivery, TFDs are 
encapsulated in bolaamphiphilic molecules. The encapsulation transcription factor decoys (TFD) 
with 12-bis-THA were achieved through self-assembly, referred to as loaded nanoparticles (LNPs) 
(Figure 1.6). TFDs are condensed in a nanoparticulate complex which improves stability in 
biological fluids and crucially transfects the bacterial cell membrane in order to deliver TFD to the 
bacterial cytoplasm (McArthur 2009b). By coupling TFD with the delivery molecule 12-bis THA (i.e. 
LNPs), they have shown successful transfection activity in vivo (McArthur 2014). They were potent 
and active against a wide range of pathogens, including multi-drug resistance strains.  It has been 
shown that nanoparticulate delivery triggers a genetic response mediating cell wall stress in the 
bacteria; it is these genes which the TFDs are designed to block giving a rapid, bactericidal effect. 
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Figure 1.6 Loaded nanoparticles are comprised of transcription factor decoy oligonucleotides that 
define the antimicrobial spectrum, which are encapsulated by delivery nanoparticles to target 
bacteria. 
From recent studies on bacteria and synthetic membrane models, it was shown that the 
mechanism of TFD delivery to bacterial cytoplasm is connected to cardiolipin (CL), an anionic lipid 
that is abundant in prokaryotic membranes (Marin-Menendez et al. 2017). Cardiolipin content has 
been shown to be related to osmotic stress. As osmotic stress is imposed upon E. coli, cardiolipin 
level increases as the phosphatidylglycerol (PE) levels decrease on the bacterial membrane 
(Romantsov et al. 2009). It was hypothesised that as bacterial membrane reorganises itself, 
membrane permeability increases, which allow TFD to be released from the nanoplexes into the 
cytoplasm. 
1.3.6 Established knowledge on TFD antimicrobials on toxicity and in vivo animal 
studies 
DNA-based therapy has emerged as a new class of therapeutic agents of high potential, as 
oligonucleotides are designed to be highly specific to sequencing data from the bacteria target, 
with low predicted toxicity and can be manufactured relatively inexpensively through chemical 
synthesis and biological replication (McArthur 2009b). Since DNA is a ‘natural’ compound, 
research and development on target identification, lead compound discovery and medicinal 
chemistry phases of a conventional drug development are truncated and allow rapid discovery of 
new drugs. 
The nanoparticulate antimicrobials are currently undergoing preclinical development for several 
indications, including a treatment for Clostridium difficile infection. It was shown in animal studies 
that the NPs could be delivered to the stomachs of Golden Syrian Hamsters and maintain good 
activity to the extent that TFD antibacterials successfully cleared a severe gut infection equivalent 
to vancomycin activity (McArthur 2009a), which provide good evidence that NPs are well suited to 
the treatment of gut disorders. 
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1.4 Potential bacterial targets for microbiota engineering for TFD 
antimicrobials 
Given the scarcity of treatment against Gram negative bacteria e.g. Salmonella and E. coli in the 
gastrointestinal tract, the development of a novel treatment against Gram negative bacteria is 
highly desirable. Unlike Gram positive bacteria, the lipopolysaccharides and proteins present on 
the outer membrane of Gram negative bacteria, forming a low permeability barrier, and thus 
make it difficult for antimicrobials to penetrate the bacterial cell (Zgurskaya et al. 2015). The 
discovery of new antimicrobials effective against Gram negative bacteria is therefore a major 
challenge and an urgent advancement of new antimicrobial agents is required (World Health 
Organisation 2017). TFD technology has shown successful delivery to a wide range of Gram 
positive bacteria including MRSA and C. difficile (McArthur 2014). It would be worthwhile to 
investigate whether our nanoparticulate delivery system could penetrate the Gram negative cell 
walls and successfully deliver the transcription factor decoy within Gram negative bacteria (see 
Section 1.3.2). 
1.4.1 Enterobacteriaceae 
Enterobacteriaceae are key members of the gut microbiota; a vast variety of genera within the 
family are gastrointestinal pathogens (e.g. Salmonella and Shigella) and commensal bacteria (e.g. 
Klebsiella, Enterobacter and Escherichia) that could be opportunistic and associated with disease 
when occasion arises (Hooper and Gordon 2001).  
E. coli is a Gram negative, non-sporulating, facultative anaerobe that is commonly found in the 
human intestinal tract (Eckburg et al. 2005), where it is most abundant in the small intestine 
(Zoetendal et al. 2012). Though it only constitutes 0.1% of the human colon microbiota, E. coli 
provides a protective effect to the healthy balance of the gut microbiota by preventing the 
colonisation of pathogens in the intestinal mucosa and supplying supplementary nutrients and 
enhancing the acquisition of nutrition in humans (Reid et al. 2001). It is the most-studied bacterial 
organism and has played a pivotal role in microbiology and biotechnology following extensive 
studies of its genome. 
Certain pathogenic strains of E. coli can be opportunistic and can cause disease when the body’s 
immunological tolerance is compromised (Belkaid and Hand 2014); pathogenic commensals such 
as adhesive invasive E. coli are found in high quantities in IBD patients (Khajah 2017) and 
Enteroaggregative strains of E. coli in persistent diarrhoea (Sarker et al. 2017). An increase in 
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Enterobacteriaceae has also been observed in diarrhoea-dominant IBS patients (Carroll et al. 
2012). Dysbiosis was shown in antibiotic-associated diarrhoea where Proteobacteria (including E. 
coli) were notably increased; the subsequent reduction of Proteobacteria following faecal transfer 
resolved the clinical complications (Shahinas et al. 2012, Shankar et al. 2014). The increase in E. 
coli/Enterobacteriaceae population may have a role in dysbiosis and disease phenotypes 
associated with the gut microbiota (Figure 1.7), as the alteration of E. coli composition has been 
observed to be associated with intestinal inflammatory disorders in both human and mice 
(Thornsberry et al. 1983, Campbell et al. 2001). 
 
Figure 1.7 Increase in facultative anaerobes (Enterobacteriaceae) is associated with dysbiosis and 
disease development including inflammatory bowel disease (IBD), colorectal cancer (CRC) and 
Type 2 diabetes (T2D). Figure was adapted from Rigottier-Gois (2013). 
 
Pathogenic strains such as AIEC are associated with Crohn’s disease and colorectal cancer, and it 
was discovered that the common expression of haemagglutinins in AIEC correlates with its 
properties to adhere and invade the intestinal epithelium (Prorok-Hamon et al. 2013). 
Enterobacteriaceae undergo an increase in levels at the onset of Crohn’s disease along with 
Fusobacteriaceae, Pasteurellaceae, Veillonellaceae, whilst Bacteroidales and Clostridiales are 
greatly reduced (Gevers et al. 2014). 
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A hallmark for IBD – dysbiosis, often lead to increase of Enterobacteria as other bacterial groups 
levels plummet (Galtier et al. 2017). The selective growth advantage of E. coli due to an increased 
host-derived nitrate availability has been proposed as the leading cause for inflammation-related 
dysbiosis (Winter et al. 2013). 
As drug resistant bacteria become more widespread, antibiotics have become less effective. 
According to the World Health Organisation, Enterobacteriaceae is one of three bacterial groups 
that is considered a critical threat to human health, and which requires the highest priority in 
finding effective antibacterial treatment (World Health Organisation 2017). It is of interest to see 
if Enterobacteriaceae can be reduced specifically in the gut microbiota for future gut microbiota 
association studies. 
1.4.2 Sulphate reducing bacteria 
Sulphate reducing bacteria (SRB) are obligate anaerobic bacteria, although phylogenetically 
diverse, they share a common function in sulphur metabolism. They are capable of reducing 
sulphate ion for energy through sulphite reduction. This results in the formation of hydrogen 
sulphide (H2S) as a by-product of respiration. 
H2S can permeate the cell membrane and has physiological importance for the gastrointestinal 
tract at non-toxic concentrations (Fiorucci et al. 2006). Though at higher concentrations, H2S could 
have a negative impact on the colonic epithelial cells by inhibiting butyrate oxidation, the energy 
source of colonic epithelial cells (Roediger et al. 1993a), and by degrading the mucus layer 
(Ijssennagger et al. 2015). SRB’s pro- and anti-inflammatory properties range from the promotion 
of inflammation in UC (Pitcher et al. 2000) to the resolution of colitis (Wallace et al. 2009) 
maintaining the balance of H2S levels within physiological level is therefore important for the 
integrity of the gut (Feng et al. 2017). 
Increased H2S has been associated with UC (Rowan et al. 2009), increased SRB populations were 
also observed in faecal samples of UC patients (Pitcher et al. 2000). It has been shown that SRB 
preferentially colonises the ileal pouches of UC patients than familial adenomatous polyposis 
patients (Duffy et al. 2002). H2S is also found to be genotoxic and causes DNA strand breakage 
(Attene-Ramos et al. 2007), cell cycle arrest at G1 and p53-induced apoptosis (Baskar et al. 2007). 
Tight regulation of the colonic H2S level is therefore crucial to maintain intestinal integrity. 
Desulfovibrio piger, a common Gram negative SRB in the human gut, could be another possible 
bacterial target for IBD (Loubinoux et al. 2002). 
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1.5 Aims and objectives of the research 
The aim of this project is to investigate the possibility of rebalancing the gut microbiota by 
selectively reducing certain bacterial groups using TFD coupled with the nanoparticulate delivery 
system, with minimal disruption to the rest of the gut microbiota.  
 
Main objectives: 
1) Investigate whether LNP loaded with TFD can act as specific antimicrobials to target 
Enterobacteriaceae. 
2) Determine whether TFD will have minimal disruption in the commensal bacterial 
community. 
3) Explore whether TFD activity in vitro can be translated to an in vivo model. 
4) To design TFDs for other bacterial targets with functional similarities e.g. SRB and 
evaluate their antimicrobial activity.  
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Chapter 2: General Materials and  
Methods 
2.1 Culturing bacteria 
All materials were purchased from Sigma-Aldrich unless stated otherwise. Molecular biology 
methods are as described in Sambrook et al (1989) unless stated otherwise. 
2.1.1 Culture media 
The compositions of media used for bacteria cultures are described as follows, and dissolved in 
ultra pure (UP) H2O: 
Luria (L) medium (Lennox): 10 g/l Tryptone, 5 g/l Yeast extract, 5 g/l NaCl, 1 g/l D-glucose. 
Luria-Bertani (LB) medium:  10 g/l Tryptone, 5 g/l Yeast extract, 10 g/l NaCl. 
Solid media were prepared by adding 15 g/l agar to the appropriate medium before autoclaving. 
Postgate medium C:  6 g/l sodium lactate, 4.5 g/l Na2SO4, 1 g/l NH4Cl, 1 g/l Yeast Extract, 0.5 g/l  
KH2P4, 0.3 g/l sodium citrate tribasic, 0.06 g/l MgSO4.7H2O, 1 ml/l FeSO4.7H2O and 0.04 g/l  
CaCl2.2H2O. Adjust pH to 7.5 then add 0.5 g/l cysteine HCl and 4 ml/l 0.02% resazurin before 
autoclaving. 
2.1.2 Bacterial strains and growth conditions 
All bacterial strains used in this thesis are listed in Table 2.1, E. coli, Desulfovibrio piger (D. piger), 
Desulfovibrio simplex (D. simplex) and Desulfovibrio vulgaris (D. vulgaris) were obtained from in-
house culture collections (QIB, Norwich, UK); some D. piger were isolated from human faeces in 
this study. Identity of bacterial strains was confirmed by 16S rRNA gene sequencing and 
Ribosomal Database Project for sequence match.  
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Table 2.1 List of organisms and growth conditions used 
Strain name Growth condition Media 
E. coli DH5α 37°C, Aerobic, 250 
rpm 
L medium 
D. piger UC15 37°C, Anaerobic, 
Static 
Postgate medium C 
Desulfovibrio simplex 37°C, Anaerobic, 
Static 
Postgate medium C 
Desulfovibrio vulgaris 37°C, Anaerobic, 
Static 
Postgate medium C 
SRB isolates from the human 
gut 
37°C, Anaerobic, 
Static 
Postgate medium C 
 
The E. coli strain was stored at -80°C in 20% glycerol and grown in L media at 37°C. Sulphate 
reducing bacteria (SRB) were stored as freeze dried cultures at 4°C and revived before use in 
Postgate medium C. Cultures were then kept at 4°C in Postgate Medium C liquid media and/ or 
agar stab for short term storage (within 3 months). 
Anaerobic bacteria were incubated in an anaerobic chamber (Don Whitney, UK), materials were 
generally pre-reduced overnight, except for SRB-related experiments, where materials were pre-
reduced for 48 h before use, at an atmosphere of 5% CO2, 10% H2 and 85% N2.  
Cell density was measured with a UV/ Vis spectrophotometer at a wavelength of 600 nm. 
2.2 Biological characterisation of LNPs 
2.2.1 Making TFD and NPs 
All reagents were filtered-sterilised (FS) with 0.2 µm filter (Millipore) unless stated otherwise. 
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TFD preparation 
Hairpin 
10 µl of oligonucleotide was suspended in UP H2O to a final concentration of 250 µM. It was 
vortexed for 5 s in a 1.5 ml microcentrifuge tube before annealing the hairpin by incubating at 
95°C for 5 min and allowing to cool to room temperature. The oligonucleotide was precipitated by 
adding 1.5 µl of 1 mg/ml glycogen per 100 µl of sample. NaCl was added to give a final 
concentration of 0.5 M followed by 2 volumes of 100% ethanol (pre-chilled at -20°C). The sample 
was mixed and incubated at -20°C for 2 h before being spun at 16000 x g for 30 min. The 
supernatant was discarded and the pellet was washed with 200 µl of 70% ethanol, before further 
centrifugation at 16000 x g for 15 min. The supernatant was discarded and the pellet was air-dried 
before it was resuspended in UP H2O. The concentration of the oligonucleotide was adjusted to 1 
µg/µl based on Nanodrop ND-1000 spectrophotometer analysis (Thermo Scientific) (see Section 
2.6.4). The final product was checked for size and integrity by gel electrophoresis using 2% 
agarose with 100 bp DNA ladder as a marker before staining in ethidium bromide (1 mg/l). 
Dumbbell 
The two complimentary oligonucleotides were resuspended in UP H2O to a concentration of 25 
µM and annealed by incubating the mixture at 95°C for 5 min. They were allowed to cool at 
1°C/min to form the dumbbell. This structure was annealed with T4 DNA Ligase (NEB) at room 
temperature overnight, the un-ligated oligonucleotides were removed by T7 Exonuclease 
digestion, before being subjected to HPLC purification. The TFD was precipitated by the addition 
of 0.1 volumes of NaClO4 and 3 volumes of acetone. This mixture was vortexed before being 
incubated at -20°C for 15 min and pelleted. The TFD pellet was washed with 1 ml of ice-cold 
acetone before being washed with 1 ml of ice-cold 100% ethanol, and air-dried at room 
temperature. The TFD pellet was resuspended in UP H2O at a stock concentration of 1 µg/µl. 
Nanoparticle preparation 
Nanoparticles were formed with a proprietary bolaamphiphilic lipid, developed by the industrial 
partner, Procarta Biosystems Limited (Mamusa et al. 2016, Marin-Menendez et al. 2017). The 
chemical is 12,12’-(dodecane-1,12-diyl)bis(9-amino-1,2,3,4tetrahydroacridinium) (termed 12-bis-
THA hereafter) with iodide/chloride counter ion and was synthesized by Shanghai ChemPartner.  
To form nanoparticles for E. coli, [12-bis-THA]I2  was dissolved in dimethyl sulfoxide (DMSO) at 10 
mg/ml, diluted in 50 mM MES buffer (pH 5.5) supplemented with 0.1% hydroxypropyl 
methylcellulose (HPMC), resulting in [12-bis-THA]I2 at a final concentration of 180 µM. To form 
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nanoparticles for SRB, [12-bis-THA]Cl2 dissolved in UP H2O at a final concentration of 180 µM and 
supplemented with 0.1% HPMC. The molecule spontaneously self-associated to form empty 
nanoparticles (ENPs). To obtain a homogenous dispersion, vigorous vortexing was performed for 
30 s. The TFD-loaded nanoparticles (LNPs) were obtained by adding the TFD to MES buffer (50 
mM, pH 5.5) at a concentration of 10 μg/mL before the ENP dispersion (180 µM) mentioned 
above.  
2.2.2 Minimum inhibitory concentrations (MIC) and minimum bactericidal 
concentrations (MBC) 
To set up MIC assay plates, 160 µl of media and 40 µl of NPs were added and mixed in the first 
column of wells (i.e. total volume of 200 µl) in a 96-well plate (Greiner Bio-One Ltd). For the rest 
of the wells, 100 µl of media was added. 100 µl of the mixture from the 1st column was added to 
the wells in the 2nd column (to perform a 1:2 serial dilution), samples were serially diluted across 
the columns until the 11th column. 100 µl of bacterial inoculum (overnight culture subcultured at 
2% just before experiment) were added to the sample wells. Positive and negative controls were 
placed in the 12th column including media only control, bacterial inoculum with media negative 
control, and antibiotic positive control (25 µg/ml carbenicillin against E. coli, or 100 µg/ml 
spectinomycin against SRB). The remaining inoculum were used to determine the total viable 
count at the start of the experiment by 1:10 serial dilution and plating 20 µl in triplicates per 
dilution. The MIC assay plate were incubated with the following conditions depending on the 
bacterial inoculum: at 37°C at 140 rpm overnight for E. coli; and at 37°C anaerobic incubator, 
without shaking for 48 h for SRB.  
For MBC, the experiment was set up as described above, the wells with no growth were plated on 
L agar (for E. coli) and incubated at 37°C overnight. Sample with the lowest concentration of NPs 
with no growth was considered the MBC. 
 
2.3 Physical characterisation of LNPs 
2.3.1 Dynamic light scattering for NP size measurement 
Dynamic light scattering signals were detected by an EMI 9863B/350 photomultiplier on a 
Brookhaven Instruments Apparatus (BI 9000AT correlator and BI 200SM goniometer) as described 
previously (Marin-Menendez et al. 2017). The hydrodynamic diameter of the particles was 
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measured by placing 450 µl in a 1 ml plastic cuvette and a value for the polydispersity index (PDI) 
was derived. PDI < 0.2 were considered monodispersed, and the z-average was used as the 
measurement for particle size using cumulative fitting. PDI ≥ 0.2 were considered polydispersed, 
the distribution fit method was used instead to measure the particle size obtained from size peak 
by intensity.  
2.3.2 Flow cytometry and fluorescence-activated cell sorting (FACS) 
To look at the amount of LNPs that were successfully bound to TFDs, TFD-bound NPs (NP for E. 
coli was used, see Section 2.2.1) and were sorted against the unbound equivalent by gating the 
populations with or without TFD (fluorescence originates from Alexa Fluor 488-TFD max 
excitation/emission 490/525 nm); or TFD were stained with DNA dye SYBR green (0.1X, diluted in 
TAE) (Life Technologies) or Acridine Orange (0.1 µg/ml) (Life Technologies) on the SH-800 cell 
sorter (Sony). Samples were sorted according to the 2 defined gates (mode: ultra purity, regular 
cell) and collected in 2 separate tubes, the sorted populations were re-run on the flow cytometer 
for further NP characterisation such as the amount of aggregation in the sample. The data were 
analysed using FlowJo software v10 (FlowJo, LLC). 
2.3.3 Time course stability study using exonuclease treatment against TFD 
Fetal bovine serum (FBS) was made up at 5% with UP H2O. Different GN Sig TFD structures (5 µl) 
including hairpin, dumbbell and duplex were added to 495 µl of 5% FBS and incubated for 0 min, 
30 min, 60 min, 90 min, 2 h, 3 h, 4 h, 5 h, 6 h and 3 days at 37°C, before analysis by 2% agarose gel 
electrophoresis by running 15 µl of sample with 8 µl of 2x loading buffer.  
2% agarose gel was made up with 1X Tris acetic EDTA (TAE) buffer (Fisher Scientific). Gels were 
run at 80 V until the loading dye was two-thirds down the gel, before the ethidium bromide-
stained gel was viewed under UV light.  
2.3.4 Pendant Drop to measure surface tension of NPs 
Theta OneAttension Optical Tensiometer was used to perform surface tension measurements. 
ENPs were prepared by a dispersion of DMSO solution of [12-bis-THA]I2 or [12-bis-THA]Cl2 in H2O 
to obtain a final concentration of 0.18 mM and 0.40 mM respectively, further dilutions were 
performed to obtain 0.18 mM, 0.018 mM, 0.0018 mM and 0.00018 mM samples. A minimum of 2 
repeated measurements were done on each sample at 25ᵒC. For each repeat, images of an ENP 
droplet were recorded in a size-controlled manner at 1 frame per second for 900 s to obtain 
surface tension data against time using the Young-Laplace equation (Berry et al. 2015).  
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2.4 Confocal microscopy 
2.4.1 Sample preparation 
Bacterial cultures were grown in their appropriate media, until E. coli reached OD 600 nm 0.3-0.5 in L 
broth or SRB OD 600 nm 0.2-0.3 in Postgate medium C (Section 2.1).  
Fluorescent LNPs were freshly made according to Section 2.2.1, except green fluorescent 
Alexa488 (max excitation/ emission 501/519 nm)-labelled hairpin TFD was used. 
A ratio of 1:1 bacterial cultures and fluorescent LNPs were mixed (200 µl + 200 µl) in a 1.5 ml 
microcentrifuge tube and incubated in the dark while shaking for 1 h and 1 h 30 min respectively 
for E. coli and SRB (SRB incubations were performed inside the anaerobic cabinet), see Table 2.2 
for details of confocal sample preparation (Marin-Menendez et al. 2017). 
Tetramethylrhodamine conjugate of wheat germ agglutinin (TMR-WGA) (max excitation/emission 
555/580 nm) (Life Technologies) and FM464-FX (max excitation/emission 565/744 nm) (Life 
technologies) were used to stain E. coli and SRB cell walls respectively at a final concentration = 10 
µg/ml per 400 µl of bacteria/LNP mixture, then incubated for 30 min while shaking. Water was 
used as a negative control to substitute fluorescent LNPs to determine base-line fluorescence.  
Samples were smeared on poly-L-lysine coated microscopy slides (Sigma-Aldrich) in quadruplicate 
with boundaries pre-defined with a wax pen.  
Additional fixation step for SRB samples only – samples were taken out of the anaerobic cabinet 
and formaldehyde (at 4% final concentration) was added to the sample on the slide. 
Slides were kept in the humid chamber (a box filled with wet tissues) and allowed to settle at 
room temperature in the dark for 30 min or 1 h respectively for E. coli and SRB. The slides were 
gently washed with FS phosphate buffered saline (PBS) and air-dried before the addition of 
Fluoroshield™ mounting media (Sigma-Aldrich). They were allowed to set horizontally for 15 min 
in the dark, at room temperature, before being stored at 4°C prior to confocal microscopy 
analysis. All confocal slides were analysed within 24 h of sample preparation.  
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Table 2.2 Difference between E. coli and SRB confocal sample preparation. 
E. coli SRB 
NPs used [12-bis-THA]I2 [12-bis-THA]Cl2 
Incubation time after adding fluorescent 
LNP and bacteria 
1 h 1.5 h 
Incubation temperature after adding 
fluorescent LNP and bacteria 
Room temperature 37°C 
 
Membrane dye added 
 
TMR-WGA 
 
FM464-FX 
 
Incubation time in humid chamber at 
room temperature 
 
30 min 
 
1 h 
 
Fixation 
 
NO 
 
YES (4% formaldehyde 
final concentration) 
2.4.2 Confocal microscopy analysis 
Confocal samples were viewed on a confocal microscope (Leica SP5 II) with a 63x magnification 
lens in the presence of Zeiss Immersol 518F oil. A I3 filter and N21 filter were used to visualise 
green and red fluorescence respectively. Sequential scans were used to prevent fluorescence 
bleeding when more than 1 laser was used to excite the samples. All images had a format of 512x 
512, zoom factor of 8 and pinhole size of 0.5 airy unit and frame average of Accu 1 unless 
otherwise stated. All samples were stored as .lif files on LAS AF software and images were 
exported as .tif files. 
2.4.3 Data analysis 
LAS AF-Lite and Fiji (JAVA based freeware from bioimaging website) software were used to add 
scale bars and to analyse confocal images by measuring the size of the bacterial cell.  
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2.5 Batch culture fermentation 
2.5.1 Preparation of media solutions and selective agar 
Batch culture fermentation were performed using a method described previously (Mandalari et 
al. 2007). 
Chemostat medium: per 1 l of medium, add peptone water (2 g), yeast extract (2 g), NaCl (0.1 g), 
K2HPO4 (0.04 g), KH2PO4 (0.04 g), MgSO4.7H2O (0.01 g), CaCl.2H20 (0.01 g), NaHCO3 (2 g), Tween 80 
(2 ml), vitamin K (10 μl of 0.5 v/v, dissolved in ethanol), cysteine.HCl (0.5 g), bile salts (0.5 g) and 
Hemin (0.02 g dissolved in 400 μl 1 M NaOH). 10 g glucose was added to the autoclaved media 
before use as a carbon source.  
Wilkin Chalgren solid medium: 43 g/l Wilkins Chalgren Anaerobic agar (Oxoid). 
Bacteroides solid medium: 28 g/l Brucella Broth (Oxoid), 15 g/l agar bacteriological (Agar No. 1) 
(Oxoid) and 10 ml/l hemin solution (0.5 mg/ml) were mixed before autoclave. After cooling, 200 
µl/l vitamin K solution (0.5 v/v, dissolved in ethanol), 3 ml/l kanamycin (25 mg/ml), 7.5 ml/l 
vancomycin (1 mg/ml) and 50 ml/l laked horse blood (Thermo Scientific) were added. 
Beerens solid medium: 39 g/l Columbia Agar Base (Oxoid), 0.5 g/l Cysteine HCl, 5 g/l Agar and 5 g/l 
glucose were boiled to dissolve ingredients. After cooling, 5 ml/l propionic acid was added and 40 
ml/l NaOH was used to adjust to pH 5. No autoclaving was required. 
Clostridia solid medium: 43 g/l Wilkins Chalgren Anaerobic agar (Oxoid); after autoclaving and 
cooling, 8 ml/l novobiocin (1 mg/ml) and 8 ml/l colistin (1 mg/ml) were added. 
MRS solid medium: 52 g/l MRS broth (Oxoid) and 15 g/l agar. 
MacConkey No. 3 solid medium: 51.5 g/l MacConkey Agar No. 3 (Oxoid). 
Antibiotics were dissolved in UP H2O before filter-sterilisation as follows: 
1 mg/ml novobiocin, 1 mg/ml colistin, 25 mg/ml kanamycin and 1 mg/ml vancomycin and then 
stored at -20°C before use. 
2.5.2 Inoculation of media solutions with faecal bacteria 
Aliquots of 135 ml of chemostat media were added to the batch fermentation vessels and were 
pre-reduced by oxygen-free nitrogen with a gentle stirring overnight. Vessels were connected to 
water jackets filled with 37°C water for temperature control. An optimal pH of 6.8 was maintained 
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with an automated pH controlled system. The pH ranged between of 6.6 to 7.0 and was adjusted 
using 1 M NaOH and 1 M HCl. 
A freshly voided faecal sample was diluted to 1:10 in a pre-reduced PBS and placed into a Seward 
stomach bag, before being homogenised in the Stomacher 400 circulator at 230 rpm for 45 s. 15 
ml of the resulting faecal slurry was then added to each of the vessels.  LNP was added to the 
faecal inoculum as a target-specific oligo-based antimicrobial against E. coli, along with control 
treatments scrambled LNP (SLNP) and vehicle control (containing all the components in LNP 
except that TFD and [12-bis-THA] was omitted), at a 2% final volume. Samples were taken at 
predose (before the addition of treatments), 0 h, 4 h, 8 h for viable colony counts, DNA extraction 
for downstream 16S rRNA gene sequencing and NMR analysis. Colonies from MacConkey No. 3 
plates were also picked for 16S rRNA gene colony PCR (Chapter 2.7) to confirm the identity of the 
bacteria present in the sample. 
2.5.3 Quantification of bacteria and analysis 
Viable bacterial cell counting 
Agar plates were pre-reduced in the anaerobic cabinet overnight before use. Faecal slurries were 
serial diluted from 10-1 to 10-7 in PBS and 20 µl were plated at each dilution in triplicates. The 
colony forming units (CFU) were calculated using the formulation: 
CFU/ml = no. of colonies x dilution factor / volume plated  
Dilution of selective and/or differential agar were plated at the dilutions as stated in Table 2.3. 
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Table 2.3 Experimental details for bacterial viable count in batch model fermentation. 
Type of agar Selective for Incubation (days) Dilution 
Wilkins Chalgren (WC) Anaerobes 1 -4 to -7 
Bacteroides Bacteroides 1 -4 to -7 
Beerens# Bifidobacterium 1 -4 to -7 
Clostridia Clostridium 1 -3 to -6 
MRS Lactobacillus 1 -3 to -6 
MacConkey No. 3* Enterobacteriaceae 
Pink colour: coliforms  
straw colour: non-
lactose fermenter 
1 0 to -7 
* incubate at aerobic conditions 
# Beerens were not measured in the mouse experiment 
2.5.4 NMR sample processing 
For batch experiment 
Samples (13 ml) were taken from the in vitro batch model at predose, 0 h, 4 h and 8 h. Samples 
were centrifuged at 5000 x g for 15 min at 4°C, then 900 µl of supernatant was transferred to 1.5 
ml microcentrifuge tube (performed in triplicates for each sample), followed by the addition of 
100 µl NMR phosphate buffer (0.51 g NaH2PO4.H2O, 2.82g K2HPO4, 34.5 mg Trisodium phosphate, 
100 mg NaN3, dissolved in 200 ml D2O). The mixtures were vortexed briefly before being frozen at 
-20°C until analysis. 
For mouse experiment 
Faecal slurry samples (diluted 1:10 in PBS) were centrifuged at 16000 x g for 15 min at 4°C. 90 µl 
of supernatant and 810 µl of PBS were added to each 1.5 ml microcentrifuge tube (performed in 
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triplicates), before 100 µl of NMR buffer was added to each of 900 µl of supernatant. The 
mixtures were vortexed briefly before being frozen at -20°C until analysis. 
2.6 Phylogenetic analysis of bacterial communities using 16S 
rRNA gene sequencing 
2.6.1 Propidium monoazide treatment to differentiate live and dead bacteria 
Propidium monoazide (PMA) (Biotium), a cell membrane impermeable DNA intercalating agent, 
was used to discriminate between live and dead bacterial DNA (Lai et al. 2016), so that only DNA 
from live bacteria were amplified for downstream 16S rRNA gene sequencing.  Faecal slurry 
diluted in 1:10 pre-reduced PBS was centrifuged at 5000 x g for 15 min at 4°C and resuspended in 
500 µl of PBS.  An aliquot of 1.25 µl of PMA (20 mM) was mixed with each sample in a 1.5 ml 
microcentrifuge and incubated on a shaker at 195 rpm in darkness for 5 min at room 
temperature. PMA photoactivation was performed on a Phast blue light apparatus (GenIUL) or 
BLU-V system (Qiagen) for 15 min. The samples were then centrifuged at 10000 x g for 8 min, and 
then the supernatant was removed, before the resuspension of the pellet in 978 µl of sodium 
phosphate buffer (buffer taken from the FastDNA SPIN kit for soil (MP Biomedicals, UK)).  Samples 
were stored at -80°C before DNA extraction.  
2.6.2 DNA extraction for bacterial community (16S rRNA gene) profiling  
Genomic DNA was extracted for bacterial community (16S rRNA gene) sequencing after PMA 
photo-activation (section 2.6.1.) using a FastDNA SPIN Kit for soil (MP Biomedicals, UK). After each 
faecal suspension was being thawed, they were mixed with 122 µl of MT buffer and allowed to 
settle at 4°C for 1 h. Each mixture (1 ml) was next transferred into a Lysing Matrix E Tube and then 
lysed 3 times at 6.5 m/s with a CY: 24*2 adaptor. There were cooling for 2 and 4 min between the 
lysis steps respectively, using a FastPrep instrument (MP Biomedicals, UK), before next being 
centrifuged for 1 min at 16800 x g. Following this, the supernatant was transferred into a clean 
1.5 ml microcentrifuge tube, before being mixed with a 250 µl protein precipitation solution (PPS) 
reagent by vigorously inverting the tube by hand for 10 times in total. Each sample was then 
precipitated out using centrifugation at 16800 x g for 5 min, before the supernatant was 
transferred into a sterile 15 ml tube. An addition of 1 ml of binding matrix was used before the 
tube was inverted by hand for 2 min, before being allowed to stand in a rack for 3 min, to allow 
the silica matrix to settle. 1 ml of supernatant was then discarded before the binding matrix was 
resuspended into the remaining supernatant. 600 µl of the mixture was then transferred into a 
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SPIN filter tube, before being centrifuged for 1 min at 14500 x g. The flow through was discarded. 
DNase-free salt/ethanol wash (SEWS-M) solution (500 µl) was added to the SPIN filter tube and 
centrifuged for 1 min at 14500 x g before the flow through was discarded, this step was 
performed a total of 3 times. The SPIN filter was centrifuged for a further 2 min at 14500 x g to 
remove residual SEWS-M wash solution and then air-dried for 5 min. For efficient DNA elution, 50 
µl of Dnase/Pyrogen Free DNA elution solution (DES) was gently stirred with the matrix; each 
sample was left for 1 min at room temperature and centrifuged at 14500 x g for 1 min before 
storing the DNA at -20⁰C. 
2.6.3 Gel electrophoresis of nucleic acids 
Agarose gels were made up at a concentration of 0.8-1% (Melford), dissolved in 0.5 x Tris borate 
EDTA (TBE, Fisher). 2-10 µl of samples were loaded into the gel and then run against 0.5 x TBE, a 
final concentration of 1X gel loading buffer was then added to the sample when required. 
HyperLadder 1 (Bioline) or 2-Log DNA Ladder (NEB) was used whenever appropriate. The gels 
were run until the loading dye was two-thirds down the gel, and then stained in 1 mg/l ethidium 
bromide for 30 min, before being rinsed briefly in deionised H2O, prior to being viewed under UV 
light on a transilluminator (302 nm). Images were then captured using the Alphaimager (Alpha 
Innotech).  
2.6.4 Measurement of DNA concentration 
Nanodrop 
Nanodrop ND-1000 spectrophotometer (Thermo Scientific) was used to determine DNA using UV 
spectrophotometry under the nucleic acid option, measuring the absorbance at 260 nm. After the 
sampler was cleaned with UP H2O, initialised and blanked, 1 µl of the sample was used for the 
measurement to obtain concentration in ng/µl. The quality of DNA can be confirmed by the 
260/280 ratio of > 1.7. 
Qubit 
To make up the Qubit™ working solution (Life Technologies), Qubit™ reagent and Qubit™ buffer 
were mixed in a ratio of 1:200 and then kept away from light beneath foil. Standard 1 and 
standard 2 (10 µl) were then added to 190 µl of working solution for the calibration and 2 µl of 
samples were next added to 198 µl of working solution using 0.5 ml clear thin wall PCR 
microcentrifuge tubes. Samples were then vortexed for 2-3 s before being incubated at room 
temperature for 2 min before measuring the DNA concentration using Qubit.  
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2.6.5 Illumina Miseq sequencing settings 
Paired-end 16S rRNA gene community sequencing was performed using the Illumina Miseq 
platform at the Earlham Institute (Norwich, UK). After genomic DNA had been extracted from 
faecal slurry, the 16S small subunit rRNA gene region V4 was amplified using degenerate primers 
515F (AATGATACGGCGACCACCGAGATCTACACGCT XXXXXXXXXXXX TATGGTAATT GT 
GTGYCAGCMGCCGCGGTAA) and 806R (CAAGCAGAAGACGGCATACGAGAT AGTCAGCCAG CC 
GGACTACNVGGGTWTCTAAT), based on literature (Caporaso et al. 2011b, Caporaso et al. 2012) 
with modification on primer degeneracy (Apprill et al. 2015, Parada et al. 2016) and using 
redesigned forward-barcoded constructs (Walters et al. 2016). On the forward primer, the 
adaptor sequence was then linked to the Golay barcode, which allows identification unique to 
each sample. Platinum Taq polymerase (ThermoFisher) was used to amplify ribosomal gene 
regions (with amplicon size ~ 390 bp) using the following conditions: 94°C for 3 min; 35 cycles of 
94°C for 45 s, 50°C for 60 s, 72°C for 90 s; followed by 72°C for 10 min before leaving at holding 
temperature of 4°C. Amplicons were quantified using Quant-iT PicoGreen dsDNA assay Kit 
(ThermoFisher). The amplicons were purified using MoBioUltraClean PCR Clean-Up Kit, before the 
concentration and A260/A280 ratio were measured for quality assurance.  
2.6.6 Bioinformatic analysis of 16S rRNA gene sequencing 
Quantitative Insights Into Microbiological Ecology (QIIME) was used to analyse the bacterial 
community (Kuczynski et al. 2012) extracted from faecal origin after Illumina Miseq sequencing 
(Section 2.6.5.). Forward and reverse reads of the samples were joined and sequences were 
filtered so that the sequences were between 200 bp and 1000 bp using prinseq lite. Other criteria 
to be met included: having an average quality score of at least 25 within a 50 bp length, read 
length between 200 and 1000 bp, and having an Illumina quality digit of > 0. Chimeric sequences 
were detected and eliminated using Usearch 6.1 (Edgar 2010) and prinseq-lite (Schmieder and 
Edwards 2011). Greengenes 13.8 were used to assign bacterial taxonomy among phylum to 
species level from the operational taxonomic units, also enabling reverse strands to be searched 
against the Greengenes database by uclust, with the confidence value of 50% as threshold and 
OTU clustered from trimmed reads at 97% identity level. Beta-diversity PcoA plots were 
generated by weighted and unweighted Unifrac distances and visualised in the Emperor tool 
(Kuczynski et al. 2012).  
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2.7 Polymerase Chain Reaction (PCR) 
2.7.1 PCR preparation and conditions 
To make DNA templates, single colonies were picked from an agar plate and resuspended in 10 µl 
of sterile UP H2O and heated at 95°C for 5 min before taking 1 µl as template in each 50 µl PCR 
reaction. PCR reaction were set up using GoTaq G2 polymerase (Promega) according to the 
manufacturer’s recommendation.  
For 16S rRNA gene amplification 
The following primers (Sigma-Aldrich) were used to yield a 1500 bp amplicon: AMP_F 5’ GAG AGT 
TTG ATY CTG GCT CAG Tm 60.6 or 62.9°C; AMP_ R: AAG GAG GTG ATC CAR CCG CA Tm 69 or 71.4°C 
(Baker et al. 2003). Components of the PCR reaction and the PCR conditions are described in 
Table 2.4. A negative control was used by replacing a DNA template with UP H2O. When the PCR 
reaction was completed, 10 µl of PCR products were analysed on 1% agarose gel electrophoresis 
(Section 2.6.3) to check for the presence of a 1500 bp PCR product. Successfully amplified PCR 
products were purified by the QIAquick PCR purification kit (QIAGEN) following manufacturer’s 
instructions and DNA was quantified by Nanodrop (see Section 2.6.4) and sequenced using the 
Mix2Seq kit (Eurofins) following manufacturer’s guidelines. 
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Table 2.4 Composition of PCR reactions and PCR cycling conditions.  
PCR reaction components Quantity 
DNA Template 1 µl 
5X GoTaq Reaction Buffer  10 µl 
dNTP (25 mM each) (Bioline) 0.4 µl 
Primer F (20 µM) 1 µl 
Primer R (20 µM) 1 µl 
GoTaq DNA Polymerase 0.25 µl 
UP H2O 36.35 µl 
Total 50 µl 
PCR reaction conditions   
Temperature Duration No. of cycles 
95°C 2 min 1 
95°C 30 s 
20# 55°C* 30 s 
72°C 30 s** 
72°C 5 min 1 
* Annealing temperature (TA) were adjusted according to the primer Tm i.e. [MAX TA = TM (of the 
lowest pair) -3°C] 
** Extension step durations were generally calculated based on 1 min/kb; for 16S rRNA gene PCR, 
30 s is sufficient for a 1.5 kb elongation 
# 20 cycles were used as a default, however, when PCR amplification was low, 25 cycles were used 
instead 
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For amplification from SRB 
PCR primer dsrB were used to amplify SRB to obtain DNA template of the dsrB gene, before qPCR 
primers (dsrB_Human or Human_desulfov) were used for qPCR standard curve (primer details can 
be found in Section 2.8.3). PCR settings are described in Table 2.5. 
 
Table 2.5 PCR conditions for different SRB primers. 
 
 
 
dsrB_Human 
F and R 
Human_desulfov 
F and R 
dsrB_F1 
and R1 for 
UC15   
dsrB_F1 
and R1 
for 
isolate 6 
and 19 
dsrB_F2 
and R1 
for UC15   
dsrB_F2 
and R1 
for 
isolate 
6 and 
19 
*Annealing 
temperature 
49°C 52°C 62°C 62°C 55°C 55°C 
**Elongation 
duration 
20 s 20 s 54 s 43 s 54 s 43 s 
No. of cycles 25 25 25 25 25 25 
* Annealing temperature (TA) were adjusted according to the primer Tm i.e. [MAX TA = TM (of the 
lowest pair) - 3°C] 
** Extension step durations were generally calculated based on 1 min/kb 
 
2.7.2. Identification of bacterial isolates  
After the purified PCR products were sent off for 16S rRNA gene sequencing (Section 2.7.1), data 
were obtained from Eurofins website and the chromatograms were checked from the .ab1 file 
using FinchTV software (Geospiza, Inc.). High quality sequences were trimmed, copied to Editseq 
(DNASTAR) and saved as .seq files; before assembling the paired forward and reverse sequence as 
a single contig on SeqMan (DNASTAR, Inc.) as .fas files where appropriate. The consensus 
sequences or single sequences (if no overlapping was possible) were exported to the Ribosomal 
Database Project (RDP release 11) (http://rdp.cme.msu.edu/seqmatch/seqmatch_intro.jsp) for 
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sequence match, using the following search options: Strain= Type and Non Type; Source= Isolate; 
Size= ≥ 1200 bp and Quality= good. Sequence identity of the bacterial isolates was determined 
based on the highest S_ab score (Cole et al. 2014).  
2.8 SRB related experiments 
2.8.1. Isolation and identification of human SRB 
To preserve anaerobic bacteria, all reagents, apparatus and media in contact with bacteria were 
pre-reduced for 24-48 h prior to use. The inner region of the human faecal sample was scooped 
and diluted 1:10 in PBS and homogenised using a pellet pestle motor in the anaerobic cabinet. 
100 µl of the resulting faecal slurry was placed in anaerobic Postgate medium C (Section 2.1). The 
samples were incubated until a black precipitation was developed, indicating the presence of Fe2S 
(Butlin et al. 1949). Serial dilution was performed on these samples from 100 – 107, 100 µl of each 
dilution was then spread on a pre-reduced Postgate medium C agar plate. When black colonies 
were grown, individual colonies were streaked on a 25-grid Postgate medium C plate. Gram-
staining was performed, and their morphologies were recorded. Colonies were subcultured 3 
times by streaking until pure and single isolates were obtained. The SRB were stabbed in Postgate 
medium C agar vials for short term storages and were then freeze dried for strain archiving. 
2.8.2. SRB identification  
Colony identification using 16S rRNA gene 
16S rRNA gene PCR was performed on isolates (Section 2.7.1), and plated on agar to check for 
contamination. This was performed on Wilken Chalgren (for anaerobic bacteria) and Nutrient agar 
(for aerobic bacteria). The identity of the SRB isolates was then analysed following steps described 
in Section 2.7.2. The 16S rRNA gene sequences that had the same species identity were then 
further aligned to check whether they were the same strain using Seqman, and finally, the level of 
confidence in the nucleotide matcher was cross-checked with the original .abi file.  
Aligning dsrB gene sequences of SRB human isolates 
Clustal omega was used to align nucleotide sequences from human SRB isolates, then alignments 
were imported to Genedoc for visualisation. The nucleotide sequence was then translated to 
amino acid sequence in Editseq in three different frames, before being searched for on Blastp to 
examine their identity against known proteins. The amino acid sequences were also uploaded to 
Genedoc to compare any difference in protein sequence for different SRB strains. 
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Gram staining 
Gram staining was performed to visually distinguish whether the human SRB isolates were Gram-
positive or Gram-negative depending on the difference in the cell walls. Working in the anaerobic 
cabinet, a loopful of water was spread across a clean glass slide. A single colony was selected 
using a disposable sterile loop and emulsified, before the slides allowed to air dry. The slides were 
then taken out of the anaerobic cabinet and the dried films were passed through the Bunsen 
flame briefly for heat fixation without direct contact with the flame. The samples were stained 
with Gram stain reagents (Remel Europe Ltd) as follows: first, samples were stained in crystal 
violet solution by flooding the slide for 1 min, before being washed briefly with tap water for no 
more than 5 s and then drained. Slides were then flooded with Gram’s Iodine solution and 
allowed to mordant for 1 min before being washed off with water and then drained. Excess water 
on slides was removed with blotting paper, before the slides were next flooded with 95% ethanol 
for 10 s for decolourisation. This was then being washed off with tap water before being drained. 
For counterstaining, slides were flooded with safranin solution for 30 s before being washed off 
with water and then drained. Samples were blotted dry using lens paper (Kimberly-Clark 
Professional) and care was taken not to rub the samples. The slides were then examined with a 
100X 1.35 oil immersion lens on an Olympus BX60 light microscope (Olympus) using bright field 
illumination.   
2.8.3. qPCR Primer Design 
PCR primers which amplify the near-full length dsrB gene were designed using Primer 3 
http://primer3.ut.ee based on dsrB gene from D. piger UC15, default settings were used except 
for product size range= 301-1000 to cover the full length of dsrB gene. The prospective primer 
sequences were checked against the human_desulfov alignment to see if it would amplify other 
Desulfovibrio species. Oligo Calc http://biotools.nubic.northwestern.edu/OligoCalc.html and 
Sigma-Aldrich OligoEvaluator http://www.oligoevaluator.com/Login.jsp were used to predict 
primer properties e.g. the presence of hairpin formation and secondary structures. The general 
criteria included avoiding runs of three nucleotides; having GC rich 3’ ends for both the forward 
and reverse primer for the last three nucleotides (i.e. no more than five nucleotides); having a 
100% matched sequence especially on the 3’ end of the primer and avoiding degenerate 
nucleotides if possible; avoiding primer-dimer by making sure the last three nucleotides at the 3’ 
of the two primer sequences were not complementary to one another; having optimal primer 
length of ~18-22 bp and optimal Tm at 52-58°C with GC content at 40-60%. For the purpose 
specific to these primers, the PCR amplicon had to flank and allow extra nucleotides on either side 
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of the PCR amplicon result from the SYBR green qPCR primers as described above. Primers were 
ordered from Sigma-Aldrich, resuspended in sterile UP H2O and stored at -20°C.  
 
PCR primers used to amplify the whole dsrb gene is as follows: 
dsrB_F1: 5’ TACAATCCCGCCAAACCGAT 3’; Tm 68.2°C 
dsrB_F2: 5’ ACCATGTCCATCACCCACA 3’; Tm 65.1°C 
dsrB_R1: 5’ GGAGGTTCGTTGGGGATGTA 3’; Tm 65.9°C 
Several SYBR green-based qPCR primers were designed to amplify the dsrB gene in SRB found in 
humans. A literature search was performed to look for common SRB found in human gut 
microbiota (Loubinoux et al. 2002, Jia et al. 2012, Nava et al. 2012, Rey et al. 2013).  
The National Center for Biotechnology Information (NCBI) protein database was then used to 
obtain dsrB gene sequences from SRB. Complete sequences were picked and the coding 
nucleotide sequences were selected and aligned using clustal W2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The sequence similarity was manually checked and 
alignment improved using Genedoc (Nicholas et al. 1997). Based on the alignment of the (i) 
common SRB in human gut; and (ii) common Desulfovibrio spp. in the human gut, qPCR primers 
were designed with the following criteria: Primers were designed based on the regions with the 
highest sequence similarity between the bacterial species, one from the forward strand and one 
from the reverse strand. Wherever possible, primers sequence were at least 18 nucleotides long 
(with a minimum of 15 nucleotides), with an amplicon size of 40 – 300 bp. Whenever appropriate, 
nucleotides with less degeneracy were preferred, with no more than 6 degenerate nucleotides in 
a primer sequence. Primers were ordered from Eurofins Genomics and resuspended in sterile UP 
H2O and stored at -20°C.  
qPCR primers used to quantify SRB are described below:  
Human_desulfov F: 5’ TGCGACATCGCCGACAA 3’; Tm 55.2°C 
Human_desulfov R: 5’ CGCACATGTTKATGCAGC 3’; Tm 55.6°C 
Or 
dsrB_Human F: 5’ TGCGAYATYGCBGACAA 3’; Tm 52.0°C 
dsrB_Human R: 5’ RCACATGTTBAKGCAGCA 3’; Tm 52.9°C 
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2.8.4. Quantitative PCR (qPCR) 
To quantify SRB from human faeces using qPCR (Fuller et al. 2007), PCR primers dsrB_F1 and 
dsrB_R1 (Section 2.7.3) were used to first amplify the dsrB gene following the method as 
described in Section 2.7.1 above, except PCR products were eluted using sterile deionised H2O 
following PCR purification, quantified by Qubit (Section 2.6.4) and then the copy number was 
adjusted to 1010 using Copy Number Calculator http://scienceprimer.com/copy-number-
calculator-for-realtime-pcr. After a serial 10-fold dilution, they were then used as the qPCR 
template to have copy numbers between 100- 1010. SYBR green-based primers dsrB_Human and 
Human_desulfov (see Section 2.7.3) were used to generate standard curves against different SRB 
strains on the qPCR machine (ABI7500 Taqman). The qPCR standard curved experiment were 
performed using QuantiFast SYBR Green PCR kit (Qiagen); the qPCR reaction mix and reaction 
conditions are listed in Table 2.6. The standard curves were analysed using 7500 Software v2.0.6 
using the auto threshold cycle (Ct) value. The Ct value at the auto threshold were plotted against 
the log10 copy number of the starting template to deduce the r2 value of the linear regression and 
efficiency of the primers for each bacterial strain using the formula efficiency= 10(-1/slope)-1. 
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Table 2.6 a) qPCR reaction mix and b) reaction conditions. 
a 
Reagents volume added 
SYBR green master mix (Qiagen) 5 µl 
Human_desulfov forward primer (10 µM) 0.5 µl 
Human_desulfov reverse Primer (20 µM)* 0.5 µl 
UP H2O 2 µl 
DNA template 2 µl 
Total  10 µl 
*20 µM of reverse primer was used to ensure equal molar of Human_desulfov forward and 
reverse primer with 100% match. 
b 
Reaction temperature Duration No. of cycles 
95°C 5 min  
95°C 10 s 
x 40 
60°C 35 s 
95°C 15 s  
60°C 1 min  
95°C 15 s  
60°C 15 s  
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2.8.5. Genomic DNA extraction of SRB 
After bacterial cultures were grown, cells were centrifuged at 3000 x g for 10 min before 
performing genomic DNA extraction using the chloroform method (Bruce M. Pearson, personal 
communication). Supernatants were discarded and the pellets were resuspended in 1 ml of PBS 
before being transferred to a 2 ml screw-cap tube. The cell suspensions were further centrifuged 
at 13000 x g for 3 min at 4°C. Supernatants were discarded and the pellets resuspended in 400 µl 
elution buffer (EB) (10 mM Tris-Cl, pH 8.5). 70 µl 10% (w/v) sodium dodecyl sulphate (SDS) and 5 
µl 10 mg/ml proteinase K were then added to the resuspension, and then mixed by inversion 
before incubating at 65°C for 10 min. 100 µl 5M NaCl was mixed in to the samples and 100 µl of 
65°C -preheated 10% cetyltrimethylammonium bromide (CTAB) in 0.6 M NaCl was next added. 
The samples were vortexed until white suspensions were formed, and were then incubated at 
65°C for 10 min. Chloroform/isoamyl alcohol (24:1) (500 µl) was next added to the samples, 
vortexed for 10 s and then centrifuged at 13000 g for 5 min at 4°C. The upper aqueous phase was 
transferred to a fresh microcentrifuge tube, to which a 0.6 volume of isopropanol was added. 
Samples were mixed and incubated for at least 30 min before a 10 min centrifugation at 13000 g. 
The supernatant was discarded, and the pellet was washed with 500 µl of 70% (v/v) ethanol 
(precooled at 4°C). The samples were centrifuged again briefly, to remove the residual 
supernatant with a pipette. The pellet was air-dried and resuspended in 50 µl EB supplemented 
with 1 µl of 10mg/ml RNase A, and incubated at 37°C for 30 min. 5 µl of 3 M sodium acetate pH 
8.0 and 100 µl of ice-cold ethanol (pre-cooled at -20°C) were gently added at the side of the tube, 
and gently mixed by flicking the tube. The DNA was spooled onto a fine glass pipette tip and 
lightly dipped into a tube filled with 70% ethanol to wash the pellet. The pellet was then dissolved 
in 50 µl of fresh EB and the resulting DNA was stored at -20°C. 
2.9 Mouse model experiment 
2.9.1. Animal Model and experimental design 
The animal work was done under approved home office animal licence and was performed by a 
personal license holder (Devina Divekar). Consideration of animal welfare was conformed under 
home office guidelines to minimise harm on animals. 
Wild type C57BL/6J mice littermates were bred and caged at the Disease Monitoring unit 
(University of East Anglia, Norwich) until 8 weeks old before the experiment commenced. Faecal 
pellets were collected three days before the start of experiment to record baseline E. coli levels. 
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On the day of the experiment, 100 µl of LNPs were administered using oral gavage tubes (Linton 
Instrumentation) both at 0 h and 2 h, faecal samples were collected at each time point according 
to the dosing regimen (Table 2.7); faecal pellets were diluted 1:10 by pre-reduced PBS and 
vortexed for 60 s to obtain faecal slurry. The resultant samples were used for viable bacterial 
plate counting (Section 2.5.3), faecal water preparation for metabonomic analysis (Section 2.5.4) 
and phylogenetic analysis of bacterial communities using 16S rRNA gene sequencing (Section 2.6). 
Table 2.7 Details for each mouse experiments including treatment group, dosing regimen and 
faecal pellet collection. 
Mouse experiment Treatment groups Time points of 
oral gavage 
(100 µl) 
Time points for faecal 
pellet collection 
Experiment 1 Vehicle control (0.7% (w/v) 
saline);  
Scrambled LNP (15 µg/ml); 
LNP (15 µg/ml) 
0 h and 2 h 0 h, 2 h, 4 h, 6 h, 24 h 
Experiment 2 Vehicle control (0.7% (w/v) 
saline); 
LNP (3 µg/ml); 
LNP (15 µg/ml) 
0 h and 2 h 0 h, 4 h, 6 h, 8 h, 24 h 
2.9.2 Sample processing and storage conditions 
When the experiment ended at 24 h, mice were euthanised and dissected. Colon tissues were 
collected and stored appropriately for further analysis. Colon intestine was stored in Neutral 
buffer formalin (NBF) for paraffin tissue sectioning. Storage methods for each samples are 
described in Table 2.8. 
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Table 2.8 Sample processing for mouse experiment. 
Samples  Storage Pre-fill with 
Faecal pellet collection Room temperature  - 
Colon for histological analysis Shake O/N, then changed to 70% 
ethanol, rock for 30 min before 
changing 70% ethanol again and 
shake O/N, then store at 4°C until 
paraffin embedding 
4 ml 10% NBF 
 
Colon were dehydrated after initial fixation from NBF (see Table 2.8 above) and encased in tissue 
cassettes (Thermo Fisher Scientific), labelled using lead pencil and placed in metal racks. Tissues 
were then immersed in 70% ethanol to prevent them from drying out. Cassettes were left in the 
tissue processor (Leica ASP300S) overnight where tissues were cycled through 70%, 80%, 90% and 
100% ethanol, before xylene and paraffin wax (Paraplast) (Sigma-Aldrich), details of steps and 
duration can be found in Table 2.9. 
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Table 2.9 Reagents used for paraffin tissue processing. 
 Reagents used to immerse tissues Duration 
70% Ethanol 1 h 
80% Ethanol 1 h 30 min 
90% Ethanol 2 h 
100% Ethanol 1 h 
100% Ethanol 1 h 30 min 
100% Ethanol 2 h 
Xylene 30 min 
Xylene 1 h 
Xylene 1 h 30 min 
Paraffin wax 1 h 
Paraffin wax 2 h 
Paraffin wax 2 h 
The processed tissues were transferred to the embedding station (Leica EG1150H), cut into 
sections, positioned and then embedded in paraffin wax. The samples were cooled and stored at 
4°C before tissue sectioning.  
Cross sections of tissues embedded in paraffin were prepared with a thickness of 5 µm with a 
rotary Microtome (Leica RM2235) using disposable microtome blades (Thermo fisher Scientific), 
for downstream histological analysis. 
Haematoxylin and eosin staining 
Cross sections of the tissues having been cut were then placed in a glass slide container and 
stained by being immersed in solutions for a set period as follows: Briefly, samples were de-waxed 
in two separate containers containing Histoclear (National Diagnostics), for 5 min each, then the 
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tissue sections were rehydrated by using descending concentrations of ethanol (100%, 80% and 
70% respectively) for 2 min each. Slides were subsequently immersed in distilled water for 5 min. 
Slides were then stained in Haematoxylin (Sigma-Aldrich) for 5 min and the bluing step was 
performed by washing slides under running distilled water to allow haematoxylin colour to 
develop. Samples were then treated in 1% HCl (dissolved in 70% ethanol) for 15 s, then briefly 
rinsed in distilled water. Slides were then incubated in 0.1% sodium bicarbonate, and were gently 
rinsed under running distilled water for 5 min, before being stained with Eosin (Sigma-Aldrich) for 
30 s. The slides were dehydrated with ascending ethanol concentration (i.e. 70%, 80% and 100%) 
for 2 min each, before being immersed in Histoclear solution for 5 min twice in two separate 
containers. Excess Histoclear was tapped and wiped off on the slide without touching the tissues. 
A drop of Neo-Mount® mounting medium (Merck Millipore) was used on each tissue section 
before it was left to dry for a few hours, prior to being viewed on microscope. 
2.10 Statistical analysis 
GraphPad Prism 5.04 (GraphPad Software) was used to perform all statistical analyses in the 
thesis. All statistical analyses, unless stated below, were performed using one way ANOVA to 
compare the data across treatment groups, and Tukey-Kramer post test to compare all pairs of 
data, with the threshold for statistical significance set at P ≤ 0.05. 
Figure 3.5b 
Paired T-test (2-tailed) was performed with a threshold for statistical significance set at P ≤ 0.05. 
Figure 5.1 and 5.2 
Our primary hypothesis was that the effect of LNP’s antimicrobial activity against 
Enterobacteriaceae would be evident at 6 and 8 hours.  Change scores from time 0 to 6 (or 8) 
hours were calculated for each mouse by subtracting the log CFU/g value at 0 h from the value at 
6 (or 8) h. Log transformation was used to stabilise variances across groups and ensure normal 
distribution of scores within groups. One way ANOVA was used to compare the change scores 
across treatment groups, and Tukey-Kramer post test was used to compare all pairs of data, with 
the threshold for statistical significance set at p<0.05. 
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Chapter 3: Characterisation of 
nanoparticulate TFDs  
3.1. Introduction 
A new type of oligonucleotide-based antimicrobial is being developed by Procarta 
Biosystems Limited called Transcription factor decoy (TFD) (McArthur 2009b, McArthur 
2014, McArthur 2015, McArthur 2017). They consist of a short sequence of synthetic 
oligonucleotides that comprise the binding site for an essential bacterial transcription 
factor. When introduced within a bacterial cell, TFDs competitively inhibit the transcription 
factor from binding to its designated site on the bacterial DNA to alter the expression of the 
targeted gene (Mann and Dzau 2000) (Figure 3.1). 
 
Figure 3.1 The mechanism of transcription factor decoy (TFD) acting on transcription 
factors (TF) of interest. Transcription factors control gene expression by binding to specific 
sequences in the bacterial genome. TFD mimics the binding site and competitively inhibits 
the transcription factor to change gene expression, resulting in the killing of bacterial cells. 
 
As the negatively charged and sizable TFDs could not pass through the bacterial membrane 
into the cytoplasm by itself, the delivery is facilitated by forming self-assembling 
nanoparticles (NPs) using a bolaamphiphilic molecule called 12-bis-THA (Mamusa et al. 
2016) (Figure 3.2), which effectively binds to TFDs (resulting in a complex termed loaded 
nanoparticle (LNP) hereafter) and protects TFDs against nuclease degradation (Marin-
Menendez et al. 2017). The NPs transfect bacteria by binding to the prokaryotic-specific 
anionic phospholipids, cardiolipin and phosphatidylglycerol. In particular, cardiolipin has a 
crucial role in the structural integrity of the respiratory chain, as cardiolipin rafts are 
responsible for anchoring them in the membranes (Arias-Cartin et al. 2012). These lipids 
are highly conserved among bacteria and were shown to be consistently present in the 
membrane of pathogenic clinical isolates (Sohlenkamp and Geiger 2016), making these 
lipids good targets for bacterial delivery. 
TF 
TFD 
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a                                                                                     b 
      
Figure 3.2 Chemical structure of bolaamphiphilic lipid, bola-amphiphile a) 12,12’-
(dodecane-1,12-diyl)bis(9-amino-1,2,3,4tetrahydroacridinium) iodide ([12-bis-THA]I2); b) 
12,12’-(dodecane-1,12-diyl)bis(9-amino-1,2,3,4tetrahydroacridinium) chloride ([12-bis-
THA]Cl2) (Mamusa et al. 2016), used for the assembly of nanoparticle (NP). It consists of 
two identical polar head groups with delocalised cationic charges and associated with a 
quaternary ammonium joined by a dodecane chain.  
 
A TFD was designed to competitively inhibit Gram-negative sigma factor 54 (GNSig) from 
binding to RNA polymerase (Wigneshweraraj et al. 2008), transcription of genes that are 
essential for bacteria’s survival is therefore not activated and this in turn leads to cell 
death. Another TFD was designed to competitively inhibit the cyclic adenosine 
monophosphate receptor protein- fumarate and nitrate reductase (Crp-FNR) transcription 
factor of E. coli, which are highly conserved among Enterobacteriaceae (Korner et al. 2003) 
to control gene expression related to anaerobic respiration (Constantinidou et al. 2006).  
Structures of TFD 
To improve the stability of TFDs, TFDs are designed as different structures such as dumbbell 
(DB), hairpin (HP) and duplex, as different means of slowing down in vivo exonuclease 
degradation to prolong their efficacy within the bacterial cytoplasm (Figure 3.3). DB forms a 
monomeric circle with two stem-loops, and duplex contains phosphorothioate nucleotides 
(i.e. one of the non-bridging oxygens is replaced by sulphur at the phosphate backbone) on 
both ends of the oligonucleotide of each linear strand to prevent degradation and minimise 
the chirality effect from the duplex (Dias and Stein 2002). Whereas HP contains one stem 
loop and free 5’ and 3’ ends that are protected by phosphorothioate nucleotides.  
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Figure 3.3 TFD structures including dumbbell, hairpin and duplex with modifications to 
resist nuclease degradation. Asterisk, phosphorothioate nucleotides. 
 
For the purpose of this thesis, empty nanoparticle (ENP) consists of the delivery NP 12-bis-
THA; loaded nanoparticle (LNP) consists of both 12-bis-THA and TFD; and scrambled LNP 
(SLNP) consists of 12-bis-THA and a non-functional TFD. Hydroxypropyl methylcellulose 
(HPMC) is added to the nanoparticles (NPs) as an excipient and to prevent aggregation. 
To better understand the properties of these NPs, dynamic light scattering was used to 
evaluate the particle size of ENP and LNP. Minimum inhibitory concentration (MIC) 
experiments were conducted to investigate the minimal dose needed to have a biologically 
relevant antimicrobial effect on the targeted bacteria. To minimising NP aggregation and 
improving antimicrobial activity, amount of excipient used in the NP formulation was 
explored, as larger particle size prevents NPs from transfecting the bacterial cell. To further 
determine the ratio of LNPs that are non-aggregated for efficient antimicrobial activity, 
flow cytometry was performed to investigate the proportion of individual NPs incorporated 
with TFDs present in the NP formulation. The pendant drop technique is often used to 
characterise a surfactant’s ability to form particles. It is done by measuring the change in 
surface tension to determine the critical micelle concentration (CMC) - the minimum 
concentration of surfactants needed to form micellar/ aggregate structures (Burlatsky et al. 
2013). To characterise NP’s biological stability against DNases degradation, the robustness 
of different TFD structures will be tested by a time course study to determine the TFD 
structure to take forward for future in vitro testing. 
3.2 Materials and Methods 
Protocols used in this chapter are described in Chapter 2 Section 2.1 Culturing bacteria, 
2.2.1 Making TFDs and NPs, 2.2.2 Minimum inhibitory concentrations (MIC) and minimum 
bactericidal concentrations (MBC), 2.3.1 Dynamic light scattering for NP size measurement, 
2.3.2 Flow cytometry and fluorescence-activated cell sorting (FACS), 2.3.3 Time course 
stability study using exonuclease treatment against TFD and 2.3.4 Pendant Drop to 
measure surface tension of NPs. For Section 3.3.1- 3.3.3, [12-bis-THA]I2 was used for 
making NPs. 
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3.3 Results 
3.3.1 Dynamic light scattering for NP size measurement 
To investigate the size distribution of NPs and their respective monodispersity, dynamic 
light scattering (DLS) was performed from 4 separate batches of NPs. DLS measures 
Brownian motion and relate this to particle size (Weatherbee et al. 2017). A typical 
distribution is shown in Figure 3.4, plotting correlation coefficient against time, and 
demonstrated the presence of aggregation as the base line did not touch the y-axis (Figure 
3.4).  
 
Figure 3.4 Representative correlation curve of 12-bis-THA with 0.1% hydroxypropyl 
methylcellulose (HPMC) complexing with transcription factor decoy (TFD), forming loaded 
nanoparticles (LNPs). 
 
Using the NP formula with 0.1% HPMC, empty nanoparticles (ENPs) and loaded 
nanoparticles (LNPs) had polydispersity indexes (PDI) of 0.41 nm and 0.33 nm respectively. 
As the PDI value is > 0.2, the particle size peak with the highest intensity was used to 
estimate the NP size due to indication of polydispersity. The particle sizes of ENPs and LNPs 
were measured from the hydrodynamic diameter, the diameter of a hypothetical sphere 
that mimics the way the measured sample diffuses, of the size 477.79 ± 53.47 nm and 
291.58 ± 51.52 nm (Table 3.1); the particle size peak with the highest intensity was used to 
determine the size of the NPs to represent the majority of the sample.  
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Table 3.1. Particle size measured by DLS Malvern Zetasizer Nano ZS. Average of 4 batches 
of NP made from 12-bis-THA were used for the analysis. Particle size is obtained from size 
peak intensity as polydispersity index > 0.2. ENP, empty nanoparticles; LNP, loaded 
nanoparticles; HPMC, hydroxypropyl methylcellulose; GN Sig HP TFD, Gram negative sigma 
factor hairpin TFD. 
Sample 
 
Polydispersity index Particle Size Peak 
  
Mean (nm) 
 
S.D.  
 
Mean (nm) 
 
S.D. 
ENP + 0.1% HPMC 
 
0.41 0.12 477.79 
 
53.47 
LNP + 0.1% HPMC (GN Sig HP TFD) 
 
0.33 0.18 291.58 
 
51.52 
3.3.2. Minimum inhibitory concentration and minimum bactericidal 
concentrations of LNPs 
Minimum inhibitory concentration 
To investigate the efficacy of LNPs in exerting antimicrobial activity, the minimum 
inhibitory concentration (MIC) of LNPs were tested against E. coli, whereby a fixed ratio of 
TFDs were added to 12-bis-THA.  
LNPs were tested with and without the addition of bulking agent/excipient hydroxypropyl 
methylcellulose (HPMC) to determine the optimum formulation of NPs with the highest 
antimicrobial activity. The use of GN Sig TFDs did not show significant difference in MIC 
between each NP pair (i.e. ENPs and LNPs with the same amount of HPMC), and was only 
significant reduced (P ≤ 0.05) when HPMC-containing LNPs were compared to ENP (Figure 
3.5 a). No significant difference (P > 0.05) in MIC was observed between LNPs with 1% and 
0.1% HPMC, implying 0.1% HPMC is sufficient to improve LNP formulation. 
To improve specificity against Enterobacteriaceae, Crp-FNR TFD was used against E. coli 
instead in a separate experiment. Also, to assess the TFD-specific activity with comparable 
NP structure/size, an LNP loaded with a scrambled sequence of TFD i.e. scrambled-TFD 
loaded nanoparticle (SLNP) was tested instead of ENPs as a more appropriate control to 
assess the TFD specific activity. It was shown that LNPs with 0.1% HPMC had a significantly 
lower MIC (P ≤ 0.01) compared to SLNPs with 0.1% HPMC (Figure 3.5 b), confirming the LNP 
activity was specific to the functional sequence of TFD against E. coli. As LNPs with 0.1% 
HPMC was more stable than with 1% HPMC (Michael McArthur, unpublished data), the LNP 
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formula containing 0.1% HPMC was taken forward for future in vitro tests along with SLNPs 
as a control. 
 
 
Figure 3.5. Minimum inhibitory concentration of empty nanoparticles (ENPs), loaded 
nanoparticles (LNPs) and scrambled loaded nanoparticles (SLNPs) to exert antimicrobial 
activity. A fixed volume of E. coli DH5α cells were added to each of the wells of a microtitre 
plate and were incubated at 37˚C with shaking overnight, after which the visible growth/no 
growth in each well was recorded. a) A representative MIC experiment of ENPs and LNPs 
loaded with Gram negative sigma factor (GN Sig) TFD in formulation with and without 
excipient HPMC. Means of 3 biological repeats were calculated ± standard deviation (SD); 
b) Minimum inhibitory concentrations of 12-bis-THA of SLNP and LNP using formulation 
with 0.1% HPMC (loaded with Crp-FNR TFD) against E. coli DH5α. The results are means of 3 
technical repeats with 3 biological repeats in each were calculated ± SD. Single and double 
asterisks denote P ≤ 0.05 and P ≤ 0.01 respectively. 
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Minimum bactericidal concentration 
Minimum bactericidal concentration (MBC) was performed to determine the mechanism 
by which the NPs work, whether they act by preventing further bacterial growth (i.e. 
bacteriostatic) or by killing the cell (i.e. bactericidal). It was shown that ENP, SLNP and LNP 
(using formulation with 0.1% HPMC) were all bactericidal at 0.9275 µg/ml, as there was a >  
log10 3 significant decrease in viable cell counts (Figure 3.6) compared to untreated samples 
(P ≤ 0.001), indicating that the NPs’ antimicrobial mechanism of action were bactericidal.   
 
 
Figure 3.6. Minimum bactericidal concentrations of NPs. Colony counts of E. coli 
significantly decrease (P ≤ 0.001) from different NP treatments compared to untreated E. 
coli control. ENP, SLNP and LNP treatments were bactericidal at 0.9275 µg/ml using NP 
formulation with 0.1% HPMC. ENP, empty nanoparticles; SLNP, scrambled nanoparticles; 
LNP, loaded nanoparticles. Means of at least 2 repeats calculated ± SD. Triple asterisks 
denote P ≤ 0.001. 
3.3.3. Flow cytometry and fluorescence-activated cell sorting (FACS) of LNP 
formulations 
To investigate the formulation that yields the highest theoretical biological activity, the 
aggregation of NPs should be minimised. Different NP formulations were explored and 
physically characterised via flow cytometry to elucidate the scattering characteristics 
between aggregates and non-aggregates in different NP formulations. FACS was used to 
investigate the yield of TFD-bound LNPs and determine amount of aggregates and their 
properties once they were segregated from the non-aggregated population. Furthermore, 
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FACS was also performed to determine the efficiency of Acridine Orange and SYBR green to 
fluorescently stain TFD as an alternative to using fluorescent-labelled TFDs. 
The fluorescence profiles of LNPs loaded with fluorescent-labelled TFDs were compared 
between two NP formulations, LNP and LNP + 0.1% HPMC, by the presence of high 
fluorescein isothiocyanate (FITC) fluorescence indicating aggregation of NPs. ENP and ENP + 
0.1% HPMC had a small amount of low level auto-fluorescence on the FITC and Brilliant 
Violet scale (Figure 3.7 a) due to the presence of 12-bis-THA. Less aggregated NPs were 
detected in the LNP + 0.1% HPMC compared to the LNP formulation, as indicated by a 
higher percentage of particles with low FITC intensity (particles with increased FITC 
intensity denote aggregation); LNPs + 0.1% HPMC had almost double the amount of non-
aggregated NPs compared to LNPs (Figure 3.7 b), indicating the presence of HPMC in the 
NP formulation markedly reduced the amount of NP aggregation.  
The effects of time on the aggregation of NPs were also studied by leaving the NPs to stand 
overnight, before repeating flow cytometry analysis the following day. LNPs + 0.1% HPMC 
had twice the amounts of non-aggregated particles compared to the results from the same 
sample obtained the day before, confirming the disaggregation of NPs over a 1-day period 
(Figure 3.7 c). To analyse the non-aggregated and aggregated NP population individually, 
FACS was performed to separate the two populations and they were re-analysed on the 
flow cytometer. It was shown that, after sorting, the aggregated NPs can disaggregate into 
smaller, non-aggregated particles, whereas non-aggregated NPs mostly remained in the 
non-aggregated gated area, with only a very small portion shifting to the aggregated-gate.  
This finding showed that NPs were dynamic and the aggregation status was reversible, with 
the tendency for the aggregated NP population to disassemble into individual particles. 
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Figure 3.7 HPMC decrease LNP aggregation in flow cytometry and fluorescent activated cell 
sorting (FACS). a) controls showing ENPs contain low levels of autofluorescence b) 
comparison of LNPs and LNPs + 0.1% HPMC fluorescence profile loaded with alexa488-
flourescent TFD; c) left: Profile of LNPs + 0.1% HPMC (loaded with alexa488-flourescent 
TFD) after 24 h; the populations gated within the aggregated and non-aggregated gates 
were sorted by FACS in HPMC-lined collection tube) and reanalysed using flow cytometry; 
middle: sorted cells originated from the non-aggregated gate; and right: sorted cells 
originated from the aggregated gate. Gates show location of particles before sorting. 
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When collecting the sorted population from FACS, it was noticed that when the sample 
collection tube was coated with HPMC (Figure 3.7 c) or bovine serum albumin (BSA) (Figure 
3.8 a), the number of sorted LNPs were higher than when samples were sorted with foetal 
bovine serum (FBS)-coating (Figure 3.8 b), as HPMC and BSA act as a buffer and exert a 
protective effect against NP degradation as they enter the collection tube with force.  
In contrast, when NPs were sorted into FBS-coated collection tubes, fewer NPs were 
collected compared to HPMC-or BSA-lined tubes. From the TFD stability experiment, FBS 
was used as a source for exonuclease for TFD degradation, it is therefore expected that 
TFDs were degraded by FBS as they came in contact with the NPs. 
 
 
Figure 3.8 Aggregates profile of LNPs with Alexa-488-fluorescent TFD in 0.1% HPMC, a) 
sorted in BSA-lined tube b) sorted in FBS-lined tube. Gates show location of particles before 
sorting, showing changes in the fluorescent profile of the aggregates. 
 
Apart from using fluorescently labelled TFDs, other methods of TFD staining, DNA dye SYBR 
green or Acridine Orange (with positive fluorescence on the FITC scale), were compared to 
see whether they would bind specifically to TFD. SYBR green did not show any fluorescence 
profile with TFD. It was shown that Acridine Orange bound strongly to TFD (Figure 3.9 a) 
and had some non-specific binding to ENPs (Figure 3.9 b), though Acridine Orange’s 
fluorescence profile for TFD and ENP can be differentiated, characterised by a lower 
intensity of Acridine Orange fluorescence for TFD and higher fluorescence for ENP. 
Interestingly, LNP’s FITC-fluorescence profile closely resembled those in ENP (Figure 3.9 c) 
and not a combined profile of TFD and ENP, suggesting that Acridine Orange either cannot 
get into the NP to interact with TFD or that the TFD-Acridine Orange fluorescence profiles 
were masked by the TFD-NP complex.  
To determine which hypothesis was correct, LNPs were treated with sodium taurocholate 
(NaTC) to break the NPs apart in the hope to reveal separate TFD and NP fluorescence 
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profile within LNP. The TFD and ENP population could be differentiated on the histogram of 
the broken LNP sample, revealing two distinct FITC-positive peaks for TFDs and ENPs 
(Figure 9 d). This finding suggests that Acridine Orange could be used as a green fluorescent 
marker for NPs and TFDs for further characterisation in the future.  
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Figure 3.9 Characterisation of ENP and LNP using flow cytometry. SYBR green and Acridine 
Orange were used to stain DNA and NP to comparatively assess suitability for fluorescently 
stained TFDs. Acridine Orange and SYBR green fluorescence profile of a) TFD; b) ENP; c) 
LNP; d) LNP broken by sodium taurocholate.  
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3.3.4. Measurement of surface tension of 12-bis-THA by pendant drop 
analysis 
To characterise the concentration of 12-bis-THA needed to form NPs for TFD encapsulation, 
critical micelle concentration (CMC), the concentration of surfactant above which 12-bis-
THA starts to form NPs, was measured via changes of surface tension with time at different 
concentrations of ENPs.  
At low concentration, the amphiphilic molecules arrange themselves near the surface of 
the water, with the hydrophobic end held above the surface while submerging hydrophilic 
head in the water, showing only little changes in surface tension (Chakraborty et al. 2011). 
The surface tension begins to decrease as the concentration of surfactant increases until 
the surface become saturated with surfactants. At this point, surface tension no longer 
decreases and reaches a stable level i.e. when 12-bis-THA begin to self-aggregate into NPs. 
CMC is defined as the concentration at which increased surfactants i.e. 12-bis-THA levels no 
longer reduces the surface tension when the surface is saturated (Burlatsky et al. 2013), 
which indicates the concentration at which 12-bis-THA is needed to form NPs. As 
surfactants at higher concentration reaches surface saturation within a short period 
compared to diluted samples, 12-bis-THA at various concentrations were measured 
through a fixed period to determine the CMC. 
Two versions of ENPs, ENP_I and ENP_Cl (made from amphiphilic molecules [12-bis-THA]I2 
and [12-bis-THA]Cl2 respectively) were tested. As water has a surface tension of ~72.6 
millinewton (mN)/meter (m) (Chakraborty et al. 2011), a decrease in surface tension value 
indicates surface activity in the samples. Large variations in surface tension measurements 
were seen between repeat measurements when the samples were measured sequentially.  
To address this problem, the needle that dispense the sample drop was washed thoroughly 
between each measurement to remove the remains of all surface active materials. Also, 
the volume of sampling drop was considerably decreased by evaporation through time, 
leading to invalid measurement of surface tension (Picknett and Bexon 1977). To reduce 
the rate of evaporation, the sampling drop was encased in a lidded-cuvette and held close 
to the meniscus of the water filled within the cuvette to create a humid atmosphere (Berry 
et al. 2015). The experiments were conducted under a temperature-controlled 
environment to reduce the effects of temperature fluctuation during long sampling period 
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and the additional insulation controls were in place to prevent the expansion and 
contraction of the glass syringe to ensure the size of the sampling drop is consistent.  
In Figure 3.10 a, the surface tension of ENPs_I at 0.18 mM decreased from 70 mN/m to 
65.4 mN/m within a 15 minute period, implying the presence of surface active material at 
this concentration. However, when the ENPs_I were diluted no surface activity was 
observed. In Figure 3.10 b, 0.4 mM and 0.18 mM of ENPs_Cl had the same decline rate in 
surface tension, which may indicate that, at these concentrations, the surface was close to 
being saturated. It was predicted that the surface tension would plateau within 1.5 h, but 
the surface tension continued to decline even after 4 h (data not shown). ENPs_I only 
showed surface active properties at the highest concentration possible (0.18 mM), 
indicating [12-bis-THA]I2’s poor surface activity. However, this concentration of NPs was 
not enough to obtain a flat base line surface tension level to determine CMC.  
Comparing [12-bis-THA]I2 and [12-bis-THA]Cl2, the latter was more surface active as 
indicated by the decrease in surface tension at lower concentration, suggesting a lower 
concentration of [12-bis-THA]Cl2 may be needed to form NPs. Even though the control 
parameters improved surface tension measurements and the repeatability of 
measurements, the point at which the surface tension no longer decreased was still not 
observed in both ENPs_I and ENPs_Cl before excessive evaporation took place, the CMC 
value therefore could not be deduced from the current experimental setting. This may 
suggests that [12-bis-THA]I2 and [12-bis-THA]Cl2 were not very surface active and a 
prolonged sampling period is required for surface tension to reach a stable level to obtain 
the CMC value. The measurement of surface tension to identify the CMC may not be 
suitable for the characteristics of 12-bis-THA. 
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Figure 3.10 Surface tension of a) ENP_I and b) ENP_Cl samples using Pendant drop with 
minimum 2 repeats at different dilutions over time, each line is an average of duplicate 
data. Blue: 0.4 mM: Red: 0.18 mM; Green: 0.018 mM; Purple: 0.0018 mM. 
3.3.5. Time-course stability study using exonuclease treatment against TFD 
To investigate the duration over which the TFDs were resistant against biological 
degradation, foetal bovine serum (FBS) containing exonucleases was used as a source for 
non-specific digestion to mimic physiological conditions. The stability of different TFD 
structures was tested via a time-course degradation; it was shown that the dumbbell 
structure was the most robust TFD structure, as DB had the strongest band intensity 
compared to HP and duplex in the presence of FBS at 300 minutes (Figure 3.11).  The 
second most robust structure was HP while duplex was the structure most prone to 
degradation. This indicated that under physiological conditions, TFDs were robust enough 
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to withstand enzymatic degradation for 6 h to prolong efficacy. TFDs were degraded after 3 
days in the presence of FBS, whereas the control TFDs without FBS treatment remained 
intact, indicating the structures were stable and robust at 37°C. 
 
 
Figure 3.11 Agarose gel image of time course susceptibility study of TFDs Duplex (with 
phosphorothioate oligodeoxynucleotides terminal modifications), Dumbbell (DB) and 
Hairpin (HP) in the presence of fetal bovine serum (FBS) (which degrades TFDs). It is shown 
that DB survived up to 360 min in the presence of FBS, followed by HP which has a more 
visible band from 60 min onwards compared to duplex. 
3.4 Discussion 
Determination of NP size for targeted delivery in the human body 
Size determination is an important physical characteristic to consider as NP size affects 
absorption and increases target efficiency in the human body (Youshia and Lamprecht 
2016). Smaller particles (10-100 nm) tend to be absorbed within the bloodstream and 
accumulate within the liver and spleen with wider organ distribution (De Jong et al. 2008), 
whereas larger particles (300 nm or more) do not penetrate the blood stream and remain 
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in the intestine and colon (Jani et al. 1990, Bergin and Witzmann 2013). Having the correct 
particle size for the intended target location is therefore crucial for effective delivery. As E. 
coli reside in the lower intestine (Katouli 2010), the desirable size would be around 300 nm 
(Bergin and Witzmann 2013), which matches the hydrodynamic diameter of LNPs + 0.1% 
HPMC measured in DLS, suggesting LNPs made with [12-bis-THA]I2 were appropriate for 
oral administration into the GI tract. 
Comparing LNPs made with [12-bis-THA]I2 in this study to those made with [12-bis-THA]Cl2 
(Marin-Menendez et al. 2017), the LNPs_Cl were much smaller in size at 180 ± 10 nm. [12-
bis-THA]I2 is soluble primarily in DMSO and methanol and scarcely soluble in water, 
whereas [12-bis-THA]Cl2 is readily soluble in water and implies increased biological activity 
(Mamusa et al. 2016). [12-bis-THA]I2 tends to precipitate and form crystal as it become 
saturated when dispersed in water after vigorous shaking. Nonetheless, as the [12-bis-
THA]I2 formulation was already established, it was used for the E. coli related experiments; 
[12-bis-THA]CI2 was then utilised in new LNPs designed specifically against sulphate 
reducing bacteria (Chapter 6). 
Due to electrostatic interactions between the anionic nanoparticles and TFDs (Marin-
Menendez et al. 2017), the LNPs are smaller in size compared to ENPs as expected, which 
evidently showed successful formation of TFD and [12-bis-THA]I2. NP polydispersity was 
indicated as the PDI value was > 0.2, though a PDI between 0.3-0.4 often indicates good NP 
synthesis when made by injection method with little aggregation, it can be assumed that 
the NPs were quality assured for the use in downstream biological experiments such as 
MIC/MBC and batch model experiments (see Chapter 4). Although no correlation has been 
found between particle size and biological activity for NPs from Procarta™ (unpublished 
data), DLS measurements are done routinely after NPs are made in order to provide 
information about their physical characteristics. 
TFD-specific activity was observed against both GN Sig and Crp-FNR TFD against E. coli 
As indicated by the MIC results, TFDs evidently exert specific antimicrobial activity against 
E. coli comparing LNPs with ENPs and SLNP controls. Apart from particle size, drug-to-
polymer ratio was also important to the drug formulation (Maderuelo et al. 2011). It was 
shown that HPMC decrease the MIC of LNPs, indicating the effectiveness of HPMC in 
increasing LNPs’ antimicrobial activity. This is as expected as the concentration of the 
polymer can hugely influence the physiochemical properties of the drug formulation 
(Agarwal and Murthy 2015). Even though LNPs with 1% HPMC and 0.1% HPMC had similar 
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MIC, LNPs with a lower ratio of HPMC at 0.1% were found to be more stable and allow 
more rapid release of drug content with less swelling for optimal drug release rate (Michael 
McArthur, unpublished data). LNPs made with 0.1% HPMC and FNR TFD was therefore 
selected to be used in the in vitro batch culture fermentation experiments (see Chapter 4). 
As the NPs are prepared manually using the injection method, variations can occur 
between runs, which may explain why the TFD-specific activity may be seen in some 
sample runs and not others. Relatively small changes in LNP MIC values could be due to 
batch to batch variation and handling difference in NP preparation. However, it is still a 
good basis for the improvement of TFD specificity. Investigating continuous growth curve 
data may be a good alternative method to elucidate any differences in the modes of action 
between ENPs and LNPs. 
HPMC improved LNP_I by reducing aggregation 
By comparing LNP_I formulations with and without the HPMC via flow cytometry, it was 
shown that LNPs + 0. 1% HPMC consisted of fewer aggregates compared to LNP. This is as 
expected as HPMC is a known excipient and a component widely used for controlled-
delivery in oral formulations in pharmaceutical industries (Osorio et al. 2011, Nokhodchi et 
al. 2012). HPMC is generally considered safe for human consumption as it is also used in 
the food and cosmetic industries, with desirable properties including being chemically inert 
and physically stable in normal conditions (Joshi 2011). This makes HPMC a great NP 
stabiliser (Ghosh et al. 2013) to be used in conjunction with the active ingredients in LNPs – 
12-bis-THA and TFDs – to improve stability and prevent aggregation in this antimicrobial 
formulation.  
Aggregation of NPs was reversible in FACS 
When the samples were passed through FACS to separate the NP aggregates from the non-
aggregated population, it was surprising that there was a change in the fluorescence profile 
in the aggregated population; some of the aggregates have in turn fallen into the non-
aggregated population. This could be explained by the fact that as aggregates could be 
small enough to be identified as one distinct cell in flow cytometry, there may be a larger 
majority of aggregates compared to the non-aggregated population; some aggregates may 
have disaggregated during the process of being sorted and mixed with the sheath fluid, the 
dilution and mixing action in the FACS machine could lead to further dissociation of NPs.  
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The presence of different linings of the collection tube result in different NP recovery; the 
recovery of NP events from HPMC and BSA-lined tubes were higher than those lined with 
FBS, as FBS are known to degrade TFD. From the fluorescence profile of the sorted 
aggregate population, it was suggested that NP aggregation is reversible; NP aggregates 
tend to dissipate into individual NPs instead of aggregating over time. This may provide an 
explanation to why NPs may increase antimicrobial activity over time. 
Acridine Orange can differentiate TFD and LNP fluorescence profile with NaTC treatment 
TFD was only released when LNP were broken by NaTC treatment, showing that TFDs were 
intact within LNPs and complexed with [12-bis-THA]I2 without signs of segregation from the 
[12-bis-THA]I2. When comparing different DNA-binding fluorescent dyes i.e. SYBR green 
and Acridine Orange, Acridine Orange appeared to bind to both TFD complexed with LNPs 
(at higher fluorescence intensity) and TFD released from NaTC treatment (at lower 
fluorescence intensity in comparison). The presence of distinct fluorescence profiles 
between the two groups would make Acridine Orange a suitable fluorescent marker for 
NPs and TFD for flow cytometry in the future. 
It is interesting that we were not able to see a distinct shift in fluorescence profile with 
SYBR green when staining TFD. Being an intercalating agent that is designed to bind double 
stranded DNA, it was expected to have specific binding activity with TFD, as previously 
tested on gel electrophoresis. This could be due to low intensity of fluorescence that is not 
distinct enough to differentiate from the background against the non-fluorescent cells. 
Pendant drop is not suitable for the CMC measurement of 12-bis-THA 
CMC is an important parameter for drug characterisation as this allows us to determine the 
minimum concentration of 12-bis-THA to form NPs, to ensure the integrity and 
functionality of LNPs in in vitro and in vivo settings. Despite trying different experimental 
settings and incorporating better controls to maintain temperature and prevent 
evaporation, it was not possible to obtain the baseline surface tension value to determine 
CMC of ENPs using the pendant drop method, as they showed no signs of surface 
saturation.  
The measurement of surface tension to evaluate CMC appeared to be unsuitable due to 
the properties of ENPs, as similar results were obtained by Procarta™ when determining 
CMC of NPs using surface tension (unpublished data). The surface activity was so low that 
we cannot derive the CMC before other factors e.g. evaporation/draught become a 
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dominating factor that further decreases surface tension. Changes in the structural 
arrangement of 12-bis-THA on the surface of the drop may explain why, as the volume of 
drop decreases, the surface tension continued to decrease (i.e. the surface still hasn’t been 
saturated). It was only possible to get similar results for the first two repeats of a sample 
(except samples with no surface activity), and has been shown repeatedly with different 
batches of ENP. ENPs may have rapid changes in surface properties over a short period of 
time and it was therefore not possible to obtain reproducible results within the sampling 
period.  
Relating the ENP_I data to the CMC results obtained previously from Nanosight (CMC at 
0.0018 mM) and DLS (CMC at 0.075 mM) by Procarta Biosystems Limited (unpublished 
data), it is surprising that no surface activity was shown at 0.018mM ENPs_I with pendant 
drop as particles were formed previously at this concentration. We would expect 0.18mM 
ENPs_I to be saturated with surfactants with no further decrease in surface tension but it 
was not the case.  
Publications from a different research group have found similar difficulty in obtaining CMC 
or critical aggregate concentration (CAC) from bolaamphiphiles in solution (Menger and 
Wrenn 1974, Yiv et al. 1976). The unique properties of Dequalinium makes determining the 
precise point of transition between monomer to aggregate difficult using methods such as 
isothermic titration calorimetry, laser light scattering and Monte Carlo simulations (Lasch 
and Hildebrand 2002). When a similar pendant drop experiment was repeated by 
coworkers (Mamusa et al. 2016), the results confirmed with our experimental finding that 
the equilibrium plateau was not obtainable within the experimental time frame despite a 
decrease in surface tension being observed.  Other techniques such as DLS, static light 
scattering were also used to determine CMC yet no conclusive results had been drawn.  
The preferred HP TFD structure was stable against exonuclease degradation 
The structures of the TFDs were also investigated for their essential stability against 
nuclease degradation within the bacterial cell. DNA structures including dumbbell (Escaja et 
al. 2003), hairpin (Bikard et al. 2010) and duplex containing phosphorothioate nucleotides 
(Eckstein 2014) were found naturally in bacterial DNA, which made them good candidates 
for antibacterial therapy. However, they are also likely to experience bacterial degradation 
as there are mechanisms in place to recycle the damaged host material.  
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We were pleasantly surprised that the TFD structures can withstand prolonged degradation 
to both exo- and endo-nuclease contained within FBS (Keum and Bermudez 2009). As the 
TFD structures were designed to protect against exonucleases degradation, the general 
degradative effect of FBS was regarded to be caused by endonucleases. 
In vitro digestion studies have demonstrated that dumbbell TFDs (a closed monomeric 
circle) had better structural integrity than the hairpin and duplex structures. The curvature 
of the loops act as a means of protection as this prevents degradation from the 3’ end 
(Wittig et al. 2002), this may explain why the dumbbell structure is the most resistant 
against enzymatic attack as 3’ ends were not available for exonucleases to act upon. 
However, dumbbell formation is time consuming and may lead to large amounts of 
wastage on malformed byproducts, and are therefore not preferred. 
On the contrary, the TFD duplex containing only three phosphorothioate internucleotide 
linkages on each end, was least resistant against degradation, as serum consists of heat-
stable nucleases (von Kockritz-Blickwede et al. 2009) that can degrade oligonucleotides 
(Segal et al. 1992). Furthermore, phosphorothioate-containing unmethylated CpG 
nucleotides can trigger mammalian immune response (Hacker et al. 2002) as prokaryotic 
DNA contains CpG dinucleotide at a much higher frequency than eukaryotic DNA (Cardon 
et al. 1994, Bode et al. 2011). The duplex TFD is therefore counterproductive for treating 
microbiome dysbiosis if repeat dosing were to be given and was therefore not taken 
forward for further testing. 
Although the TFD hairpin, containing a stem loop and phosphorothioate linkages, was less 
stable than the dumbbell, it was more resistant to degradation than the duplex as it had 
substantial resistance due to containing both modifications. Overall, hairpin is the 
preferred TFD structure due to the ease of formation, less wastage and relatively good 
stability, therefore was used in future experiments. Being biodegradable also makes TFD 
advantageous as there will be less concerns about the adverse effect of undigested DNA 
within the host body (Kawane et al. 2014). The ability for LNPs to survive in harsh acidic and 
enzymatic environment through the gastrointestinal tract before reaching its bacterial 
target is also an important consideration. It would be interesting to determine LNPs’ 
stability in bodily fluids such as amylase, pancreatic acid and stomach acid to investigate 
the likelihood that LNPs would be remain intact when testing in vivo experiments. 
To conclude, LNPs made with [12-bis-THA]I2 + 0.1 % HPMC, with an appropriate 
hydrodynamic diameter to target the colon, were the most biologically and physically 
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optimal formulation. The preferred HP TFD structure was robust against nuclease 
degradation for up to 6 h. TFD-specific activity was observed compared to ENP and SLNP 
against E. coli, whereby SLNP was considered a better matched control for LNP in future in 
vitro experiments. The current experimental set up was not suitable to obtain CMC of 12-
bis-THA. Combining the flow cytometry and MIC data, a lower concentration of 0.1% HPMC 
was therefore used instead of 1% HPMC to reduce aggregation and enhance biological 
activity. LNP_I + 0.1 % HPMC will be used for downstream in vitro and in vivo experiments 
e.g. batch model fermentation against E. coli. 
  
 
 
 
 
 
 
TFD specific targeting against E. coli 
Chapter 4 
 
  
TFD specific targeting against E. coli 
 
78 
 
Chapter 4: TFD specific targeting against 
Enterobacteriaceae 
4.1. Introduction 
Antimicrobial resistance incidence has become more prevalent and there is an ever-increasing 
need for new antimicrobials (Penchovsky and Traykovska 2015). One of the novel approaches is 
oligonucleotide therapeutics, to which selected bacteria are targeted at the genetic level within 
the cytoplasm. The use of antisense technology allows the inhibition of bacterial mRNA from 
being translated, however, a very high concentration is required for efficacy. The inhibition of 
transcription by blocking a transcription factor from binding to its consensus site is therefore a 
more attractive option. Oligonucleotide copies of the DNA binding site, named Transcription 
Factor Decoys (TFDs) (McArthur 2009b, McArthur 2014, McArthur 2015, McArthur 2017), 
competitively inhibit transcription factors from turning on essential bacterial genes in order to 
exert antimicrobial activity. A delivery system is also utilised to facilitate TFD delivery by 
encapsulating them with a lipid molecule (12-bis-THA) to form loaded nanoparticles (LNPs). These 
protect the TFDs from enzymatic degradation and deliver the bulky oligonucleotides to the 
bacterial cytoplasm (Marin-Menendez et al. 2017).  
Gram-negative bacteria have become a major concern to the general public as complexity of the 
bacterial outer membrane makes it difficult for antimicrobials to penetrate. As 
Enterobacteriaceae is a family of bacteria that include some of the most challenging species of 
pathogenic bacteria that require urgent attention including the development of new antimicrobial 
treatments (World Health Organisation 2017). In this study, E. coli was used as a model organism 
for Enterobacteriaceae infection, which is commonly found in the healthy gut microbiota in 
human (Hooper and Gordon 2001) and its overgrowth is associated with Crohn’s disease (Lupp et 
al. 2007, Garrett et al. 2010). The aim of the study was to determine whether a TFD can be 
developed to selectively remove E. coli, and other Enterobacteriaceae, as a demonstration of 
microbiome engineering.  
A TFD that binds and competitively inhibits cyclic AMP receptor protein- fumarate and nitrate 
reductase (Crp-FNR) transcription factor was used in this study. It is highly conserved amongst 
Enterobacteriaceae (Korner et al. 2003) to regulate respiration and its stress response against 
host immune response (Unden and Schirawski 1997). Moreover, even though homologues of Crp-
FNR exist in other bacterial families, including those comprise obligate anaerobes, the 
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corresponding binding site sequences are different to those in Enterobacteriaceae and have 
different functions all together, making Crp-FNR a good genomic target to selectively modify 
Enterobacteriaceae levels in the gut microbiota (Matsui et al. 2013).  
The three main aims of the study were to 1) investigate TFD internalisation within E. coli, 2) to 
identity the optimum dose of LNP for bespoke bacterial targeting and 3) to test the TFD efficacy in 
the in vitro gut microbiota setting. The main experimental approach for each aim is detailed 
below.  
Confocal scanning microscopy experiment 
To visualise whether TFDs can penetrate bacteria cell membrane and transfect E. coli, confocal 
laser scanning microscopy was used to explore different cross-sections of the bacterial cell with 
adjustable depth of field. Confocal microscopy is a superior technology to wide field microscopy 
for biological samples as dichroic mirrors not only separate the excitation and emission light, they 
also allow the separate detection of light of different wavelengths (Jonkman and Brown 2015). 
The presence of a pinhole eliminates background haze and allows only the focal point to be visible 
on the objective, while the scanning mirrors rapidly and repeatedly scan one pixel at a time to 
produce a complete scanning image of the sample at the same depth of field (Prasad et al. 2007). 
Together this allows the build-up of 3-dimensional samples by scanning through the sectioning 
depths of the sample layer by layer to visualise intact bacterial cells in situ without physically 
slicing the bacterial cell. 
Dosing determination experiment 
In chapter 3, we determined the MIC of LNP + HPMC formulation against E. coli. In order to 
translate the dosage needed from a single culture to an in vitro batch model, experiments to 
ensure the LNP dose is high enough to exert antimicrobial activity were performed. Transitional 
experiments were designed that looked at the dosing proportions, different doses of LNPs were 
added to human faecal microbiota samples to estimate dosing required by altering the NP: human 
microbiota ratio. As a control, scrambled loaded nanoparticles (SLNPs), which are NPs loaded with 
TFD with a matching but non-functional scrambled sequence, were used to compare TFD-specific 
activity against LNPs. Whereas ‘control’ was composed of all the reagents used in the formulation 
of LNP except the NP and TFD as a base line control.  
In the dosing determination experiment, the 1x dose equates to 0.66% (v/v) dose of total batch 
media volume, with doses up to 90x being tested in triplicate in order get a better idea of the 
optimal dose for the batch model experiment. The experiments were set up to mimic the batch 
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model in a smaller scale but without the pH control and stirring. Samples were taken at predose, 0 
h, 8 h and 24 h to evaluate the viable counts of coliforms and total anaerobes in the sample by 
plating serial dilutions on selective media.  
Batch culture fermentation 
To investigate the gut microbiota’s response to LNP treatment in an anaerobic, temperature- and 
pH- controlled system, in vitro batch model fermentation experiments were conducted 
(Mandalari et al. 2007). Samples were collected at selected time points for viable counts of 
different bacterial populations and the identity of the colonies on the MacConkey no. 3 plates 
(selective and differential agar that support Enterobacteriaceae growth) were subsequently 
confirmed using 16S rRNA gene PCR based sequencing. Cell pellets were processed both with and 
without propidium monoazide (PMA) to differentiate live/dead cells (Fujimoto et al. 2011) prior to 
Illumina Miseq sequencing to enrich our knowledge of the viable bacterial community (including 
non-culturable organisms) that were present in each treatment. 16S rRNA gene sequencing using 
the Illumina Miseq platform was then performed to determine the taxa of the gut microbiota 
community upon LNP treatments, PCoA plots were analysed to detect any structural changes 
occurring between different time points and treatments. Metabonomic analyses were also 
performed to identity any possible metabonomic changes to gain further insight into how LNP 
impact upon the gut microbiota function. 
4.2. Materials and Methods 
For methods relating to confocal microscopy, see Section 2.4; for batch culture fermentation, see 
Section 2.5. Methods for propidium monoazide treatment, DNA extraction for bacterial 
community profiling and subsequent 16S rRNA gene analysis can be found in Chapter 2.6. 
4.2.1. LNP dosing determination experiment 
To explore which NP: bacteria ratio is most effective against E. coli from human faecal slurry, 
different types and doses of NPs (i.e. control, SLNP and LNPs) and faecal bacteria ratios were used 
to achieve 1x (equivalent to 0.66% NP dose v/v in batch fermentation model), 1.65x, 3.36x, 12.5x 
and 90x dose compared to the standard ratio used in batch model. These were added to 1.35 ml 
of pre-reduced chemostat media and incubated without stirring in an anaerobic cabinet (see 
Table 4.1). Samples were taken at predose, 0 h, 8 h, 24 h for viable counts. In the scaled up 
experiment, volume of all components was 100x higher as stated below. 
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Table 4.1 Experimental details for dosing determination experiment. 
 original dose (1x) 1.65x dose 3.36x 
dose 
12.5x 
dose 
90x dose 
media (ml) 1.35 1.35 1.35 1.35 1.35 
faecal dilution % in PBS 10% 6% 6% 6% 3.33% 
faecal volume (µl) 150 150 150 100 50 
total faecal % 0.99% 0.60% 0.59% 0.40% 0.11% 
NP added (µl) 10 10 20 50 100 
NP % 0.66 0.66 1.32 3.33 6.67 
NP (ml): faeces (g) ratio 1: 1.5 1: 0.9 1: 0.45 1: 0.12 1: 0.0167 
4.3 Results 
4.3.1 TFD delivery in E. coli using confocal microscopy 
LNPs formed with a fluorescently labelled TFD (Alexa-488 (green)) were used to determine 
whether they could transfect E. coli. Bacterial cell wall was labelled with TMR-WGA (red) when 
visualised with laser scanning confocal microscopy. TFD had been internalised or was associated 
with the outside of the bacterial cell. In Figure 4.1a, an E. coli cell control showed red fluorescence 
signal only on the surface of the bacterial cell, with no green fluorescence in the green channel; 
demonstrating that red fluorescent dye only causes fluorescence on the surface of the bacteria. 
When LNPs with green fluorescent-labelled TFDs were added to the bacteria (Figure 4.1b), green 
fluorescence can be seen within the boundaries of the red-fluorescently labelled bacterial cell 
wall, revealing that TFDs had successfully incorporated into the bacterial cell after 1.5 h 
incubation with LNPs (Figure 4.1 c) .  
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Figure 4.1 Confocal scanning images of (a) E. coli control and (b) E. coli cells with loaded 
nanoparticles in L media. The incorporation of Transcription Factor Decoy (TFD) from the LNP was 
shown in (biii) but not when TFD is absent in (aiii). Red: E. coli cell wall; Green: TFD. i) green 
channel; ii) red channel; iii) red and green channel overlay. 
 
To compare the efficiency of TFD incorporation within E. coli when used in physiologically relevant 
in vitro conditions, E. coli cells were treated with the NP formulation of choice, LNP + 0.1% HPMC 
in the presence of chemostat media, to imitate the conditions used in the batch model 
fermentation.   
When LNP-treated E. coli were incubated in chemostat media and a water control, both 
treatments showed successful delivery after 1.5 h of TFD incubation with delivery increasing at 4 
h; more TFD incorporation was observed when incubated in water (Figure 4.2 c) compared to 
those in chemostat media at both 1.5 h (Figure 4.2 a) and 4 h (Figure 4.2 b). This showed that 
LNPs incubated in different solution i.e. Luria (L) broth (Figure 4.1), water (Figure 4.2 c) and 
chemostat media (Figure 4.2 a) can be transfected within the same time frame of 1.5 h; though 
the transfection efficiency is lower when incubated in chemostat media compared to the water 
control. In summary, LNP were able to incorporate within E. coli in L broth and chemostat media 
for nanoparticle delivery, and 4 h of LNP incubation result in optimal nanoparticle delivery with 
the current experimental settings (Figure 4.2 b and d).  
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Figure 4.2 Confocal scanning images of a) E. coli with LNP + 0.1% HPMC in chemostat media 
incubated for 1.5 h; i) green channel; ii) red channel; iii) red and green channel overlay; b) broad 
view of E. coli + LNP + 0.1% HPMC incubated in chemostat media for 4 h; c) broad view of E. coli + 
LNP + 0.1% HPMC incubated in water control for 1.5 h; d) broad view of E. coli + LNP + 0.1% HPMC 
incubated in water control for 4 h. Red: E. coli cell wall; Green: TFD. 
 
4.3.2. Analysis of viable microbial community in human faecal bacteria cultures in 
dosing determination experiments 
Bacteriostatic activity was achieved at 1x LNP dose in triplicate experiments 
As NPs will likely adhere to other bacteria in the gut microbiota, to ensure successful NP delivery 
to the Enterobacteriaceae, it is important to adjust the NP dosage accordingly to allow efficient 
targeting. To investigate the amount of LNPs needed to show antimicrobial effect in a mixed 
faecal bacterial community, different ratios of NPs: faecal microbiota (including 1x, 1.65x, 3.36x, 
12.5x and 90x dose) were tested in triplicate experiments to determine the minimum NP dose 
needed to display antimicrobial activity (see dosing scheme in Section 4.2.1). To achieve 
bacteriostatic antimicrobial activity (> 1 log10 and < 3 log10 decrease in colony forming units) 
(Pankey and Sabath 2004, Basri et al. 2014), as little as 1x dose was needed repeatedly when 
comparing the experimental observations from the triplicate experiments (Figure 4.3). At this 
minimum 1x dose, sufficient antimicrobial activity against coliforms was observed with LNP + 0.1 
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% HPMC, while anaerobic bacteria were unaffected with all treatments (control, SLNP + 0.1% 
HPMC and LNP + 0.1% HPMC). SLNP treatment did not reduce coliforms level, indicating the 
antimicrobial activity in LNP treatment was TFD-specific. LNPs were effective against coliforms in 
the triplicate experiments, despite there were large variations in the efficacy ranging from log10 1 
to > log10 5 CFU/ml decrease in the coliforms viable counts.  
 
 
 
Figure 4.3 Bacterial viable counts of anaerobes (left) and coliforms (right) in dosing determination 
experiments at 1x NP dose in a) experiment 1; b) experiment 2; c) experiment 3. Same donor was 
used in all 3 experiments.  
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Variation in minimum bactericidal dose in triplicate dosing determination experiment 
Unlike bacteriostatic activity, the minimum LNP dose required for bactericidal antimicrobial 
activity (≥ 3 log10 decrease in CFU) (Lee and Burgess 2013) differed between experimental runs. A 
minimum of 1x, 3.36x and 12.5x LNP doses were needed in the triplicate experiments respectively 
(Figure 4.4). As there was a 12.5x difference in the minimum LNP dose required for bactericidal 
activity, large variation in LNP dose required to target sufficient quantities of coliforms were 
noted even though the freshly void faecal samples originated from the same donor. In general, 
minimal changes in the viable bacterial counts of total anaerobes were observed from LNP 
treatment compared to control and SLNP in most LNP doses for all 3 experiments, suggesting LNP 
were mostly TFD-specific against coliforms and did not reduce the population in the rest of the 
gut microbiota samples as indicated by total anaerobe viable counts. Non-specific antimicrobial 
activity was observed at 90x LNP dose in experiment 1; a log10 3 CFU/ml decrease in total 
anaerobe viable counts were observed in LNP treatment compared to control and SLNP from 8 h 
onwards (Figure 4.4 a). However, non-specific damage to the total anaerobes at 90x were only 
observed in one out of three experiments, suggesting that large quantities of LNP (90x more than 
the minimum bactericidal dose) was needed to cause non-specific antimicrobial effect on the rest 
of the gut microbiota. 
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Figure 4.4 Bacterial viable counts from anaerobes (left) and coliforms (right) for dosing 
determination experiment a) experiment 1 - 1x dose is already enough for significant 
antimicrobial activity specific to E. coli, however 90x dose showed some sign of broad spectrum 
effect on the rest of the gut microbiota; b) experiment 2 - 3x dose is needed for significant 
antimicrobial activity specific to E. coli; c) experiment 3 - 12.5x dose is needed for significant 
bactericidal (≥ log10 3 decrease in CFU/ml) antimicrobial activity specific to E. coli. 
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Dosing determination at a larger volume 
To determine whether the NP dosage needed is scalable for future batch culture fermentation 
experiments, a scaled-up experiment with a larger total volume (150 ml instead of 1.5 ml) was run 
in parallel with dosing determination experiment 2 and 3.  
In dosing determination experiment 2, 1x dose was tested in the scaled up experiment (without 
stirring just like the dosing determination experimental set up), there were no differences in 
viable bacterial counts for total anaerobes and coliforms (Figure 4.5 a). Both the scaled up 1x dose 
and the 1x dose from the dosing determination experiment (Figure 4.3 b) did not show 
bactericidal activity as expected. 
Even though no bactericidal activity was observed at 1x dose in dosing determination experiment 
3 (Figure 4.3 c), a minimum of 12.5x LNP dose was needed for bactericidal activity (Figure 4.4 c). 
When the experiment was scaled up with stirring, a ≥ log10 5 decrease in coliforms viable counts 
was observed with 1x LNP dose at 8 h compared to control (Figure 4.5 b). Suggesting bactericidal 
activity was enhanced and the minimal bactericidal dose needed was lowered (i.e. from 12.5x to 
1x) when scaled up with stirring. Combining the results from Figures 4.3, 4.4 and 4.5, it was 
decided that a 3x dose was a feasible LNP dosage that could provide sufficient antimicrobial 
activity against Enterobacteriaceae without collateral damage to the rest of the gut microbiota 
when scaling up for the batch culture fermentation experiments which involves stirring, the 
results will be detailed in the next section (Section 4.3.3). 
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Figure 4.5 Bacterial viable counts of anaerobes (left) and coliforms (right) in a scaled up study of 
a) dosing determination experiment 2; b) dosing determination experiment 3, in 150 ml vessels 
(with no pH control). 
4.3.3 Assessing effects of LNPs in human faecal bacterial cultures mimicking colon 
condition in vitro  
After determining the predicted dosing range suitable for the mixed human gut microbiota 
samples, 3x dose (equivalent to 2% of total volume in the batch culture fermentation) were used 
to determine whether LNP can efficiently reduce the coliforms population without affecting the 
rest of the gut microbiota communities in a temperature- and pH- controlled anaerobic 
environment mimicking conditions in the human colon, using different faecal donors in 
experiment 1 to 4.  
Batch culture fermentation experiment 1 
In the first batch culture fermentation experiment, the bacterial viable counts were at similar 
levels at predose for all the bacterial groups examined. The composition of the overall viable total 
anaerobe and Lactobacillus community treated with control, SLNP and LNP were similar over the 
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8 h period (Figure 4.6). This shows that LNPs did not damage the overall gut microbiota or the 
beneficial Lactobacillus population.  
Total Enterobacteriaceae viable bacterial counts were decreased by log10 3 CFU/ml with LNP 
treatment at 0 h, whereas there was a log10 2.5 CFU/ml decrease at 4 h compared to the control, 
a log10 3 CFU/ml drop was also observed at 8 h with SLNP treatment. The viable coliforms 
population were log10 5 CFU/ml at predose for all treatments. Notably, immediately after the 
addition of LNPs at 0 h, a significantly decreased were observed with LNP treatment, whereby no 
coliforms were detected (limit of detection < 16 CFU/ml), compared to log10 6.5 CFU/ml in control 
and SLNP treatments. The lack of detectable coliforms in LNP-treated sample was maintained for 
8 h until the end of the experiment, as compared to the control which had log10 8.5 and log10 9 
CFU/ml of coliforms at 4 h and 8 h respectively. For SLNP, the coliforms levels were similar to 
those in control up to 4 h, before the levels decrease to log10 6 CFU/ml. 
Bifidobacterium population was not shown as no detectable colonies were present (limit of 
detection < 1.67 x 105 CFU/ml). In general, control and SLNP treatments had similar bacterial 
counts at 0 h and 4 h for the bacterial groups examined, though some decrease has been 
observed across all groups in the vessels containing SLNP at 8 h. A higher final volume was 
observed in the sample vessel containing SLNP treatment compared to the control and LNP, this is 
due to automated pH buffer addition. This may have diluted the samples in the SLNP vessel 
leading to a reduction in countable colonies in a given volume. 
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Figure 4.6 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus, coliforms 
and Enterobacteriaceae for control, SLNP and LNP treatments at 2% doses in batch culture 
fermentation experiment 1. PD, predose-treatment; treatments were added at 0 h prior to 
sampling.  
Colonies on MacConkey no. 3 plate with LNP treatment at 0 h, 4 h and 8 h (bright pink coloured 
with lots of bile precipitation) were notably different to the samples from other treatments and 
time points (pink coloured) (Figure 4.7), suggesting the change in the Enterobacteriaceae 
population subject to LNP-treatment from 0 h was effective until the end of the experiment at 8 
h. By comparing the identity of 10 randomly selected MacConkey no. 3 colonies from each of 
SLNP and LNP treatment, sequencing results from 16S rRNA gene colony PCR suggests the 
presence of E. coli (pink) with SLNP treatment, whereas 8 colonies were suggested as Klebsiella 
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pneumonia (bright pink) and 2 colonies were identified as E. coli (pink) in LNP-treated samples at 
4 h (Table 4.2). This suggests that E. coli levels was reduced by LNP though Klebsiella spp. 
appeared less sensitive. 
 
 
Figure 4.7 Enterobacteriaceae colonies on MacConkey no. 3 plates for batch culture fermentation 
experiment 1. Pink colonies were mostly present at predose for all treatments and in control and 
SLNP treatments at 0 h, 4 h and 8 h, whereas bright pink colonies were mostly present with LNP at 
0 h, 4 h and 8 h. 
Batch culture fermentation experiment 2 
The second batch culture fermentation experiment was performed using a different donor (Figure 
4.8). While the viable counts of the total anaerobic microbiota were similar between control and 
SLNP throughout the course of the experiment, the total anaerobes level were lowered in LNP-
treated samples by log10 2 CFU/ml at 8 h compared to the controls. Bacteroides viable levels for all 
3 treatments corresponded with the trend seen in total anaerobes. Bifidobacterium had similar 
levels across all 3 treatments at each of the time points, while Clostridium were at relatively 
similar levels across treatments up to 4 h and had around log10 2 decrease from LNP treatment 
compared to the control.   
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Lactobacillus levels were similar between SLNP and control up to 4 h, levels were decrease in 
SLNP approximately log10 2.5 CFU/ml at 8 h compared to the control; whereas for LNP-treatment 
lactobacillus level decreased by log10 2 CFU/ml at 4 h and 8 h compared to the control treatment. 
Total Enterobacteriaceae viable bacterial counts were decreased to an undetectable amount (< 16 
CFU/ml) with LNP treatment at 0 h. Although some growth was observed from 4 h onwards, there 
was still a log10 4 and log10 2.5 CFU/ml decrease at 4 and 8 h respectively compared to their 
controls. 
The coliforms viable levels with control and SLNP treatment had similar trends to total anaerobes 
and Bacteroides; immediately after the addition of LNPs at 0 h, viable coliforms levels decreased 
to an undetectable amount (< 16 CFU/ml) up to 4 h, before levels recovering at 8 h to log10 6.5 
CFU/ml. This evidently suggests LNP’s ability to exert antimicrobial activity against 
Enterobacteriaceae without disrupting other commensal bacterial communities in the 
microbiome.  
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Figure 4.8 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus, coliforms 
and Enterobacteriaceae for Control, SLNP and LNP treatments at 2% doses in batch culture 
fermentation experiment 2. PD, predose-treatment; treatments were added at 0 h prior to 
sampling.  
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Colonies on MacConkey no. 3 plate with LNP treatment at 4 h (straw coloured) were notably 
different to the samples from other treatments and time points (pink coloured) (Figure 4.9), 
suggesting LNP treatment changed the population of Enterobacteriaceae present in the gut 
microbiota 4 h after the treatment; the Enterobacteriaceae colonies with LNP at 8 h again had 
similar morphology as the corresponding samples presented in control and SLNP. Ten colonies 
from each of the coliforms no. 3 agar plates with LNP- and SLNP-treated samples were processed 
with 16S rRNA gene colony PCR and sequenced via 16S rRNA gene sequencing. This identified the 
colonies taken from plates with SLNP treatment as Escherichia/ Shigella spp. (pink colonies). Only 
Pseudomonas aeruginosa (straw-coloured) colonies were present with LNP treatment, suggesting 
Escherichia/Shigella species was reduced with LNP treatment between 0 h and 4 h (Table 4.2). 
 
 
Figure 4.9 Enterobacteriaceae colonies on MacConkey no. 3 plates for batch culture fermentation 
experiment 2. Pink colonies were mostly present at predose for all treatments and in control and 
SLNP treatments at 0 h, 4 h, 8 h and with LNP at 8 h, whereas straw-coloured colonies were 
mostly present with LNP treatment at 0 h and 4 h.  
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Batch culture fermentation experiment 3 
In the third batch culture fermentation experiment, no difference in the viable counts in the 
anaerobes, Lactobacillus, Bacteroides, Clostridium, Bifidobacterium, Enterobacteriaceae and 
coliforms population were observed between control, SLNP and LNP from predose to 8 h (Figure 
4.10). As the NPs activity were tested against E. coli pure cultures in parallel of the batch 
fermentation, we were able to determine whether LNPs contributed towards the lack of 
antimicrobial activity against the gut microbiota. The LNPs used in experiment 3 showed > 3 log10 
decrease in CFU/ml of E. coli compared to the control, suggesting bactericidal antimicrobial 
activity was present in the LNPs. Furthermore, it was also noticed that the starting coliforms 
bacterial population of this faecal sample were higher than those observed in the previous two 
experiments (log10 7 CFU/ml as opposed to log10 6 CFU/ml previously), thus suggesting other 
factors such as bacterial load could contributing towards the lack of notable antimicrobial activity 
from LNP treatment against coliforms. A higher dose may therefore be required to show sufficient 
antimicrobial activity against coliforms in the mixed human gut microbiota sample in future 
experiment. 
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Figure 4.10 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus, 
coliforms and Enterobacteriaceae for control, SLNP and LNP treatments at 2% doses in batch 
culture fermentation experiment 3. PD, predose-treatment; treatments were added at 0 h prior to 
sampling.  
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Batch culture fermentation experiment 4  
Following the lack of antimicrobial activity against coliforms in the third batch culture 
fermentation experiment, both 2% (i.e. 3x dose, the original dose also used in experiment 1 and 
2) and 10% (i.e. 15x dose) doses of NPS were administered in parallel in the fourth batch culture 
fermentation experiment using the same faecal sample. At the usual 2% NP dose (Figure 4.11), 
viable bacterial counts were similar between SLNP, LNP and the control for Bacteroides and 
Clostridium population throughout the course of the experiment. Only small decrease in viable 
counts (≤ log10 1 CFU/ml) were observed with LNP treatment in total anaerobe, Lactobaccilli, total 
Enterobacteriaceae and coliforms population at 4 h compared to the control and SLNP, while 
having similar viable counts between all treatments at predose, 0 h and 8h. Just like the third 
experiment, no bactericidal activity was observed against coliforms with 2% LNP treatment. 
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Figure 4.11 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus, 
coliforms and Enterobacteriaceae for control, SLNP and LNP treatments at 2% doses in batch 
culture fermentation experiment 4. PD, predose-treatment; treatments were added at 0 h prior to 
sampling.  
 
In contrast, with 10% LNP a log10 3 CFU/ml decrease in Enterobacteriaceae and coliforms was 
observed at 0 h and 4 h compared to the control (Figure 4.12), indicating that the LNP targeted 
antimicrobial approach is dose dependent. The levels of total Enterobacteriaceae/ coliforms with 
LNP treatment grew to similar levels to those with control and SLNP treatment at 8 h. A log10 2 
CFU/ml decrease in viable bacterial counts for total anaerobes and Lactobacillus population were 
observed at 4 h with LNP treatment, though they returned to similar levels to those in the control 
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and SLNP treatment after 8 h, suggested the temporal disturbance in the mentioned bacterial 
groups against a high LNP dose were reversible. Bacteroides and Clostridium viable bacterial 
counts were decreased by about log10 1 CFU/ml with LNP at 4 h compared to the control, and 
remained similar levels at 8 h. 
 
  
Figure 4.12 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus, 
coliforms and Enterobacteriaceae for control, SLNP and LNP treatments at 10% doses in batch 
culture fermentation experiment 4. PD, predose-treatment; treatments were added at 0 h prior to 
sampling. 
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16S rRNA gene sequencing confirmed that selected colonies present in both 10% SLNP and 10% 
LNP treated samples (10% dose) on MacConkey no. 3 agar were Escherichia/Shigella spp. and 
Klebsiella spp., suggesting that there were little difference in the composition of 
Enterobacteriaceae population subject to 10% SLNP and LNP treatments even though the viable 
population were sufficiently decreased (Table 4.2). 
Table 4.2 Summary 16S rRNA gene colony PCR sequencing identity of MacConkey no. 3 colonies 
from Batch culture fermentation model. 
 Escherichia/Shigella spp. Klebsiella pneumonia Pseudomonas aeruginosa 
 SLNP LNP SLNP LNP SLNP LNP 
Experiment 1 10 2 - 8 - - 
Experiment 2 9 - - - - 10 
Experiment 4 9 8 1 2 - - 
We did not see coliforms-targeting antimicrobial activity in batch culture fermentation 
experiment 3 (at 2% LNP) and in experiment 4 antimicrobial activity was exerted only at 10% but 
not 2% dose. Therefore there may be a dose dependant effect relating to the quantity of bacteria 
presented in the faecal sample against the amount of NPs administered. To determine whether 
the density of the inoculum affects response to LNP, the starting viable count for anaerobes and 
coliforms in control treatment were plotted against LNP dose added at 0 h. There were no linear 
correlations when the total anaerobe colonies were plotted against the volume of LNP (Figure 
4.13), either from the dosing range (R2= 0.302) or batch culture fermentation experiments (R2= 
0.152). However, when the quantity of starting coliforms were plotted against the volume of LNP, 
a positive linear regression was obtained with R2 of 0.992 and 0.998 respectively for LNP dosing 
determination (Figure 4.13 a) and batch model experiments (Figure 4.13 b), suggesting the 
successful exertion of LNP antimicrobial activity is associated with the starting coliforms quantity, 
but not total anaerobes, at the time of NP administration from preliminary data.  
The correlation equation was applied to some experiments that did not show antimicrobial 
activity against Enterobacteriaceae. By inserting the starting Enterobacteriaceae levels in to the 
equation, the volume of LNP required for antimicrobial activity was predicted. As expected, the 
LNP dose used was lower than the predicted effective dose (Figure 4.13 c), which further suggests 
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the importance of the starting coliforms population in defining the effective dose of LNPs to exert 
bactericidal antimicrobial activity. 
 
c 
Relative LNP dose used (%) 2% 2% 2% 2% 
 
LNP dose used (ml) 
 
3 3 3 3 
Starting coliforms in control when 
LNPs were added at 0 h (CFU/ml) 
 
9.18x106 
 
3.50x107 
 
3.85x107 
 
2.02x107 
 
Predict LNP dose needed for 
sufficient bactericidal activity 
with x=(y+7x106)/4x106 (ml) 
 
4.05 
 
10.50 
 
11.38 
 
6.79 
 
Is the LNP dose used sufficient for 
bactericidal activity from the 
prediction? 
No No No No 
 
Figure 4.13 Linear relationship between starting coliforms quantity and LNP dose for a) dosing 
determination experiment; and b) batch model fermentation; c) prediction of minimum dose 
required for sufficient antimicrobial activity in the batch model with different gut microbiota 
samples. 
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To elucidate growth (or the lack of) at later time points upon NP administration, the change in 
CFU compared to their respective predose value were used for statistical analysis. LNP only 
significantly reduced (P ≤ 0.001) the CFU of Enterobacteriaceae and coliforms at 0 h, when 
compared to their respective controls, when data from experiment 1,2 and 4 at 2% LNP dose 
were combined. When viable count data from batch experiments 1, 2 and 4 were combined 
(based on a bactericidal dose of 2%, 2% and 10% NPs respectively), it was suggested that while 
coliforms viable counts were reduced by > log10 3 CFU/ml at 4 h, other bacterial groups such as 
Bacteroides, Bifidobacterium, Clostridium and Lactobacillus and the total anaerobes were 
maintained, with small decrease in total anaerobes as expected from the decrease in coliforms 
population (Figure 4.14). This suggests that overall, given the LNP dose were appropriately 
administered according to the starting quantity of coliforms, LNPs has the ability to exert 
antimicrobial activity targeting coliforms specifically without altering the rest of the gut 
microbiota community.  
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Figure 4.14 Averaged viable bacterial colony counts for in vitro batch culture fermentation 
experiments 1, 2 and 4. Bacterial viable counts for anaerobes, Bacteroides, Clostridium, 
Lactobacillus, coliforms and Enterobacteriaceae with control, SLNP and LNP treatments were 
calculated from bactericidal dose of 2%, 2% and 10% respectively. 
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4.3.4. Metataxonomic analyses of microbial community in human faecal bacteria 
cultures 
To determine the viable numbers of Enterobacteriaceae in the 16S rRNA gene community 
analysis, it is important to only take account of the live bacteria in the sample and omit the dead 
community to elucidate the antimicrobial effect in the viable portion of the gut microbiota 
community. Samples taken from the batch culture fermentation were treated with propidium 
monoazide (PMA) that was photo-activated. This photo-activation causes intercalation of double 
stranded DNA from dead bacteria to prevent PCR amplification for subsequent 16S rRNA gene 
sequencing (Fujimoto et al. 2011). The comparison between untreated and PMA-treated samples 
are shown in Figure 4.15 a and b respectively. The PMA-treated samples more closely resembled 
the viable Enterobacteriaceae trend in the viable bacterial counting results (Figure 4.6) compared 
to the untreated sample and was used for the determination of viable populations for all 16S 
rRNA gene analysis thereafter. 
16S rRNA gene sequencing data obtained from the Illumina Miseq platform showed that while 
bacterial communities at the family level were similar at predose for all 3 experiments, a notable 
decrease in the proportion of Enterobacteriaceae out of the total bacterial community were seen 
in LNP-treated samples at 4 h in batch model experiments 1, 2 and 4 individually (Figure 4.15, 4.16 
and 4.17 respectively). Due to the variations in the microbiota composition from different donors, 
it is not possible to make statistical comparisons. 
In batch culture fermentation experiment 1, samples were dominated by Lachnospiraceae, 
Bacteroidaceae and Ruminococcaceae in descending proportions at predose and 0 h. 
Enterobacteriaceae only form a small percentage of the whole gut microbiota community at 
predose and 0 h, only making up 5.92%, 2.64%, 1.73% at predose, and 2.8%, 2.7% and 0.1% at 0 h 
in control, SLNP and LNP respectively (Figure 4.15 b), indicating LNPs were reducing 
Enterobacteriaceae at 0 h. At 4 h, abundance of Enterococcaceae, Bacteroidaceae, 
Bifidobacteriaceae, Streptococcaceae and Lachnospiraceae were greatly increased when 
Enterobacteriaceae levels declined to 3.46% with LNP treatment compared to the control 
(83.76%) and SLNP (73.38%). While SLNP had slightly lower levels of Enterobacteriaceae 
compared to the control at 4 h, there were increased abundance of Bacteroidaceae and 
Bifidobacteriaceae. At 8 h, both SLNP- (3.32%) and LNP-treated (4.72%) samples both had reduced 
the proportion of Enterobacteriaceae compared to the control (69.56%) (Figure 4.15 b), the 
reduction in Enterobacteriaceae by SLNP may suggest non-TFD specific disruption occurring at 8 h. 
Large increases in proportions of Enterococcaceae were shown in LNP (59.19%) and SLNP 
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(75.59%) compared to the control (11.52%). A smaller increase in Bifidobacteriaceae and 
Streptococcaceae with decrease in Bacteroidaceae levels were observed in SLNP and LNP 
compared to the control respectively. Similar diversity between family levels were seen across all 
time points with all three treatments, suggesting LNP did not cause overall damage to the gut 
microbiota in general.  
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Figure 4.15 Bacterial community analysis of 16S rRNA gene sequencing at family level for in vitro 
batch culture fermentation experiment 1; a) live and dead bacterial community in untreated 
samples; and b) live bacterial community in PMA treated samples. 
 
In batch culture fermentation experiment 2, samples at predose and 0 h showed similar 
proportions of bacterial group at the family level, consisting mainly of Lachnospiraceae, 
Bacteroidaceae, Ruminococcaceae, Bifidobacteriaceae and Coriobacteriaceae in descending 
proportions. Large proportions of Enterobacteriaceae were shown in control (33.76%) and SLNP 
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(78.81%) at 4 h compared to 0 h; though interestingly, the overall bacterial composition of the 
LNP-treatment at 4 h largely resembled those at 0 h, with only 0.2% of Enterobacteriaceae in LNP-
treated samples. The control sample at 4 h and 8 h also showed a large increase in 
Fusobacteriaceae (Figure 4.16) which was absent in the SLNP and LNP sample. 
Enterobacteriaceae levels with LNP (18.21%) remained lower than the controls at 8 h, while the 
SLNPs-treated sample was largely composed of Enterobacteriaceae (97.76%) compared to the 
control (42.66%). The diversity of bacterial groups were higher in LNPs compared to the control 
and SLNP as the constituents resembled more closely to the bacterial community at the start of 
the experiments i.e. Bacteroidaceae, Ruminococcaceae and Lachnospiraceae, suggesting LNP 
were able to maintain the diversity of the gut microbiota while targeting Enterobacteriaceae. 
Increase proportions of Pasteurellaceae, Streptococcaceae, Bifidobacteriaceae and 
Coriobacteriaceae were also observed at 8 h in LNP compared to the control and SLNP.  
 
 
Figure 4.16 Live bacterial community analysis of 16S rRNA gene sequencing at family level for in 
vitro batch culture fermentation experiment 2 (PMA-treated) at 2% NP dose. 
In batch experiment 4, the gut microbiota predominantly comprises Enterobacteriaceae, 
Verrucomicrobiaceae, Ruminococcaceae and Bacteroidaceae at predose in descending order. 
While no notable difference in the composition of the gut microbiota community was observed at 
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each time point between treatments at 2% NP dose (Figure 4.17 a), changes in the proportion of 
Enterobacteriaceae were shown with 10% LNP treatment as described below. Enterobacteriaceae 
was markedly decreased at 0 h from 16.27% in the control and 31.26% with SLNP to 0.86% with 
LNPs, with increased Clostridiales (in the order level) and Clostridiaceae at 0 h (Figure 4.17 b). 
At 4 h, Enterobacteriaceae levels with LNP treatment (16.06%) were still notably lower than those 
in control (92.17%) and SLNP treatment (93.76%). Verrucomicrobiaceae were increased from 
2.55% and 1.87% in control and SLNP respectively to 29.65% with LNP at 4 h; Turicibacteraceae, 
Rikenellaceae, Bacteroidaceae, Bifidobacteriaceae and Methanobacteriaceae were also increased 
proportionally with LNP compared to the controls. 
 
At 8 h, all treatments were consisted mainly of Enterobacteriaceae at 95%, 95% and 97.78% for 
control, SLNP and LNP respectively, with decreased proportions of Bacteroidaceae and 
Bifidobacteriaceae in LNP. The above data suggested that while 2% LNP had no effect on the gut 
microbiota, Enterobacteriaceae was inhibited by 10% LNP from 0 h to 4 h, with growth observed 8 
h after LNP treatment. 
 
LNP-treated gut microbiota maintained similar diversity of bacterial groups compared to the 
samples at the start of the experiment. LNP-treated samples were also more diverse compared to 
the control and SLNP at the same time points, suggesting LNP did not reduce the diversity of the 
gut microbiota, unlike traditional antibiotic treatments.  
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Figure 4.17 Live bacterial community analysis of 16S rRNA gene sequencing at family level for in 
vitro batch culture fermentation experiment 4 (PMA-treated) at a) 2% dose and b) 10% dose. 
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Principal Coordinates Analysis 
To determine the community structures of the gut microbiota samples upon LNP treatment, 
weighted unifrac Principal Coordinates Analysis (PCoA) plots were used to look at the spatial 
relationship between different samples in the same experiment run. 
For PCoA plots from experiment 1 (Figure 4.18), predose samples all clustered together before the 
addition of NP treatments. At 4 h the LNP sample was spatially closer to all predose samples and 
were further away from 4 h control and SLNP on the PC1 axis (which accounts for 57.81% of the 
variability), indicating community structure had more similarity to the predose samples than the 
control treatments at 4 h. The samples at 8 h shifted further away from their previous time 
points, suggesting a structural shift associated with time. Overall, LNPs had shifted less on the PC1 
axis compared to the control and SLNP treatment, suggesting the shift in the gut microbiota 
structure in LNPs were less than those associated with control and SLNP over time, suggesting 
LNP structurally resembled the gut microbiota from the predose samples. 
 
Figure 4.18 Principal coordinates analysis (PCoA) plots of Illumina sequence data for in vitro batch 
culture fermentation model experiment 1. 3D PCoA plot was generated from weighted UniFrac 
analysis, where x- and y- and z-axis represents the first, second and third principal coordinates 
respectively.  
For experiment 2 (Figure 4.19), predose and 0 h samples had similar spatial arrangement 
regardless of treatment. At 4 h, control and SLNP become more distant on the PC1 axis 
(accounting for 83.34% of the total variability) from the original samples while LNP remain closely 
clustered with the samples at predose and 0 h. At 8 h, there is a further shift in all treatments, 
though LNP treatment remain most similar to all samples at predose and 0 h compared to control 
and SLNP, again suggesting less overall change occurred in the gut microbiota with LNP 
treatment. 
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Figure 4.19 Principal coordinates analysis (PCoA) plots of Illumina sequence data for in vitro batch 
culture fermentation model experiment 2; 3D PCoA plot was generated from weighted UniFrac 
analysis, where x- and y- and z-axis represents the first, second and third principal coordinates 
respectively.  
 
For experiment 4 (Figure 4.20), all treatments at the same time points clustered together for 2% 
NP dose, suggesting no notably difference in gut microbiota structure (Figure 4.20 a). At 10% NP 
dose, sample treated with LNPs at 4 h are more spatially related to all the predose samples than 
control and SLNP-treated samples on the PC1 axis (accounting for 69.36% of the total variability), 
suggesting LNPs were structurally more similar to predose and 0 h samples (Figure 4.20 b). 
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Figure 4.20 Principal coordinates analysis (PCoA) plots of Illumina sequence data for in vitro batch 
culture fermentation model experiment 4. 3D PCoA plot was generated from weighted UniFrac 
analysis, where x- and y- and z-axis represents the first, second and third principal coordinates 
respectively. a) at 2% dose; b) at 10% dose. 
4.3.5. Metabonomic analysis in the human gut microbiome in the presence of TFD 
1H NMR spectroscopy allowed the examination of the metabolites present in the in vitro batch 
culture fermentation samples with different NP treatments. A representative NMR spectrum, 
shown from batch model experiment 3 (Figure 4.21), comparing NMR spectra between 2% and 
10% LNPs provided insight into the LNP dose response effect on the concentration of metabolites.  
In general, not much difference in metabonomic profile was seen between control and SLNP, both 
at 2% and 10%, indicating the delivery compound 12-bis-THA is not affecting the bacterial 
community metabolically, suggesting LNPs are good vehicle for drug delivery. The difference in 
profile derived from SLNP and LNP treatments indicated that the TFD was the driving force of the 
metabonomic changes. 
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LNP-treatment resulted in a lower yield of products of anaerobic metabolism (Figure 4.21) such as 
ethanol and lactate compared to the control and SLNP at 4 h and 8 h. The upward trends for 
propionate, formate and acetaldehyde production were less prominent compared to the control 
and SLNP, indicating a reduction in bacterial growth and anaerobic metabolism. This trend is more 
prominent in 10% than 2% LNP, which may be associated with the discrepancy in antimicrobial 
activity observed between the doses.  
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Figure 4.21 Metabolites concentrations involved in anaerobic metabolism. Ethanol and lactate, 
and short chain fatty acids propionate, formate and acetaldehyde. A minimum of two repeats 
were analysed and the mean ± SD were plotted. 
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Metabolites such as cystine, glucose and glutamate were depleted by control and SLNP batch 
fermentation vessels at both 2% and 10% dose at 8 h (Figure 4.22), while they were mostly 
diminished by 2% LNP at 8 h, the levels remained high for 10% LNP samples. This may indicate 
growth was slower with LNP compared to control and SLNP as the use of these metabolites were 
delayed in a dose-dependent manner.  
Phenylalanine, leucine and isoleucine, valine, tyrosine, histidine and methionine were used at 8 h 
regardless of dose (Figure 4.23 and 4.24). Asparagine and aspartate levels were depleted in the 
2% and 10% treatment vessels (including control, SLNP and LNP), except 10% LNP at 4 h (Figure 
4.25). 
 
Figure 4.22 Metabolite concentrations of cystine, glucose and glutamate. A minimum of two 
repeats were analysed and the mean ± SD were plotted. 
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Figure 4.23 Metabolite concentrations of phenylalanine, leucine and isoleucine, valine and 
tyrosine. A minimum of two repeats were analysed and the mean ± SD were plotted. 
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Figure 4.24 Metabolite concentrations of histidine and methionine. A minimum of two repeats 
were analysed and the mean ± SD were plotted. 
 
 
Figure 4.25 Metabolite concentrations of asparagine and aspartate. A minimum of two repeats 
were analysed and the mean ± SD were plotted. 
TFD specific targeting against E. coli 
 
118 
 
Other metabolites were affected differently by LNP treatment (Figure 4.26). Succinate was 
reduced in line with the LNP dosage. Levels of succinate plummeted at 4 h and reduced by two 
thirds at 8 h compared to the controls with 10% LNP treatment, whereas succinate levels were 
higher than the control at 2% dose. The decrease in 3-phenyllactate and 4-hydroxyphenylacetate 
levels as breakdown products of aromatic amino acids for phenylalanine and tyrosine respectively 
were seen only with 10% LNP treatment at 8 h. This suggests the impact of LNP dose-response; 
the 2% LNP treated bacterial communities appeared to be able to adapt to the stress conditions, 
while the metabolism of amino acids was dampened by the higher LNP dose at 10%.  
 
Figure 4.26 Metabolite concentrations of succinate, 3-phenyllactate and 4-hydroxyphenylacetate. 
A minimum of two repeats were analysed and the mean ± SD were plotted. 
 
Intermediate metabolites showed a delayed trend compared to control and SLNP (Figure 4.27). 
Fumarate levels increase with 2% and 10% LNPs at 4 h, but were reduced at 8 h compared to 
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control, indicating fumarate had higher yield at 4 h and used up at 8 h for both 2% and 10% LNP 
compared to the control and SLNP at their respective dose. Similarly, pyruvate levels showed a 
delayed response only with 10% LNP as levels remained high after 8 h, unlike at 2% dose to which 
pyruvate were used by all treatments. The time delay in the concentrations of these transitionary 
compounds could again be an indication of delayed bacterial growth in the LNP-treated samples, 
in a dose dependant manner. Also, betaine levels were decreased with 2% LNP at 8 h, while little 
change was observed with 10% LNP. While uracil levels were increased earlier at 4 h with both 
LNP treatments compared to control and SLNP (Figure 4.28). 
 
 
Figure 4.27 Metabolites concentration of fumarate and pyruvate. A minimum of two repeats were 
analysed and the mean ± SD were plotted.  
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Figure 4.28 Metabolites concentrations of betaine and uracil. A minimum of two repeats were 
analysed and the mean ± SD were plotted. Pink, control; purple, SLNP; orange, LNP. 
 
4.4 Discussion 
Successful TFD delivery by LNPs within E. coli 
It has been shown by laser scanning confocal microscopy when formulated with 12-bis-THA TFDs 
successfully crossed the Gram-negative cell wall and enter the cytoplasm of E. coli. This indicates 
the delivery NP has the ability to penetrate Gram-negative cell wall to introduce TFD to exert the 
antimicrobial effect. Marin-Menendez et al. (2017) have demonstrated 12-bis-THA attached to 
the polar and septal regions of E. coli and biophysical studies have related this to binding to the 
prokaryotic anionic phospholipid cardiolipin. LNPs have also been shown to enter Gram-positive 
bacteria including MRSA, Clostridium difficile, Pseudomonas aeruginosa and even Mycobacterium 
smegmatis which has distinctive cell wall characteristics compared to Gram-negative bacteria 
(McArthur 2014), suggesting LNP transfection can be applied to both Gram-positive and Gram-
negative bacteria. The conical structure of cardiolipin domains are typically present in areas of 
greater curvature (Fishov and Woldringh 1999, Renner and Weibel 2011) to ensure proper spatial 
segregation for respiration and cell division of bacteria (Huang et al. 2006, Lewis and McElhaney 
2009). Therefore, LNPs are designed to be a bacterial-selective delivery system, due to the 
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absence of cardiolipin in eukaryotic cell membranes and its high degree of conservation amongst 
all bacteria (Mileykovskaya and Dowhan 2009).  
We confirmed that the NP formulation (LNP + 0.1% HPMC) can transfect E. coli when incubated in 
the media used in in vitro batch culture fermentation. It was shown that LNPs were able to deliver 
TFD within the cytoplasm despite the high salt content. Moreover, there were increased 
proportion of transfected E. coli at 4 h compared to 1.5 h, this indicated that TFD delivery occurs 
in a time-dependent manner and that transfection is still taking place 4 h after the initial LNP 
administration. 
Importance of LNP dosage optimisation for target specific activity 
It is worth to notice that in the MIC bioassay, log10 6 CFU/ml of E. coli is present in each well, 
whereas the in vitro batch culture fermentation model found to have log10 9 CFU/ml of total 
anaerobes, meaning that there was a 1000-fold increase in bacterial density in the batch model 
compared to those in the MIC bioassays. To allow the 2 experimental systems to be comparable, 
the amount of bacteria/TFD had to be readjusted for a direct evaluation of antimicrobial effect. 
This indicates that a dose-response effect needs to be fine-tuned to ensure sufficient 
antimicrobial activity, especially in in vitro and in vivo settings where the starting bacterial load is 
unpredictable. As LNPs can bind to both Gram-positive and Gram-negative bacteria, sequestration 
might occur and should be taken into consideration as a factor that could reduce LNP efficacy 
against E. coli.   
From the NP dosing determination experiment, a minimum of 1x LNP dose (equates to 1.5 g of 
faeces/ml of LNPs) was required to achieve bacteriostatic antimicrobial activity (Figure 4.4.). 
However, to exert a bactericidal effect more LNPs were needed and there were larger variations 
in the minimum LNP dose required: the effect seen at 1x, 3.36x and 12.5x respectively (Figure 
4.5). It indicates a possible 12.5x difference in the minimum dose needed to exert a ≥ log10 3 
CFU/ml decrease in coliforms levels, using different faecal samples from the same donor in the 
space of 4 months. Changes in the microbiota composition and density within the sampling period 
may account for the intra-individual difference to the LNP responses. Environmental factors such 
as diet and stress could also change the microbial composition during the experimental period. It 
has been observed that the amount of total bacteria and Gram-negative bacteria in mice 
increases under stress conditions (Yoshikawa et al. 2016). This may account for why the 
bactericidal activity is less apparent in the subsequent dosing determination experiments using 
the same donor during a relatively short period. A higher dose is needed to exert the same 
antimicrobial effect as there are more bacteria or/and bacteria with the transcription factor target 
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present in the sample. As the LNPs were freshly made before each experiment, the batch-to-
batch variations could also contribute towards the differences in biological activity. 
This has highlighted the variability between experiments that could occur, it is important to 
optimise the dosage accordingly to ensure efficacy. As expected, the more efficacious the LNP 
doses were, the more likely they are to have non-TFD specific influence on the gut microbiota, 
though the reduction in other bacterial communities were minimal and did not substantially alter 
the gut microbiota.  
By comparing the viable bacterial counts between SLNP and LNP treatment, the target specificity 
of TFDs was illustrated as coliforms were mostly affected only by LNP but not SLNP at the 
minimum dose needed for bactericidal activity for each experiment (Figure 4.5). The total 
anaerobe levels were similar between all treatments at the minimum dose, further suggesting 
LNPs’ ability to target only the organism of interest as designed.  
When the dosing determination experiments were conducted in a larger scale, the antimicrobial 
activity was enhanced – 1x instead of 12.5x LNP was needed to produce an antibacterial effect 
when additional stirring was incorporated (Figure 4.6). This may be an explanation for the 
variability seen in these experiments: as the microcentrifuge tubes in the dosing determination 
experiments were not shaken while the large scale vessels were mixed using a magnetic stirrer, 
the LNPs may not have comprehensively mixed with all bacteria to utilise their full antimicrobial 
activity, therefore creating a discrepancy between the experimental set ups. After considering the 
practical feasibility and the possible non-specific side effects against the gut microbiota, a 3x dose 
was used in future in vitro batch culture fermentation model experiments. 
Non target-specific activity occurs only at very high LNP dose 
The dosing determination experiment also allowed us to investigate whether a detrimental effect 
on the gut microbiota would occur at high doses. At high LNP doses such as 90x dose in 
experiment 1, non-specific bactericidal activity was observed where there was a log10 3 CFU/ml 
decrease in the total anaerobic community from 8 h for SLNP treatment compared to control 
(Figure 4.5). Coincidently, this side effect was only observed in experiment 1, where the minimum 
bactericidal LNP dose was the lowest (hence the highest efficacy) among the 3 experiments; only 
minimal disruptions to total anaerobes were shown in the other 2 repeats. Inferring only very high 
concentrations of NPs (90x higher than the minimum LNP dose needed for bactericidal activity) 
could exert target non-specific damage on the gut microbiota. As 90x dose is unrealistic to use in 
practical terms, it was decided that 3x dose was to be taken forward for batch model experiment, 
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as it will likely have minimal effect on the total anaerobe levels and exert the target-specific 
antimicrobial activity.  
Coliforms: LNP dose ratio for successful bactericidal activity  
In the batch culture fermentation model experiments (Figure 4.6-4.12), different donors were 
used and the LNP dose required to reduce coliforms varied. This could be due to differences in 
bacterial cell density and types in the starting inocula. As freshly voided samples were required 
for batch fermentation to maintain anaerobic bacteria, it would be difficult to deduce the faecal 
dry weight without compromising the bacterial community. 
The use of a standard dilution series means some samples may fall outside the normal limit due to 
the dilution by essential pH buffering. This may explain why viable colonies of Bacteroides, 
Clostridium and coliforms were decreased at 8 h with SLNP treatment in experiment 1, as there 
was a greater increase in total volume of the vessel due to pH buffering. 
From LNP dosing determination experiment and batch model fermentation experiments, it was 
demonstrated that the bactericidal LNP dose could be up to 12.5x different between individual 
runs. To look for possible explanation for these discrepancies, the ratio between the quantity of 
starting bacterial inoculum: volume of LNPs were compared. While there was no correlation 
between the total viable bacteria and LNP dosage required at predose and 0 h, interestingly there 
was a positive linear correlation between the starting coliforms colony forming units in the 
control treatment at 0 h and the LNP dose needed for bactericidal activity for each of dosing 
range (Figure 4.13 a) and batch model experiments (Figure 4.13 b) (R2= 0.992 and 0.998 
respectively).  
We have interpolated the LNP dose required for a bactericidal effect from the known levels of 
coliforms into the equation from the line of best fit; the predicted bactericidal dose required for 
the gut microbiota samples which did not show bactericidal activity were notably higher than the 
experimental dose e.g. batch model experiment 3 at 2% dose and 3 other donors also used for 
batch model experiments (Figure 4. 13 c); therefore providing an explanation as to why some gut 
microbiota samples respond to LNP treatment better, as they have lower E. coli levels at the point 
of LNP addition. 
More importantly, we have suggested that the LNP dosage effect is not associated with the total 
anaerobic counts, but has a positive correlation with the coliforms population (Figure 4.13), 
indicating that the LNPs are more effective in targeting the bacterial group of interest. This gives 
us confidence that LNP are suitable to be used in a complex bacterial environment to target E. 
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coli, as the antimicrobial response is rapid and LNP dose needed were not affected by the other 
bacterial community present in the sample, thus minimising the amount of LNPs required for 
antimicrobial activity.   
Potential donors were screened for the levels of E. coli before conducting the experiment and 
preliminary tests were done to have a broad estimation of LNP dose needed. However, it is not 
always easy to predict the bacterial community in the starting inoculum in batch model 
fermentation prior to the start of experiment, as the prediction of the LNP dosage response is not 
always indicative as faecal composition can rapidly change through time by environmental factors 
such as diet (David et al. 2014). Furthermore, the analysis of large population scale studies have 
identified stool consistency (Vandeputte et al. 2016) and medication as major non-redundant 
covariances which considerably impact on the composition of gut microbiota (Falony et al. 2016); 
these variables should be considered and recorded in future studies involving faecal samples to 
allow better conclusions to be drawn. These multifactorial relationships need to be explored 
further to gain a full picture of how the microbiota can be accurately rebalanced.  
Also, the formulation of LNP used in this study have limited therapeutic potential, their poor 
solubility result in large excess of 12-bis-THA to TFD. The use of TFD-conjugates could be another 
way of increasing the TFD:12-bis-THA ratio to lessen the 12-bis-THA-associated cytotoxicity while 
increasing TFD-specific antimicrobial activity (Zhao et al. 2015).  
Impact of non-coliforms Enterobacteriaceae on the magnitude of antimicrobial activity 
As the TFD was designed to act on Enterobacteriaceae, it should theoretically be active also 
against P. aeruginosa if delivery is not limiting. It was therefore interesting to see how the 
Enterobacteriaceae population shifts using differential plating and 16S rRNA gene community 
sequencing approach following LNP treatment. Using 4 h time point in the batch culture 
fermentation experiment as an example, different colour colonies of Enterobacteriaceae colonies 
were randomly picked for 16S rRNA gene sequencing for identification at the genus/ species level. 
The proportional reduction of pink colonies (identified as E. coli) were replaced with bright pink 
colonies (identified as Klebsiella pneumonia) in LNP treatment in batch model experiment 1 
(Figure 4.6 b). As Klebsiella pneumonia is a pathogen that has a thick capsule layer (Amako et al. 
1988), this makes it challenging for particles to penetrate the cell surface (Zgurskaya et al. 2015). 
In experiment 2, Escherichia/Shigella spp. was not recovered by sampling for 16S rRNA gene 
colony PCR with LNP but Pseudomonas aeruginosa was; as Pseudomonas largely comprises penta-
acylated LPS (Pier 2007, Kocincova and Lam 2011), which differs from the hexa-acylated LPS that 
E. coli commonly consists of (Caroff and Karibian 2003). The different compositions of outer 
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membrane could affect cell permeability considerably; along with the presence of multiple efflux 
pumps (Ziha-Zarifi et al. 1999, Poole and Srikumar 2001, Zgurskaya et al. 2015), this may allow 
Pseudomonas to be less prone to LNP treatment. As microbiota composition from different 
individuals could vary, it was good to have an indication of the impact LNPs have on other closely 
related organisms in the gut microbiota. Comparing the identity of the Enterobacteriaceae 
colonies from the three batch culture fermentation experiments, it was suggestive that LNP are 
able to reduce Escherichia/Shigella spp. from the gut microbiota repeatedly from three different 
donors.  
Bacterial composition and diversity 
From the 16S rRNA gene Illumina sequencing results, by comparing LNP treatment to control and 
SLNP at the same time point for each experiment, it was confirmed that LNP effectively reduced 
the Enterobacteriaceae abundance while maintaining the diversity of the gut microbiota 
community for all 3 batch model experiments, at 4 h and 8 h for experiment 1 and 2 and at 4 h for 
experiment 3.  Since PMA excludes the dead bacterial community prior to sequencing, 16S rRNA 
gene community analysis became more relevant for the evaluation of the viable bacterial 
community including unculturable bacteria. The decrease in Enterobacteriaceae levels from 16S 
rRNA gene sequencing roughly resembled the trend seen from viable counts (see Section 4.3.3), 
thus confirming LNP acted on both culturable and non-culturable Enterobacteriaceae. For the 
data that had > log10 2.5 decrease in CFU/ml in the batch culture fermentation experiment, a 
decrease in Enterobacteriaceae was also seen in Illumina sequencing data. 
It was unexpected to see Enterobacteriaceae as the majority of the gut microbiota community at 
4 h and 8 h with SLNP treatment in batch experiment 2, as this trend was not seen in viable colony 
count results; the presence of non-culturable Enterobacteriaceae could be a possible reason why 
there were discrepancies in the proportion of Enterobacteriaceae obtained from viable counts 
and 16S rRNA gene sequencing. As Illumina sequencing only display results in relative quantity 
compare to the total bacterial load in each sample, it is difficult to quantify the exact number of 
bacteria in each sample, let alone compare between different samples. It could be that there is a 
lower bacterial load in SLNP than in the control sample, therefore for the same amount of 
Enterobacteriaceae, it appeared as a higher % in SLNP due to less bacteria being present than in 
the control.  
Coliforms were the most rapidly growing bacterial group among the colony count results (log10 3 
CFU/ml increase compared to the start of experiment) for both control and SLNP in batch culture 
fermentation experiment 2, there may be food or energy sources that are more favourable for the 
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growth of Enterobacteriaceae than other commensal bacteria. The collective effect of reduced 
Lactobacillus, Clostridium and Bifidobacterium colony counts in SLNP-treated sample at 8 h may 
contribute towards the reduction in total bacterial load in SLNP-treated sample compared to 
control. 
To evaluate whether the LNP’s preferential antimicrobial activity would fit into categories of 
Enterotype (Arumugam et al. 2011), the donors from experiment 1 and 2 were enriched by 
Bacteroides (Enterotype 1). For the donor in experiment 4, as the levels of Bacteroides were 
marginally higher than Prevotella and Ruminococcus but the overall Ruminococcaceae abundance 
were higher than Bacteroidaceae at the family level. It is hard to define especially when the 
definition of Enterotypes were found to be less clear than originally thought, with some 
researchers favouring the concept of having a gradient of species functionality instead (Jeffery et 
al. 2012). Both donors from experiment 1 and 2 with enriched Bacteroides were effective against 
2% LNP treatment dose showed a preference in reducing Escherichia/ Shigella spp. over Klebsiella 
or Pseudomonas, while donor 4 required a higher LNP dose but did not show observable 
difference in the presence of Escherichia/ Shigella spp. or Klebsiella spp. As the Prevotella and 
Bacteroides groups are functionally overlapping (Holmes et al. 2012), the difference in the 
antimicrobial impact on different donors could be coincidental and are more likely due to a dose-
response effect.  
Principal coordinates analysis 
The overall comparison of the spatial similarity between gut microbiota samples were observed 
using PCoA of the weighted Unifrac. Similar trends have been observed throughout batch culture 
fermentation experiments 1, 2, and 4, where PCoA of the weighted Unifrac distances showed that 
there was a shift in the gut microbiota composition with time for all treatments. For each sample, 
the principal coordinate shifted in a linear direction for consecutive time points from predose to 8 
h, suggesting progressive structural changes occurring through time due to experimental set up.  
At early time points e.g. predose, control and SLNP treatment were clustered in close proximity, 
reflecting these samples have similar microbial community structures. LNPs resembled more 
closely to the starting gut microbiota community structure compared to the controls, this may 
give us an insight into the mechanism by which LNPs act against the gut microbiota in a 
community level; while targeting Enterobacteriaceae, treatment with LNP may also minimise or 
resist change in community structure through time. 
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Microbiome structural changes were shown to be prominent at certain time points when 
comparing PCoA results to plate counting results and 16S rRNA gene community taxa plots. 
Effective LNP treatment resulted in decreased Enterobacteriaceae or coliforms in viable counts 
and 16S rRNA gene community analysis also showed a shift in PCoA plot compared to controls, 
except for samples at 0 h. Changes in taxa plot proportion were relatively small at 0 h as 
Enterobacteriaceae only made up a very small proportion of all the bacteria in the sample, 
therefore explaining why it did not lead to major structural changes in the overall gut microbiota. 
Enterobacteriaceae outgrow other bacterial groups in the batch culture fermentation model 
through time, which made the specific antimicrobial activity of LNPs clearer at later timepoints.  
Metabonomic analysis 
Anaerobic vs aerobic respiration 
Following treatment with an effective dose of LNP i.e. 10% at 0 h and 4 h in experiment 4 (Figure 
4.12), the concentration of metabolites lactate and ethanol were reduced at this LNP dose, 
suggesting decreased anaerobic respiration compared to the controls. The changes in succinate 
concentration with 10% LNPs differs to those with 2% LNP and therefore may explain the 
difference in antimicrobial activity. Succinate is primarily produced by the TCA cycle leading to the 
production of propionate. Though propionate was produced via 3 different pathways by the gut 
microbiota as an energy source (Reichardt et al. 2014), the reduction in its levels suggests a 
reduced rate of growth. As for formate and acetaldehyde, both levels were reduced in LNP-
treated samples regardless of dose. 
Fumarate and nitrate reductase (FNR), a transcription regulator that respond to physiological 
changes depending on environmental and metabolic challenges in E. coli (Balletto and Mikulska 
2015), has been shown to increase expression as a result of the nanoparticulate delivery (Michael 
McArthur, unpublished data). While the docking of LNPs on the bacterial membrane is mainly 
driven by the electrostatic interaction between the cationic LNPs and anionic lipids such as 
cardiolipin and PG, the membrane destabilisation leads to increased bacterial permeability and 
allows TFD to be released within the cytoplasm, possibly by formation of transient pores (Marin-
Menendez et al. 2017). This process is likely to cause stress response within the cell, linking to the 
destabilisation of respiratory chains as cardiolipin have a structural role in anchoring the 
respiratory chains in the membranes (Arias-Cartin et al. 2012). 
The in vitro batch culture fermentation is anaerobic, therefore no advantage is expected for 
facultative anaerobes. Conversely, the batch culture may not be as anaerobic as anticipated and 
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could be microaerobic in part; also the nanoparticle delivery may have a secondary effects on 
anaerobic respiration as the physical disruption of membrane-bound respiratory pathways also 
links to oxidation of iron-sulfur clusters (Beinert and Kiley 1999). 
Aerobic respiration is preferable compared to anaerobic respiration then fermentation for 
facultative bacteria (Crack et al. 2004), as the 2 latter are less efficient in yielding ATP compared 
to aerobic respiration, it would therefore make sense that the bacterial growth is delayed due to 
the switch in a less efficient metabolic pathway to counteract the stress response. As TCA cycle is 
part of aerobic respiration, this data is in conjunction with the finding that, as FNR switches to its 
active, anaerobic form, aerobic respiration ceased and therefore leads to a reduction in aerobic 
respiration compared to the controls. As fumarate is an intermediate metabolite for several 
pathways, it is difficult to pin point what the trend of concentration confers. Other metabolites 
such as glucose and cysteine are also involved in the FNR switch to anaerobic respiration; the 
levels of these metabolites have also fluctuated, suggesting an indicative, yet undefined role of 
FNR on the mechanism of how LNP act on the bacterial community.  
Insight into how the changes in metabolite might indicate the state of the gut microbiota 
Reduction of break down products such as 3-phenyllactate and 4-hydroxyphenylactate was 
observed. As Lactobacillus plantarum has been found to produce phenyllactate as an 
antimicrobial agent in high levels (Lam et al. 2016), it may indicate that the reduction of 3-
phenyllactate was a result of the 2 log10 decrease in lactobacillus viable count at 4 h that was 
observed only with 10% LNP treatment (Figure 4.12).   
In experiment 3, compensating mechanisms have been triggered under stress as suggested by the 
differential concentrations of betaine present in LNP-treated samples. This is an amino acid 
known to improve stress tolerance in bacteria (Metris et al. 2014), suggesting LNP treatment may 
be inducing this response. It is speculated that with 2% LNP, there were insufficient amount of 
LNP to inhibit the stress response from being transcribed as a result of TFD stimulation, betaine 
levels were decreased with LNP-treatment to combat stress (Sleator and Hill 2002, Wargo 2013, 
Metris et al. 2014) and therefore continued to grow as usual. Whereas in 10% LNP-treated 
samples, the levels of LNPs were sufficient to completely inhibit the gene expression in response 
to stress, no stress response was therefore recognised and acted upon from 0 h, which may 
explain why no difference was observed between betaine levels between treatments at 10% 
dose, yet the levels of Enterobacteriaceae was decreased in viable bacterial counts and 16S rRNA 
gene Illumina sequencing. 
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The larger decrease in amino acids i.e. tyrosine, leucine, isoleucine, valine and methionine at 8 h 
compared to the control and SLNP with 2% LNP, may indicate that even though no visible 
differences in growth were observed, the bacterial community was more metabolically active to 
maintain its growth rate. Furthermore, the earlier onset of uracil production for 2% and 10% LNP 
compared to the controls at 4 h were observed. It could indicate an increase in transcription as a 
result of stress response with the uracil being converted to RNA by 8 h. Uracil is also found to be 
synthesised by opportunistic pathogens (but not commensal) to induce reactive oxygen species 
(Lee et al. 2013, Lee et al. 2015), although uracil levels were increased earlier in LNP than in the 
controls, the levels were lower in LNP and was decreased at 8 h to the starting levels, suggesting 
the effects were only temporal and there is no overall adverse effect from LNPs.  
For 10% LNP treatment, the declined use of metabolites i.e. asparagine, aspartate and glutamate 
at 4 h and phenylalanine at 8 h, which are normally used up by control and SLNP, suggest the 
delayed growth from 4 h onwards. Other intermediate metabolic products such as pyruvate and 
fumarate also have a delayed usage compared to control and SLNP may also indicate delayed 
growth as the control and SLNP most likely have used these metabolites up and arrive at 
exponential growth phase before LNP reach the same growth phase. Although the gut microbiota 
struggles to grow, with 2% LNP, it managed to grow regardless as suggested by the decrease of 
methionine, histidine and glucose as substrates and the production of acetate, propionate and 
formate. Although samples treated with 10% LNP had difficulty in growth initially, the momentum 
was also regained at 8 h.  
Lower level metabonomic products such as propionate, ethanol, formate, acetaldehyde and 
lactate suggested that growth occurred at a delayed rate in LNP-treated samples (both at 2% and 
10%) compared to control and SLNP. The metabonomic data is concurrent with the 16S rRNA 
gene Illumina taxa plot and PCoA plot for 10% LNP treatment as the 4 h sample closely resembles 
the community at predose and 0 h. 
Comparing LNPs with currently available antibiotics against Enterobacteria 
The side effects of antibiotics also targeting Enterobacteria were compared to LNPs with FNR TFD. 
Decrease bacterial diversity were observed after Ciprofloxacin (Dethlefsen et al. 2008, Dethlefsen 
and Relman 2011) treatments. This suggests that LNPs may be a better alternative to antibiotics 
as it reduces disruption to the gut microbiota and maintained microbiota diversity. 
To conclude, by combining different experimental approaches e.g. viable bacterial counting, 16S 
rRNA gene sequencing and NMR metabonomic analysis, this allowed the exploration of how LNPs 
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interact with the complex gut microbiota and improved understanding of how might LNPs reduce 
the targeted organisms with minimal disruption to the native microbiota.  
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Chapter 5: TFD specific targeting against 
Enterobacteriaceae in mouse model 
5.1. Introduction 
In vitro experiments in the previous chapter provided insights into how the gut microbiota would 
respond to LNP treatment. However, they do not account for host-drug or host-microbiota 
interactions which have an equally important role in evaluating the success of a drug intervention 
(Kostic et al. 2013). 
Testing the efficacy of TFD in vivo is therefore needed. For this, animal models are often used as 
the next step to evaluate the drug efficacy before clinical trials are performed (Hughes and Karlen 
2014). Murine studies are the easiest and most widely used to evaluate changes to the gut 
microbiota. They provide insights on how drug intervention can affect both the gut microbiota 
and the host, allowing comparison of the host-microbiota interaction (Nguyen et al. 2015, Grigg 
and Sonnenberg 2017). The organs of the intestinal tract in mice are anatomically similar to 
humans and are composed of similar sectional tissues (such as mucosa, lamina propria and 
submucosa) and cell types (such as absorptive colonocytes, goblet cells and enteroendocrine 
cells). As such they can used to monitor changes to the integrity of the intestinal mucosal barrier 
in the small and large intestine (Ju et al. 2017). 
Following the validation in vitro of LNP’s antimicrobial activity against human gut microbiota in 
the previous chapter, a mouse model was used to determine whether the antimicrobial activity 
can be translated to a setting in vivo and to determine whether any side effects could be observed 
in mice when LNP are administered. C57BL/6J wild type mice were used to assess the LNP’s 
target-specific efficacy against Enterobacteriaceae in the native gut microbiota setting using a 
physiologically relevant dosing regimen, using similar experimental parameters as the previous 
chapter such as viable bacterial counts, 16S rRNA gene community analysis and metabonomic 
profiling. Additionally, the effects of LNP on epithelial barrier integrity were evaluated. 
5.2 Methods 
Methods specific for mouse experiments are described in Chapter 2, Section 2.9.  
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5.3 Results 
5.3.1 Analysis of viable microbial community in mouse faeces 
Experiment 1 
An effective way to monitor changes in the murine gut microbiota is to perform microbiological 
analysis of their faeces. Faecal samples were collected and serial diluted for subsequent 
quantification by bacterial counts on agar plates, to assess the main bacterial communities 
including anaerobic bacteria, Bacteroides, Clostridium, Lactobacillus and coliforms. As the transit 
of materials through the stomach is expected to take 6 h (Padmanabhan et al. 2013), decrease in 
coliforms were observed with LNP treatment at 6 h after the initial treatment as expected, with 
two oral gavage treatments at 0 h and 2 h. No effect was seen in all other measured bacterial 
communities in control and SLNP treatments (Figure 5.1), this indicated that the viable bacterial 
communities were unaffected by the LNP treatment except the targeted coliforms population.  
Significant reduction in coliforms at 6 h were observed in LNP treatment compared to the control 
and SLNP (P ≤ 0.01). As the coliforms measured at 6 h were below the detection limit (< 200 
CFU/ml) with LNP treatment, this equates to a decrease in coliforms numbers of at least log10 3.5 
CFU/ml implying a bactericidal effect. Also, a log10 2 CFU/ml decrease in coliforms at 24 h was 
observed in LNP treatment compared to the SLNP and control.  
The control and SLNP colony counts for anaerobic bacteria, Bacteroides, Lactobacillus and 
coliforms were similar throughout the mouse experiment, suggesting that the nanoparticles 
themselves had little effect on the viability of gut microbiota and the antimicrobial activity is 
mostly TFD specific with the current dosing regimen. Mice with LNP treatment had similar 
bacterial counts to those with SLNP treatment except coliforms. The Clostridium levels in the LNP 
group mice were higher than the mice in the control and SLNP group before oral gavage 
treatments, suggesting some intrinsic gut microbiota variation between groups of mice when 
caged separately. The prevailing trend of Clostridium levels between mice in different groups 
were nonetheless consistent across all time points. This suggests LNP’s ability to specifically 
reduce the coliforms viable population 6 h after the initial drug administration into the stomach, 
without altering the viability of the rest of the gut microbiota community. 
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Figure 5.1 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus and 
coliforms for mouse experiment 1. Means were calculated from a minimum of 3 samples of faecal 
pellet (n=3) as some did not produce a faecal pellet at certain time points. Double asterisks 
denotes P ≤ 0.01. 
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Experiment 2 
As signs of distress were indicated in mouse experiment 1, faecal sampling at 2 h was omitted to 
allow the mice to recover from the initial drug administration procedure. As SLNP treatment 
showed no difference in viable counts compared to LNP in experiment 1, a lower dose of LNP (i.e. 
LNP diluted 1:5 in vehicle control) was used instead of SLNP to elucidate whether the LNP activity 
against coliforms was dose-dependent. With this new experimental set up, all mice produced 
faecal pellets at all the required time points.  
Coliforms counts were similar between control and low dose LNP treatment at 0 h, 4 h, 6 h, 8 h, 
and 24 h (Figure 5.2). The coliforms population significantly decreased by log10 2 CFU/g at 6 h (P ≤ 
0.01) and log10 3 CFU/g at 8 h (P ≤ 0.001) by LNP treatment compared to control and SLNPs, 
though the viable colonies returned to similar levels to the control and low dose LNP treatments 
by 24 h. This indicates a dose dependant response was present with the LNP treatment as only 
the undiluted LNP treatment showed antimicrobial activity against coliforms. Control, low dose 
LNP and LNP had generally similar viable colony counts for anaerobic bacteria, Bacteroides and 
Lactobacillus. Like experiment 1, variability was seen in the amounts of Clostridium at the start of 
the experiment, though difference were not notable.  
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Figure 5.2 Bacterial viable counts for anaerobes, Bacteroides, Clostridium, Lactobacillus and 
coliforms for mouse experiment 2. Means of colony forming units of 5 mice (n=5) were calculated 
± SD. Double and triple asterisks denote P ≤ 0.01 and P ≤ 0.001 respectively. 
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5.3.2 Metataxonomic analysis of microbial community in mouse faeces 
To determine the viable amounts of Enterobacteriaceae using 16S rRNA gene sequencing 
methods, samples were taken from each mouse at each time point and treated with PMA and 
photo-activation before DNA extraction. The metataxonomic profiles were characterised by 
sequencing of 16S rRNA gene V4 region from faecal contents.  
Despite Enterobacteriaceae making up only a low proportion of the total bacterial community, the 
averaged relative abundances were plotted for each treatment (Figure 5.3). It was shown in 
experiment 1 that the proportion of Enterobacteriaceae was higher in the control sample than 
SLNP (by > 3 fold) and LNP (by > 5 fold), indicating SLNP and LNP treatments resulted in lower 
proportions of Enterobacteriaceae compared to control. Also, Enterobacteriaceae decreased to 
0% at 6 h with LNP-treated samples while this group was still present in the control and SLNP-
treated samples. Similar trends was seen in experiment 2, where Enterobacteriaceae levels were 
higher in the control than LNP treatment at 4, 6 and 8 h. The similarities observed in both 
experiments may indicate the increase in Enterobacteriaceae levels were inhibited in the 
presence LNP. 
 
 
Figure 5.3 Relative abundance of Enterobacteriaceae taken from taxa plot from 16S rRNA gene 
community analysis. Data extracted from taxa plot of community analysis. Left, exp 1; right, 
experiment 2.  
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To look at the overall changes in the 16S rRNA gene community, the samples were grouped by 
treatments at each time point. Samples at 0 h were dominated by the family S24-7 (from the 
order Bacteroidales), an unclassified family (in the order Clostridiales), Lachnospiraceae and 
Ruminococcaceae and Rikenellaceae, with the LNP group mice having proportionally more S24-7 
and less of an unclassified family of Clostridiales, Lachnospiraceae and Ruminococcaceae than 
those in the control and SLNP groups (Figure 5.4). 
In experiment 1, changes in the bacterial community were seen in the samples treated with saline 
vehicle control at different time points (especially between 0 h and 4 h), indicating that gut 
microbiota can rapidly change within the sampling period. Comparing samples at 0 h and 4 h, 
there is generally a higher relative abundance of family S24-7 in the control and SLNP and a 
relative decrease with LNP treatment. LNP-treated samples have in turn increased proportions of 
an unidentified family (in order Clostridiales), Lactobacillaceae, Lachnospiraceae and 
Ruminococcaceae at 4 h, with similar community proportions to the 0 h control and SLNP 
samples. 
At 6 h, control samples had a similar trend to that seen at 4 h. With a decrease in S24-7 family, an 
unidentified family in Order Clostridiales, Lachnospiraceae and Ruminococcaceae were in turn 
increased with SLNP treatment at 6 h. In contrast these communities were decreased with LNP-
treated samples with a large increase in Bacteroidaceae, Prevotellaceae and Rikenellaceae 
abundances. 
At 24 h, S24-7 decreased and Lachnospiraceae and Ruminococcaceae were increased in all 
treatment groups. In addition, control samples have decreased Lactobacillaceae and increased 
unidentified family in Order Clostridiales, Rikenellaceae, Prevotellaceae and Bacteroidaceae. SLNP 
had decreased Lactobacillaceae and increased Rikenellaceae, Prevotellaceae and Bacteroidaceae 
levels. With LNP-treated samples, S24-7 were hugely decreased with increases in an unidentified 
family in Order Clostridiales, Lactobacillaceae, Lachnospiraceae and Ruminococcaceae. 
In general over the 24 h period, SLNP-treated samples had similar gut microbiota communities 
and abundances to the control or the SLNP profile at 0 h, suggesting the delivery nanoparticles did 
not pose obvious change to the gut microbiota. LNP on the other hand, had an overall decrease in 
the S24-7 family and increases in unidentified family in Order Clostridiales, Lachnospiraceae, 
Ruminococcaceae, Prevotellaceae, Bacteroidaceae and Rikenellaceae. 
In experiment 2, similar trends were observed with LNP treatment compared to experiment 1. 
Samples in experiment 2 were populated by similar bacterial family to experiment 1, with S24-7 
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being the majority, along with Clostridiales order, Lachnospiraceae, Ruminococcaceae and 
Rikenellaceae.  
Like experiment 1, S24-7’s relative abundance fluctuated across time points, with some 
proportional shift of other members in the community consequently. The fluctuation of S24-7 
were consistent in experiment 1 and 2 at 0 h, 4 h and 6 h with LNP treatment compared to the 
control, the consequential shifts of other communities were also similar. However, the levels of 
S24-7 with LNP treatment were higher than the control at 24 h in experiment 2, which is opposite 
to the trend observed in experiment 1. Instead, relative abundance of S24-7 is higher than 
control, with decrease in Clostridiales, Lachnospiraceae and Ruminococcaceae.  
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Figure 5.4 Bacterial community analysis of 16S rRNA gene sequencing at family level for mouse 
experiment with PMA-treatment with average bacterial populations. a) experiment 1; b) 
experiment 2. (O) indicates an unidentified family in the described order.   
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Principal Coordinates Analysis 
To determine the community structures of the gut microbiota samples upon LNP treatment, 
weighted unifrac Principal Coordinates Analysis (PCoA) plots were used to look at the spatial 
relationship between different samples in the same experimental run. For PCoA plots from mouse 
experiment 1, LNP were structurally more distant from control and SLNP at 0 h on the PC1 scale 
(which accounted for 45.15% of the variability) (Figure 5.5 a). At 4 h, control and SLNP shifted 
towards the LNP-treated samples at 0 h (on the right along PC1 axis) whereas 2 out of 3 LNP-
treated samples were situated closer to the control and SLNP samples at 0 h (on the left along PC1 
axis), suggesting the LNP-treated gut microbiota were structurally similar to the control samples 
at the start of the experiment.  Although all treatments were scattered at 6 h and 24 h, the 6 h 
samples were on the right half of the PC1 axis. At 24 h, LNP scattered on the left-hand side, SLNP 
samples were in the middle and controls remained on the right-hand side of the axis. In 
experiment 2, there was no clustering of samples for each time point, as samples from mice with 
the same treatment were evenly scattering along the PC1 axis at each time point (Figure 5.5 b). 
However, there was spatial separation between the two treatment groups since the start of 
experiment, all the control samples were located at the bottom half of the PC2 axis and the LNP 
samples were situated at the top half on the axis.  
As the structure of the gut microbiota is different in the control and LNP group at the start of both 
experiments, it is hard to compare the structural dynamics of LNP-treatment compared to the 
controls from these data. 
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Figure 5.5 Principal coordinates analysis (PCoA) plots from 16S rRNA gene community analysis for 
in vivo mouse model. a) experiment 1; b) experiment 2. 3D PCoA plot was generated from 
weighted UniFrac analysis, where x- and y- axis represents the first and second coordinates 
respectively. 
 
5.3.3 Metabonomic analysis of mouse faeces 
To determine whether similar metabonomic profiling observed in LNP treatment in the previously 
chapter can be seen in vivo and if they would mirror the changes in the microbial community, 1H 
NMR spectroscopy was used to identify the metabolites present in the mouse experiment 
samples with different NP treatments. A representative NMR spectrum, shown from mouse 
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experiment 1 (Figure 5.6), is shown to evaluate the profile of metabolites following LNP 
treatments.  
No noticeable difference in metabolite concentration was shown between treatments at different 
time points, including metabolites butyrate, acetate, propionate, isobutyrate, isovalerate, 
valerate, ethanol, formate, trimethylamine, putrescine, 3-hydroxyphenylpropionate, 3-
hydroxyphenylacetate, 3-phenyllactate, 3-phenylpropionate, glucose, xylose, alanine, aspartate, 
glutamate, glutamine, glycine, isoleucine, lysine, methionine, tyrosine, taurine, pyruvate, 
succinate, hypoxanthine and uracil. Large variation were observed within mice and between mice 
samples, along with limited amount of faeces were available for sampling, making it difficult to 
draw meaningful deductions from the data. 
The metabonomic results from mouse experiment 1 and experiment 2 were comparable, 
suggesting the lack of notable metabonomic separation between samples with control, SLNP and 
LNP (low or normal dose) treatments. 
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Figure 5.6 A representative of metabonomic profile from mouse experiment 1, showing the large 
variation within and among mouse faecal samples. M= mouse identification in each group. 
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5.3.4 Experimental observations of mouse health 
Experiment 1 
The treatments were administered by two 100 µl oral gavages to the mice at the commencement 
of the experiment (0 h) and 2 h following. The treatments were the vehicle control and the SLNP 
and the LNP. The mice were observed throughout the experimental period to monitor early 
indicators of distress to minimise suffering following the treatments. In addition faecal samples 
were collected at the following time-points post the experimental start: 0 h, 2 h, 4 h, 6 h and 24 h 
(see Section 2.9). This process involves handling the mice causing them to defecate. One mouse 
with SLNP treatment and two mice with LNP treatment were euthanised after the 2 h and 4 h 
faecal collections respectively, as physical signs of illness were observed followed by the dosing/ 
sampling regimen. 
After dissection, tissues from the SLNP and LNP group had abnormal morphology compared to the 
controls. Shortened small intestine and colon with more liquid faecal pellets were generally 
observed in mice treated with SLNP. One of the SLNP treated mice also looked ill, had very thin 
and narrow intestine and a smaller caecum; whereas another mouse had no faecal content in the 
duodenum, jejunum and ileum and had a smaller cecum. LNP-treated mice had similar 
observations as seen in SLNP, a shorter small intestine was observed compared to control and 
faecal pellets were found to be soft in Ileum but normal in the colon. 
Experiment 2 
With the aim to reduce stress of animals, faecal sample collection at 2 h was omitted after the 
oral gavages and collection was at 8 h instead (see Section 2.9). To determine if there is a dose-
dependent effect, the SLNP treatment was replaced with a lower dose LNP that had been diluted 
in the vehicle (1:5 diluted). At 6 h and 8 h, the mice in LNP treatment group started to show signs 
of stress, including hunchback posture and piloerection. At 8 h, mice with low dose LNP showed 
signs of piloerection; one mouse with LNP treatment had unusually narrow faecal pellets. Mice 
with LNP treatments (both low-dose and normal) had harder stools. No euthanisation was 
required before the end of experiment. At the point of dissection, two mice with low dose LNP 
treatment had very thin small intestines whereas one mouse in the LNP treatment group did not 
have any colon content. 
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5.3.5 Histological analysis of mouse intestinal tissues 
Haemotoxylin and eosin staining was performed to assess whether any signs of epithelial damage 
occurred in the colon occurred after LNP treatment. Haemolysin is a purple stains that binds to 
acidic components in cells such as DNA and RNA. Whereas eosin reacts with basic structures such 
as protein and cytoplasmic components and stain them pink. Representative histological samples 
from mouse experiment 1 are shown in Figure 5.7. In control mice, colon samples have normal 
histological morphology as healthy colonic crypts; colon crypts in LNP- treated mice (either 
healthy or ill) both had similar morphology to those seen in control mice.  
Normal crypt architecture, no observable inflammatory cell infiltration and no muscle thickening 
were seen, globet cell depletion was absent, as were crypt abscess, indicating no histological 
damage typical to colitis was observed according to Kim et al. (2012). The lamina propria appears 
normal and intact, with no signs of inflammations or cell shedding observed as per Erben et al. 
(2014).  
Moreover, comparing the histology of LNP-treated mice that remained healthy during the 
experiment or were culled after 4 h, no histological differences in the healthy or ill LNP-treated 
mice were observed. This may indicate that, even though some mice showed signs of illness 
during the experimental period, it could be a transient effect as little difference was observed in 
their epithelial morphology in the colon.  
Overall, no cell shedding or inflammation in colonic crypts observed was upon LNP treatment 
compared to control mice. This indicated that LNP treatment did not affect the colonic epithelium 
during the experimental period. While there was no observable difference in colonic crypt lengths 
between control and LNP-treated healthy mice, the colonic crypts were considerably shorter in 
LNP-treated mouse that was euthanised before end of experiment compared to the control by 
about 50%. However, this could be due to sectioning variation in the position of colon, as the 
sectioning from mouse euthanised prior to the end of experiment (Figure 5.7 c) resembled the 
proximal colon, as opposed to control and LNP healthy mice (Figure 5.7 a and b) which resembled 
the distal colon. 
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Figure 5.7 Histological photomicrograph of mouse colon stained with haematoxylin and eosin at 
4x and 20x magnification from a) saline control mouse; b) LNP-treated healthy mouse; and c) LNP-
treated mouse with signs of illness that was euthanised prior to the end of experiment.  
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5.4 Discussion 
Antimicrobial activity was observed when two oral gavages were given in experiment 1 and 2, 
coliforms viable bacterial counts were specifically reduced at 6 h and 6-8 h with LNP treatment 
respectively without changing the rest of the commensal bacterial community observed by viable 
bacterial plate counting, indicating that TFD specific antimicrobial activity against coliforms (which 
are members of Enterobacteriacae) was observed in the in vivo mouse model. Antibiotics 
norfloxacin and ampicillin was found to significantly decrease anaerobic bacteria by log10 3 CFU/g 
of faeces in another mouse study (Membrez et al. 2008). The CFU decrease is comparable in the 
mouse experiments but showed a more selective approach with minimal changes to the rest of 
the culturable faecal community, suggesting that LNP have a more specific approach on the 
alteration of the mouse gut microbiota. As most mouse studies typically evaluate antimicrobial 
activity after a minimal of 1 day (Spees et al. 2013, Lackraj et al. 2016, Yao et al. 2016), the fast 
acting nature of LNP may be an advantageous to reduce rapidly multiplying bacteria particularly 
at the start of an infection.    
16S rRNA gene community analysis has shown that the bacterial community may be more diverse 
than expected, as Enterobacteriaceae only made up a small percentage of the total abundance in 
the faecal samples in both experiments. Enterobacteriaceae abundance was nonetheless 
diminished at 6 h with LNP treatment, with temporal fluctuation in the proportion of other 
bacterial families, but did not affecting the communities present in the samples. The huge relative 
abundance of unculturable gut microbiota preserved in the samples compared to those 
detectable from bacterial culturing method may explain the large discrepancy to the expected 
abundance of Enterobacteriaceae. 
The main constituents of the gut microbiota at the family/order level in mouse experiments 
showed some similarities in the microbiota composition in C57BL/6J mouse from the literature, 
where Bacteroidetes and Clostridiales were the predominant members of the gut microbiota 
(Zakostelska et al. 2016). S24-7 is one of the main members in the 16S rRNA gene analysis of gut 
microbiota in a C57BL/6 mice model (Yao et al. 2016); Lactobacillaceae, Lachnospiraceae and 
Ruminococcaceae were also seen in other studies at the family level (Steegenga et al. 2014, Yao et 
al. 2016). S24-7, an uncultured family in Bacteroidales that dominated the mice gut microbiota 
from 16S rRNA gene community analysis in both experiments (Figure 5.4), was also previously 
described as a predominant member of the gut microbiota in mice (Salzman et al. 2002) and at 
lower abundance in other homeothermic animals e.g. humans (Ormerod et al. 2016). Increased 
abundance of S24-7 was found in diabetes-sensitive mice with a high fat diet (Serino et al. 2012) 
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and C57BL/6J male mice with increased exercise when fed a low-fat diet (Evans et al. 2014). 
However, the implication of the fluctuations in this family is still not well studied.  
Effects of other antibiotics on the commensal microbiota in mouse models in 16S rRNA gene 
community analysis 
The gut microbiota abundance was not changed by time and treatment over the 24 h period, the 
only taxon with substantial compositional decrease was S24-7, several taxa e.g. Clostridales order, 
Rikenellaceae family and Bacteroidales order had compensating compositional increase to 
maintain bacterial abundance when S24-7 declined. Similar observations (except increase in 
Bacteroidales) were described in a pathogen-selective treatment with minimal disturbance of the 
mouse gut microbiota (Yao et al. 2016), who demonstrated a recovery of gut microbiota 
composition 2 days after the treatment had stopped compared to 7 days with antibiotic 
treatments. As whole genome sequence of S24-7 is not available, it was difficult to elucidate 
whether the decrease was due to the presence of Crp-FNR transcription factor. S24-7 is a member 
of the Bacteroidales order, therefore it would be rational to speculate other families in this order 
e.g. Prevotellaceae and Bacteroidaceae were increased to preserve similar functional roles in the 
gut microbiota.  
As our experimental end point stopped only 24 h after the initial treatment, the assessment of the 
mice gut microbiota with an extended recovery period is required to fully evaluate the recovery of 
the gut microbiota post-LNP treatment in the future.  
No metabonomic difference has been found between different treatments in both experiment 1 
and 2, it was suspected that metabonomic changes due to the specific reduction of 
Enterobacteriaceae may not be observable as Enterobacteriaceae only make up a diminutive 
portion of the total gut microbiota community from 16S rRNA gene analysis. As limited amounts 
of faecal samples were obtained from the mice to minimise stress, the NMR samples were diluted 
by nine times compared to the typical protocol to obtain the volume for NMR analysis, this lead to 
weakening of signals for sugars such as xylose, glucose, arabinose and galactose etc 
proportionally. The quality of the data was good nonetheless and the substantial dilution of the 
samples has not affected the quantification of metabolites otherwise.  
Antibiotics have been found to result in extensive alterations in the microbial intestinal 
metabonome, further contributing to the imbalances that interfere with the intestinal 
homeostasis (Antunes and Finlay 2011, Perez-Cobas et al. 2013). It may be of advantage for the 
antimicrobial to have minimal effect on the metabonomic responses, as they may suggest 
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minimal disruption to the metabonomic profile of gut microbiota when exerting antimicrobial 
activity only on a small group of bacteria, implying LNP’s selective antimicrobial activity has 
minimal disruption in the gut microbiota metabonome that would minimise further metabonomic 
damage to an already imbalanced gut microbiota. However, as there were interindividual 
differences between the 16S rRNA gene community gut microbiota profile, the metabonomic 
profile may also differ between mice within the treatment group, making it difficult to pinpoint 
the typical changes in metabolites following the treatment regimen. 
Evaluation of mice’s health status  
Multiple oral gavage dose of LNPs were administered in Golden Syrian hamster model in a C. 
difficile study and no adverse effect was seen, it was not expected that LNPs would cause harm to 
animals by multiple gavage dosing (Marin-Menendez et al. 2017). A few mice had to be 
euthanised before the end of the experiment 1 with SLNP and LNP treatment as the extent of 
poor health reached humane endpoints (National Research Council 2009). The initial experimental 
design has included collection of a faecal pellet after gavage dosing at 0 h and 2 h, as mouse 
would usually produce a pellet following a gavage procedure. However, the acquisition of faecal 
sample was not as easy as expected and may have increased pressure on the mice to provide a 
faecal sample after gavage was administered.  
To improve well being of mice, faecal collection was omitted from 2 h and was changed to 8 h 
instead in the next experiment. Low-dose LNP (1:5 diluted) was used instead of SLNP to 
determine whether dose-dependent LNP activity was present. The presence of coliforms specific 
antimicrobial effect with LNP was consistent with experiment 1, while low dose LNP did not 
produce any changes in the gut microbiota, this emphasised the dose-response effect of LNP and 
the higher dose is needed to alter the microbiota given the high density of bacteria. Mice also 
showed delayed and fewer signs of poor health such as first signs of pain, distress and discomfort 
compared to experiment 1 and none reached the humane endpoint before the end of 
experiment, suggesting an improvement in experimental design to relieve stress can avoid 
adverse health in mice. This may be due to increased time given to mice to recover from the oral 
gavage before the faecal pellet was demanded. Stress phenotypes were displayed at an earlier 
time point in LNP compared to low dose LNP in experiment 2, suggesting that the indication of 
pain-associated behaviour may also be dose-dependent.   
From the observations from both experiments, it was suspected that the combination of repeat 
dosing and faecal pellet collection at 2 h in experiment 1 may be too stressful for the mice. The 
adverse effect could also originate from the delivery agent. Even though the delivery nanoparticle 
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is selective for bacterial membranes, it also has some residual activity for eukaryotic membranes 
as slight haemolysis was previously observed (Marin-Menendez et al. 2017). The combination of 
both factors may exceed the mice’s tolerance and accentuate signs of distress after the SLNP and 
LNP treatment were administered.  
It has been found that the oral gavage process can lead to stress in C57BL/6 male mice by 
increasing systematic stress response (Walker et al. 2012). Increased stress and mortality was also 
observed upon repeated gavage dosing (Arantes-Rodrigues et al. 2012). Furthermore, as B57BL/6 
males were used in the study, while being more prone to bacterial infection, they have increased 
stress-related gene expression compared to their female counterparts upon E. coli LPS challenge 
(Everhardt Queen et al. 2016), which could explain why stress phenotypes were observed as male 
mice were used in the experiments.  
Effect of LNP on the histological morphology of colon 
Even though some LNP-treated mice showed signs of stress and were associated with shortening 
of intestine and reduced cecum size in experiment 1 and 2, the histological morphology was 
similar between control- and LNP-treated colon for mice that remained in a healthy physical state. 
Colonic crypt length was only shortened in the LNP-treated mouse that required euthanisation 
before the end of experiment 1, suggesting mortality could be affected by stress and/or the 
extent of tissue damage. The above observations were also noted in other animal models of colitis 
and inflammatory bowel disease (Siegmund et al. 2001, Noti et al. 2010, Mishra et al. 2013). As 
only one mouse were euthanised before the end of experiment, it would be difficult to 
differentiate sectioning variation from the histological damage at the current sample size. The 
shortening of small intestine with SLNP and LNP treatment may suggest that the delivery 
nanoparticle could be cytotoxic to mice reaching certain levels and affect tissue morphology with 
double gavage dose, though the histopathological changes were less severe compared to broad-
spectrum antibiotics such as streptomycin (Spees et al. 2013). To increase efficacy and reduce side 
effects from the delivery nanoparticles, TFD-conjugates, which decrease 12-bis-THA: TFD ratio by 
1000, were tested by co-workers to have comparable antimicrobial activity as LNP and 
Levofloxacin in a in vivo Galleria mellonella model infected with pathogenic E. coli (Michael 
McArthur, unpublished data), this derivative would likely overcome toxicity issues the current LNP 
formula has experienced.  
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Lessons learnt and future work  
Combining both experiments, we would test for single dose of TFD-conjugate (so more TFD and 
less 12-bis-THA is used compared to the current LNP formula to reduce toxic effect) using female 
mice and/ or in a disease model (e.g. DSS-induced colitis) and evaluate antimicrobial activity for a 
longer period to see if the gut microbiota recover to the control community after treatment (to 
determine whether any alterations of gut microbiota is transient or long term). The translational 
potential of a murine model to human terms is limiting as the composition of mice and human 
microbiota differs. A human-microbiota-associated animal model can be used instead for a more 
in depth investigation on how the LNP affect the human microbiota in vivo (Lundberg et al. 2016, 
Staley et al. 2017). Also for the existing mouse experiments, evaluating liver toxicity would be 
beneficial to determine the presence of a systemic effect of LNP if more time is allowed. 
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Chapter 6: TFD specific targeting against 
SRB  
6.1. Introduction 
Sulphate reducing bacteria (SRB) are commensal residents of the human gut microbiota and have 
been described as having a physiological role in health (Motta et al. 2015) and disease 
(Ijssennagger et al. 2016). They are a phylogenetically diverse group of strict anaerobes that are 
classified by their ability to obtain energy by oxidizing hydrogen while reducing sulphate to 
hydrogen sulphide (H2S) as the end product of sulphate reduction (Muyzer and Stams 2008). Gut 
microorganisms can use H2S as an energy source (Ley et al. 2006, Goubern et al. 2007) and it has 
been reported to play a role in maintaining the integrity of microbiota biofilm and improving 
colonic mucus production (Motta et al. 2015). Endogenous H2S are produced by host cells at low 
levels and are used as a signalling molecule in epithelial tissues (Wang 2012), and are carefully 
balanced to maintain physiological relevant levels to avoid cell toxicity from excess H2S (Pouokam 
and Althaus 2016).   
However, deleterious mechanisms by which H2S can degrade the colonic mucus layer 
(Ijssennagger et al. 2015) and induce DNA damage (Attene-Ramos et al. 2007, Attene-Ramos et al. 
2010) have been reported. High levels of H2S can also induce damage in the intestinal epithelium 
(Nakamura et al. 2010, Medani et al. 2011) and are associated with IBD (Roediger et al. 1993b, 
Wallace et al. 2009) and colon cancer (Cao et al. 2010, Carbonero et al. 2012, Ijssennagger et al. 
2016).  
The balance between the interplay of beneficial and detrimental effects of H2S are crucial for gut 
health (Feng et al. 2017), and the need to develop tools that modulate the levels of SRB and H2S 
to improve the understanding of their role in health and to facilitate the investigation of disease 
association is clear.  
As SRB carry non-redundant functions to utilise hydrogen and sulphate and are represented by 
relatively few species in the gut (Marchesi 2011), mainly members of the genus Desulfovibrio in 
the class of Deltaproteobacteria (Scanlan et al. 2009), this makes SRB a good target to reduce the 
H2S producing niche that has a pivotal role in human health.  
Transcription factor decoy (TFD) has an adaptable spectrum of antimicrobial activity depending on 
the transcription factor the TFD is designed to target. This system can therefore be explored to 
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evaluate SRB targeting. Functional genes that are highly conserved among SRB include 
dissimilatory (bi) sulphite reductase (dsrB), which is essential for the reduction of sulphite to 
sulphide, and has been utilised as a phylogenetic marker for SRB identification (Geets et al. 2006, 
Giloteaux et al. 2013, Guan et al. 2014, Gao et al. 2015, Tian et al. 2017). As SRB are a 
phylogenetically diverse group, targeting shared metabolic genes is a logical and promising 
approach. 
In the previous chapter, we focused on TFD targeting using Enterobacteriaceae as a model 
organism. In this chapter, we extend the application of the TFD to another GI tract organism, to 
determine whether TFD could be utilised to selectively reduce SRB that have conserved metabolic 
functions. SRB were isolated from human faeces and their whole genomes sequenced for future 
characterisation. Primers were designed to identify human SRB and used to develop an 
alternative method of quantification using qPCR. Genome mining was performed to identify 
possible SRB gene targets, their transcription binding sites were used for the design of SRB-
targeting TFD before their antimicrobial activities were tested. Confocal scanning microscopy was 
also utilised to evaluate the TFD delivery within the SRB.  
6.2. Materials and Methods 
For materials and methods relevant to this chapter, see 2.8.1 for Isolation of human SRB, 2.8.2 for 
Gram staining, 2.7.1 for PCR conditions,2.6.3 for gel electrophoresis, 2.6.4 for Measurement of 
DNA concentration (all samples were measured using Nanodrop except PCR products amplified 
from gDNA of SRB, which were measured with Qubit), 2.7.2 for identification of bacterial isolates, 
2.7.3 for qPCR primer design, 2.7.4 for qPCR, 2.7.5 for genome DNA extraction of SRB, 2.8.4 for 
Designing TFD to target SRB, 2.2.1 for Making TFD and NPs, 2.2.2 for Minimum inhibitory 
concentration, and 2.4 for confocal microscopy. 
6.3 Results 
6.3.1 SRB Isolation of SRB from human faeces 
SRB were isolated from human faeces from four different donors using Postgate Medium C to 
identify human isolates for subsequent experimental analysis. Based on analysis of 16S rRNA gene 
sequencing, 16 isolates were identified as Desulfovibrio piger (S_ab score ≥ 0.96), 5 isolates were 
identified as Veillonella tobetsuensis (S_ab score ≥ 0.98), 5 isolates identified as Veillonella parvula 
(S_ab score ≥ 0.97) and 1 isolate as Veillonella spp. (S_ab score =1). 
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One representative Gram staining image for each group is presented in Figure 6.1, the cell wall of 
D. piger (Figure 6.1 a) appeared pink and had rod shaped morphology, confirming that they are 
Gram-negative bacteria (Beveridge 2001). V. parvula (Figure 6.1 b) and V. tobetsuensis (Figure 6.1 
c) retained the purple crystal violet stain on the cell wall and were identified as Gram-positive 
cocci. All the above data are summarised in Table 6.1. 
 
    
Figure 6.1 Gram staining of human gut SRB isolates. Representative images of isolates as 
presumptive left) D. piger (Gram negative) bacteria; middle) V. Parvula (Gram positive) and right) 
V. tobetsuensis (Gram positive). 
 
Table 6.1 Summary table of SRB isolated from human faecal samples. S_ab score is the 
percentage of shared similarity between sequences compared. 
16S rRNA gene 
identification 
S_ab 
score 
Isolates no. Gram stain (+/-) Cell morphology 
Desulfovibrio piger ≥ 0.96 1-10,16-21 - rod 
Veillonella tobetsuensis ≥ 0.98 12,22-25* + cocci 
Veillonella parvula ≥ 0.97 13-15,25*,26 + cocci 
Veillonella spp. 1 28 + cocci 
*isolate 25 has been identified as both Veillonella tobetsuensis and Veillonella parvula 
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6.3.2 Primer designs and qPCR method development 
Designing dsrB qPCR primers 
To develop a method of quantifying human SRB using qPCR, the coding nucleotide sequence of 
dsrB genes from various SRB species that have been identified in the human gut microbiota from 
relevant literature (Loubinoux et al. 2002, Carbonero et al. 2012, Jia et al. 2012, Nava et al. 2012, 
Rey et al. 2013) were collected from the NCBI database (NCBI 2017). Sequences from 
Desulfovibrio NY682 (EU294503.1), Desulfovibrio sp. 6_1_46AFAA (ACWM01000066.1), 
Desulfovibrio piger (ABXU01000058.1), Desulfovibrio desulfuricans (CAC09931.1), Desulfovibrio 
intestinalis (BAB55572.1), Desulfovibrio vulgaris Hildenborough (U16723.1) were aligned for the 
design of human_desulfov qPCR primer set (to amplify human Desulfovibrio spp.). An addition of 
Desulfobacter vibrioformis (CAB95043.1), Desulfotomaculum kuznetsovii (CAC36145.1), 
Desulfobulbus rhabdoformis (CAB95039.1) were also used for the design of dsrB_Human qPCR 
primer set for the amplification of a wider range of human SRB (Figure 6.2). Based on the 
alignment, sequences used for Human_Desulfov primer set were F: 5’ TGCGACATCGCCGACAA 3’, 
R: 5’ CGCACATGTTKATGCAGC 3’. For dsrB_Human primer sets, the sequences F: 5’ 
TGCGAYATYGCBGACAA 3’ and R: 5’ RCACATGTTBAKGCAGCA 3’ were used. 
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Figure 6.2 The dsrB gene sequence alignment for the design of qPCR primer sets for 
Human_desulfovibrio (using the top 6 gene sequences) and dsrB_Human (using all gene 
sequences). Colouring of letters indicates degree of nucleotide conservation between sequences 
(black, 100%, dark grey, 80%; light grey, 60%). Location for alignment used for the design of 
primers were marked (green, forward primer; red, reverse primer) for both primer sets.  
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Design of dsrB primer 
To test the quantitative efficiency of the SYBR green-based qPCR primers and to allow absolute 
quantification using qPCR, primers (named dsrB primer) were designed to amplify the dsrB gene. 
The amplicon of dsrB primer sets are designed to flank the alignment region used in the 
Human_desulfov or dsrB_Human qPCR primer sets, so the PCR product (amplified by dsrB primer 
sets) can be used as a DNA template (with known copy numbers of dsrB gene) to perform qPCR 
standard curve for future SRB quantification. The dsrB primers were designed from the dsrB 
sequence obtained from a human gut D. piger UC15 (Wegmann et al. 2017) using Primer3 
(Koressaar and Remm 2007, Untergasser et al. 2012) and searched against the Human dsrB 
(Figure 6.2 above) to determine which primers had the best matching sequence to other 
members of human SRB. OligoCalc (Kibbe 2007) was used to check the properties and minimise 
the occurrence of the hairpin formation, 3’ complementary and self-annealing site on the 
prospective primer sequences before dsrB_F1, dsrB_F2, and dsrB_R1 were designed (Figure 6.3). 
5’ATGGCTTTTATTTCTTCCGGGTACAATCCCGCCAAACCGATGGAAGGCCGCATTACCGACATCGGCCCCCACAAGTACG
ACGAATACTTCCCGCCGGTCATCAAAAAGAATTTCGGCAAGTGGCTGTACCACGAAATTCTTGAGCCCGGCGTGCTGATGC
ACGTGGCCGAAGGCGGCGACAAGGTGTACACCGTCCGCGTGGGCGGCACCCGCACCATGTCCATCACCCACATCCGCGAGA
TCTGCGACATCGCCGACAAGTACTGCGGCGGCTACCTGCGCTGGACCACCCGTAACAACATCGAGTTCATGGTGGAAGACG
AAGCCACCATGAAGGCCCTGCGCGACGACCTGAACAGCCGCAAGTTCGACGGCGGTTCCTTCAAGTTCCCCGTGGGCGGCA
CCGGCGCCGGCATCAGCAACATGGTGCACACCCAGGGCTGGGTGCACTGCCACACCCCCGCCACCGACGCCTCCGGCCCGG
TGAAATGCGTGATGGACGCCATCTTTGACGACTTCAAGGACATGCGTCTGCCCGCTCCCGTGCGCATCGCCCTGGCCTGCT
GCATCAACATGTGCGGCGCCGTGCACTGCTCCGACATCGGCCTGGTGGGCATCCACCGCAAACCGCCCATGATCGACCACG
AATGGGCCGACCAGCTGTGCGAAATCCCGCTGGCCGTGGCCGCCTGCCCCACCGCTGCCGTCCGTCCCACCAAGGTGGAAC
ACAACGGCCAGAAGGTGAACTCCATCGCCATCAAGGAAGACCGCTGCATGTACTGCGGCAACTGCTACACCATGTGCCCCG
CCCTGCCCATCGCCGACCACGAAGGCGACGGCATCGCCATCATGGTGGGCGGCAAGGTGTCCAACCGCATCAGCATGCCCA
AGTTCTCCAAGGTGGTCGTGGGCTACATCCCCAACGAACCTCCCCGCTGGCCCAGCCTGACCAAGACGGTGAAGCACATCG
TCGAAGTCTACGCCGCCAACGCCAACAAGTACGAACGTCTGGGCGACTGGGCCGAACGCATCGGCTGGGAAAGCTTCTTCA
AGCTGACCGGCCTGAAGTTCACCCACCACCTCATCGACGACTTCCGCGACCCGGCGTACTACACCTGGCGCCAGAGCACCC
AGTTCAAGTTCTAG 3’ 
Figure 6.3 The dsrB gene sequence for the design of PCR primers from D. piger UC15 of human 
gut origin. Colouring of letters indicate the location of dsrB primer sequences. Grey, dsrB_F1; 
yellow, dsrB_F2; blue, dsrB_R1. Letters in bold indicate the relative location (but not the sequence 
of) Human_desulfov and dsrB_Human qPCR primers. 
 
Various PCR conditions including different elongation durations, annealing temperatures and 
numbers of cycles were tested for the two dsrB primer combinations and optimised for each SRB 
species/isolate. As the dsrB sequence of the Gram negative isolates differed to those in D. piger 
UC15, we optimised the PCR conditions used in D. piger UC15 and the presumptive human gut D. 
piger isolates (see Section 2.7.1).  
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To produce DNA templates of dsrB gene with known copy numbers, gDNA of SRB were used for 
dsrB gene amplification. Primer set dsrB_F1 and dsrB_R1 produced more specific PCR products 
when amplifying D. piger UC15 and presumptive D. piger (isolate 6 and 19) compared to primer 
set dsrB_F2 with dsrB_R1. Visible bands of PCR products using gDNA of SRB were present at the 
expected band size of 911 bp using dsrB_F1 and dsrB_R1 primers, indicating that dsrB gene of D. 
piger UC15, isolate 6 and19 were successfully amplified (Figure 6.4). The resulting PCR products 
were quantified and their copy numbers adjusted to 1010 copies, before they were 10-fold serial 
diluted (100- 1010 copies) and used as DNA templates for qPCR standard curves. 
 
Figure 6.4 Gel electrophoresis of PCR products using gDNA of SRB. Successful amplification was 
achieved with D. piger UC15 and presumptive D. piger isolates 6 and 19. PCR products from 
dsrB_F1 and dsrB_R1 primer sets were preferred and used as DNA template for qPCR standard 
curves. Primer sets a) dsrB_F1 with dsrB_R1; and b) dsrB_F1 with dsrB_R1 were used, showing 
expected band sizes of 911 bp and 719 bp respectively. HyperLadder 1 (Bioline) was used to 
reference DNA band size. 
qPCR standard curve  
To determine whether the qPCR primers can accurately quantify SRB, standard curves were 
performed in triplicates to evaluate the efficiency of the qPCR primers in quantifying SRB (Figure 
6.5). It was shown that D. piger UC15, isolate 6 and isolate 19 had efficiency of 98.7%, 101.3% and 
103.3% respectively, which is within the acceptable efficiency range of between 90-110%. The R2 
value of the slopes are 0.9936, 0.9957 and 0.9954 respectively, indicating good linearity of the 
PCR assay (≥ 0.985 is acceptable). This qPCR standard curve can be used in future quantification of 
human SRB.  
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Figure 6.5 qPCR standard curves for D. piger UC15, presumptive D. piger isolate 6 and isolate 19 
using Human_desulfov qPCR primers sets. Strong linear correlation was obtained for absolute 
quantification of SRB. Means of 3 technical replicates were measured with 3 biological replicates 
in each experiment ± SD. 
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Differentiation of distinct dsrB genes between human isolates  
To confirm whether the isolated colonies contained the dsrB genes, 16S rRNA gene colony PCR 
was performed to amplify the dsrB gene using Human_desulfov and dsrB_Human primer sets. All 
the presumptive D. piger isolates were amplified by both dsrB_Human and Human_desulfov 
primers. Comparing amplification of D. piger UC15 and presumptive D. piger isolates, 
Human_desulfov primer set produced a single PCR product of the expected size; whereas with 
dsrB_Human primer set, non-specific amplification was also present (Figure 6.6). The presumptive 
V. tobetsuensis and V. parvula isolates were not amplified at the expected size (336 bp) by either 
primer set despite testing them under various experimental conditions. The presence of dsrB 
genes in these isolates was not detected by primers designed from known dsrB alignments of SRB, 
despite the presence of FeS when culturing on Postgate Medium C, indicating H2S production 
(Bernardez and de Andrade Lima 2015). 
 
Figure 6.6 PCR amplification using left, Human_desulfov primer set; and right, dsrB_Human 
primer set. Isolates identified as D. piger were successfully amplified at 336 bp while isolates 
identified as V. tobetsuensis and V. parvula were not. D. piger UC15 and D. simplex were used as a 
positive control. HyperLadder 1 (Bioline) was used to reference DNA band size. 
 
To compare the dsrB sequence of the Human SRB isolates, dsrB_F1 and dsrB_R1 primers were 
used and showed that the human presumptive D. piger isolates shared very similar dsrB 
nucleotide sequences from the PCR amplicon and were divided into 2 groups (group 1: isolates 1, 
19 and 20; group 2: isolates 4, 6, 8, 10). Two nucleotide differences were observed in dsrB genes 
between the two groups (Figure 6.7), suggesting that they may present 2 different strains of SRB. 
Also, the qPCR primers sequence human_desulfov matched the dsrB gene amplicon from all 
isolates, indicating that the qPCR primer sequence would amplify these isolates when performing 
qPCR. 
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Figure 6.7 Alignment of a) nucleotide sequences of Gram negative human gut isolates amplified 
by dsrB_F1 and dsrB_R1 primers. Colouring of letters indicates the degree of nucleotide 
conservation between sequences (black: 100%, dark grey, 80%; light grey, 60%), the marked 
region indicates the location of Human_desulfov and dsrB_Human primers. Green, forward 
primers; red, reverse primers. 
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The translated amino acid sequence of the 2 groups (using isolate 6 and isolate 19 as 
representatives) were compared and no differences were observed, indicating the differences 
were due to codon degeneracy and did not affect the protein (Figure 6.8). The amino acid 
sequences were searched on blastp (Altschul et al. 1997) and were identified as sulphite 
reductase, a dissimilatory-type beta subunit from D. piger (accession WP_040369683.1) with 
100% sequence match. Isolates 6 and 19 were sent off for whole genome sequencing for future 
projects. 
 
Figure 6.8 Alignment of translated amino acid sequence of group 1 and group 2 from PCR 
products amplified by dsrB_F1 and dsrB_R1 primers, showing that isolate 6 (representing isolate 
group 2) and isolate 19 (representing isolate group 1) have the same amino acid sequence in the 
dsrB PCR amplicon. Colouring of letters indicates the degree of nucleotide conservation between 
sequences (black: 100%, dark grey, 80%; light grey, 60%). 
6.3.3 Designing TFD for SRB 
To target SRB, a literature search was performed to identify non-redundant genes critical for 
SRBs’ survival under stress conditions. Homologous regulatory components were described 
among the phylogenetically diverse deltaproteobacteria class which SRB are a member of, ferric-
uptake regulator protein (FUR) (Rodionov et al. 2004), NrfR (Rajeev et al. 2015) and RpoN/ σ54 
(Price et al. 2011) transcription factors were identified as possible TFD targets. To ensure TFD 
targeting will work against SRB of human gut origin, the locations of genes regulated by these 
transcription factors were determined from the annotated output of the D. piger UC15 genome.  
-400 bp upstream promotor sequences were selected on Artemis relative to translational start 
sites of the targeting gene and searched for sequences similar to the predicted binding site 
sequence motifs shown in Figure 6.9 a and bi. The critical consensus nucleotides of the σ54-
dependent promotor nifH (Guo and Gralla 1998) with strong binding was also taken into account 
in the design of the RNA polymerase σ54 (RNAP54) TFD (Figure 6.9 b ii). FUR TFD was designed 
based on predicted palindromic consensus sites GATAATGATnATCATTATC from other 
Desulfovibrio spp. (Rodionov et al. 2004). As the transcription factor binding site sequence of FUR 
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targeting genes in the D. piger UC15 genome was not definitive, Softberry BPROM prediction of 
bacterial promotors (Solovyev and Salamov 2011) and EMBOSS palindrome search (Rice et al. 
2000) were used to aid the design of TFD. The designed TFD sequences of RNAP54.1, nrfR and 
FUR TFD and their scrambled TFD sequences are listed in Table 6.2. 
a 
 
b 
i 
 
ii 
 
5’ GGCTGGCACGACTTTTGC 
3’ CCGACCGTGCTGAAAACGTGC  
Figure 6.9 Predicted consensus binding site motif for a) NrfR TFD based on upstream regions of 
nrfHA orthologs in Desulfovibrio and Bilophila genomes (WebLogo taken from Rajeev et al. 
(2015)); b) RNAP54.1 TFD based on i) RpoN (σ54) for alternative Desulfovibrio sigma factor 54 
(WebLogo taken from Price et al. (2011)); ii) DNA fork junction, bold nucleotides indicate critical 
consensus nucleotides of the sigma 54-dependent promotor nifH with strong binding to σ54 
isolated protein (Guo and Gralla 1998)). The height of the nucleotide shown in the sequence logo 
of each motif is proportional to the information content in bits (Crooks et al. 2004).  
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Table 6.2 a) TFD sequences designed to target SRB. Functional and scrambled sequences 
(including linker and modifications) were included to investigate the sequence-specific 
antimicrobial activity. Structures of b) internal C3 Spacer (iSpC3); and c) internal dSpacer (iSpPC). 
TFD sequences were ordered from Integrated DNA Technologies. 
a 
TFD Sequence Name Sequence 
RNAP54.1 5’ C*G*T GCA /iSpC3/T*G*C 
Scambled RNAP54.1 5’ G*T*C AGC /iSpC3/G*C*T 
nrfR TFD 5’ A*A*C AGA AAA TAA CGA T/iSpPC/AT CGT TAT TTT CTG* T*T 
Scrambled nrfR TFD 5’ A*G*A CTA AAA GAA ATA C/iSpPC/GT ATT TCT TTT AGT* C*T 
Fur TFD 5’ G*A*A AAT GAT TTT C/iSpPC/GA AAA TCA TTT* T*C 
Scrambled Fur TFD 5’ A*T*T ATA GTC AAG T/iSpPC/AC TTG ACT ATA* A*T 
* indicates phosphorothioate bond 
b                                                    c 
      
iSpC3: Internal C3 Spacer           iSpPC: Internal dSpacer 
 
6.3.4 Minimum inhibitory concentrations of SRB against TFDs  
To test the antimicrobial activity of the designed TFDs, minimum inhibitory concentration (MIC) 
assays were performed on SRB.  The samples were incubated for 48 h inside the anaerobic 
cabinet to allow sufficient growth for MIC experiments. For method development, preventive 
measures to avoid sample evaporation were in place, including sealing the assay plates with 
paraffin, then wrapping in plastic bags before storing within a sealed plastic container. 
Different LNPs containing either RNAP54.1, FUR or nrfR TFD were tested against D. piger UC15, 
isolate 6 and D. vulgaris. In each technical replicate, three biological replicates were tested for 
SLNP (with scrambled TFD sequence) and LNP treatments (Figure 6.10). The averaged MIC data 
showed that TFD-specific antimicrobial activity in LNP was not observed with all three TFDs. TFD-
specific antimicrobial activity was only shown in 2 out of 3 biological replicates in an individual 
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experiment, where LNP with FUR TFD had a 2-fold less MIC value than the ENP and SLNP controls 
against D. piger UC15. This suggests some activity originated from the delivery particles but no 
TFD-associated activity was observed. A larger amount of LNP is required to inhibit D. vulgaris 
compared to D. piger UC15 and presumptive D. piger isolate 6, implying that D. vulgaris is more 
difficult for NPs to target than D. piger.  
 
Figure 6.10 Minimum inhibitory concentration of D. piger UC15, presumptive D. piger isolate 6 
and D. vulgaris. No TFD-specific antimicrobial activity was observed from LNP compared to ENP 
and SLNP for all 3 TFD tested. MIC values are means of three technical replicates with three 
biological replicates in each experiment ± SD. ENP: empty nanoparticles; SLNP: scrambled loaded 
nanoparticles; LNP: loaded nanoparticles. 
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6.3.5 Confocal microscopy to visualise the delivery of TFD in D. piger 
To investigate whether LNP can successfully deliver TFD to SRB, confocal scanning microscopy was 
performed. Different cell membrane fluorescent dyes including TMR-WGA, DiD, Mitotracker Deep 
Red FM and FM464-FX were tested for their ability to stain SRB, FM464 FX was the best in 
visualising the cell wall of the human SRB isolates and was used for cell membrane fluorescence 
staining hereafter.  
Several isolates representing group 1 and 2 with 16S rRNA gene sequence similarities to D. piger 
(group A and group B) were tested with the usual incubation time of 30 min, but no 
internalisation was observed in SRB or the positive control E. coli. Repeat attempts of increasing 
1) incubation time of bacteria with fluorescent TFD-loaded NP, 2) incubation of fluorescent TFD-
loaded NP and bacteria with the addition of membrane dye, and 3) the duration of the bacteria 
and fluorescent TFD-loaded NP mixture were adhered to the confocal microscopy slides before 
rinsing have been carried out. This showed that these batches of NP required incubation of E. coli 
positive control with fluorescent TFD in LNP for 90 min with 1 h attachment on the confocal slide 
to visualise successful internalisation and suggests that these batches of delivery NPs required a 
longer incubation period for TFD-internalisation. Under these conditions, TFD incorporation 
within most SRB isolates was not seen, TFDs were gathered on the outside of the bacterial cell 
wall with no clear internalisation observed (Figure 6.11 a and b). However, internalisation was 
seen in isolate 19 (Figure 6.11 c). TFDs observed within presumptive D. piger isolate 19 appeared 
to attach to the bacterial membrane in spherical structures, even when successfully visualised 
within the cytoplasm. SRB transfection was rare compared to E. coli as only one isolate 19 
bacterial cell showed TFD incorporation out of 20 fields of view on 1 out of 4 slides, suggesting D. 
piger may be a more difficult target for LNPs to deliver TFD. This low transfection rate may relate 
to the lack of positive TFD-specific MIC data.  
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Figure 6.11 Representative confocal scanning microscopy images of Gram negative presumptive 
D. piger isolates. 60 min of LNP incubation of a) isolate 6; and b) isolate 17; c) 120 min of LNP 
incubation of isolate 19. TFD delivery was observed after prolonged LNP incubation after 120 min. 
Red: SRB cell wall; Green: TFD. i) green channel; ii) red channel; iii) red and green channel overlay. 
6.4 Discussion 
Isolation of novel SRB strains 
Novel strains of human gut SRB were isolated from human faecal samples, the presence of dsrB 
genes was confirmed in the Gram negative isolates (with ≥ 96% similarities with D. piger) showing 
similar dsrB gene sequences to known human SRB from the literature. The genomic DNA of two 
Gram negative SRB isolates with unique dsrB sequences was sequenced and can be used to 
evaluate the selectivity of SRB TFD for future TFD refinement. In contrast, even though sulfide 
production was observed in culturing experiments, the Gram positive isolates (with ≥ 98% 
similarities with Veillonella spp.) did not give a product of expected size with dsrB primers. There 
could be differences in nucleotide sequence or codon usage in the dsrB gene typical in human gut 
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SRB. It was found that a strain that belongs to the Veillonellaceae family was identified as sulphite 
reducer and can produce sulphide by utilising sulphite and organic sulphur compounds like 
cysteine (Feng et al. 2017). The Gram-positive sulphide-producing isolates in this study may adopt 
similar reactions to obtain sulphide. 
dsrB primers designed for qPCR may be useful for SRB quantification  
To design an accurate quantification method for human gut SRB, several primers were designed 
and qPCR standard curves were established for future SRB quantification in human gut samples to 
evaluate TFD activity. Although dissimilatory sulphite reductase primers based on environmental 
samples e.g. marine/ soil origin were widely investigated (Leloup et al. 2007, Bae et al. 2015, 
Pelikan et al. 2015), these primers tailored to SRB of human gut origin remained largely 
unexplored. The design of dsrB primer sets that amplified human gut SRB/ Desulfovibrio spp. and 
demonstration of successful standard curves showed that these primers can be a useful resource 
to allow future quantification of human gut SRB.  
Identification of transcription factor targets 
To target human gut SRB, potential TFD targets against transcription factors FUR, nrfR and RNA 
polymerase σ54 were identified in the human gut D. piger UC15 genome, and were explored as a 
proof of principle study to impair SRB growth for TFD development.  
Overall MIC data indicated an absence of TFD-specific antimicrobial activity among all 3 TFDs 
tested against D. piger UC15 and two other presumptive D. piger (isolates 6 and 19). Although 
some TFD-specific antimicrobial activity was observed in the first MIC experiment with FUR TFD 
against D. piger UC15, showing a 2-fold decrease in MIC compared to ENP and SLNP in 2 out of 3 
biological replicates. There could be handling variation when the NPs were prepared by different 
people, leading to discrepancies in the results. As SRB are obligate anaerobes, every effort has 
been made to prevent the introduction of oxygen into the samples, the MIC plates were therefore 
not shaken during the experimental incubation period. LNP are likely to settle within the 48 h 
period and reduce the full potential of LNP antimicrobial activity, as LNP were less likely to be 
readily in contact with the bacteria in the culture. As the availability of iron can affect the 
antimicrobial potential of FUR TFD, the inhibition of iron metabolism may not be critical to SRB 
growth (Rodionov et al. 2004) if iron was not limiting in the anaerobic experimental setting, the 
addition of iron chelator may be needed to confirm this speculation. 
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SRB may be a more difficult target for TFD delivery  
Combining the biological activity with the confocal microscopy data, results suggested that TFD 
delivery within SRB by 12-bis-THA was inefficient compared to E. coli. Longer LNP incubation was 
required for TFD internalisation in E. coli (as a positive control) and SRB, suggesting the batches of 
12-bis-THA may be unstable or have lower delivery capacity, which could lead to less efficient TFD 
delivery. Although TFD fluorescence was observed in one bacterial cell in isolate 19, TFD 
fluorescence was presented as separate particle structures within the bacteria, which differs to 
the diffused TFDs signal observed within the E. coli cell (Chapter 4 Section 4.3.1).  
Marin-Menendez et al. (2017) proposed the TFD delivery could be a 2-step process, 1) LNP 
interacts with bacterial membrane, indicated as green puncta amongst the red fluorescent-
labelled cell wall on the confocal images; and 2) TFD are released within the cell cytoplasm. 
Interestingly, the green Alexa-488 fluorescent signal was observed to be diffused within the 
cytoplasm of E. coli and C. difficile. This diffused TFD phenomenon was not observed in SRB, on 
the contrary, the LNPs appeared as individual spherical structures following the entry of TFD 
within the cytoplasm, it may suggest that the TFD signal was internalised but yet to be diffused. 
As confocal microscopy only takes a snapshot of the bacterial sample, increased LNP dosage and 
extensive time course experiments may be required to determine the optimal transfection time 
for D. piger. 
On the whole, this may suggest that the cell wall structure of SRB may differ to those in E. coli and 
may be more difficult to gain entry within the cytoplasm. There may also be differences in the 
bacterial membrane structure of SRB compared to E. coli as we also saw reduced antimicrobial 
activity against Pseudomonas aeruginosa (Chapter 4 Section 4.3.3) which also have distinct cell 
wall structures compared to other Gram negative bacteria. Cardiolipin, a phospholipid on the 
bacterial membrane, was described to have a role in 12-bis-THA delivery (Marin-Menendez et al. 
2017). The levels of cardiolipin were compared in Desulfovibrio spp. and E. coli and it was found 
that the levels of cardiolipin were comparable (5.8% (Makula and Finnerty 1974) and 5% (Garrett 
et al. 2012) by mass respectively) among all the phospholipids present on the bacterial 
membrane. Although the phospholipid composition of D. piger is not yet described in the 
literature, cardiolipin synthase protein was present from D. piger (NCBI 2017), suggesting that the 
lack of TFD delivery is unlikely due to absence of cardiolipin. To improve TFD delivery, TFD-
conjugates can be utilised instead of LNP (Zhao et al. 2015), as they have smaller chemical 
structures compared to LNPs and may gain better entry to the bacterial membrane.  
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A prebiotic has shown specific modulation of gut microbiota by reducing Desulfovibrio spp., while 
reducing inflammation and increasing concentration of SCFA in the caecum in a mouse model 
(Sawin et al. 2015). Herbal saponins also demonstrated SRB reduction while enhancing beneficial 
bacteria and lessen the inflammatory phenotype as part of colorectal cancer prevention (Chen et 
al. 2016), indicating the potential benefit of SRB reduction. However, none have thus far 
specifically ‘knocked out’ SRB, thus the TFD approach remains a valuable tool for the direct study 
of disease association to further understand the role SRB perform in health and disease.  
In conclusion, novel strains of human gut SRB were isolated and used for TFD testing. Although we 
could not identify the presence of dsrB gene in the presumptive Veilloneilla spp., they may have a 
different dsrB sequence that cannot be detected by our primer sets. We have found potential TFD 
targets that are predicted to be critical for SRB growth in stress conditions. However, 
antimicrobial activity was not demonstrated and this is likely due to low delivery efficiency by the 
delivery nanoparticles within the bacteria. TFD-conjugates may be a better system for future 
delivery of TFD targeting SRB. 
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Chapter 7: General discussion 
The overall aim of the thesis was to determine whether nanoparticles loaded (LNPs) with 
transcription factor decoys (TFDs) are suitable for development as antimicrobials capable of 
altering the microbiome in a predictable manner. The work in this thesis established that LNPs 
have in vitro antimicrobial activity in pure cultures and also have effects on the gut microbiota 
community composition, diversity and metabonomic output when introduced in an in vitro batch 
fermentation model. These results formed the basis of an in vivo mouse model study which 
consolidated the findings from in vitro studies and further investigated the effects LNPs have on 
the host.  
7.1. The use of TFD in LNP as target-specific antimicrobials 
7.1.1 Can TFD specifically target organisms of interest? 
In chapter 4, it was demonstrated via confocal scanning microscopy that TFDs can be 
incorporated within the cytoplasm of E. coli, indicating successful TFD delivery within E. coli cells. 
Chapter 3 established that the preferred hairpin TFD structure was stable against in vitro nuclease 
degradation for up to 6 h. The best LNP formulation against E. coli was identified by MIC assays, 
where TFD-specific activity was demonstrated in LNPs with 0.1% HPMC in the formulation, which 
decreased the MIC by ≥ 2-fold compared to the empty nanoparticles (ENPs) and scrambled load 
nanoparticles (SLNPs). This LNP formulation was utilised for E. coli-related experiments thereafter. 
The optimal LNP dose was established by a dosing study in batch culture fermentations, which 
demonstrated TFD specificity in reducing Enterobacteriaceae viable bacterial communities from 
gut microbiota of multiple donors. The degree of antimicrobial activity against Enterobacteriaceae 
was found to be dependent on the starting Enterobacteriaceae levels upon the addition of 
treatment. No correlation was drawn with the starting total anaerobe community and TFD 
activity, thus indicating the TFD antimicrobial capacity is associated with levels of 
Enterobacteriaceae and not total anaerobes. Enterobacteriaceae reduction was also 
demonstrated by bacterial 16S rRNA gene community sequencing, indicating both culturable and 
non-culturable Enterobacteriaceae were targeted by TFD. 
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7.1.2 Does TFD targeting interrupt the commensal gut microbiota community in 
vitro? 
LNP did not lead to major changes in the bacterial counts of the total anaerobes, Bacteroides, 
Bifidobacterium, Clostridium, and Lactobacillus in the in vitro batch culture fermentation 
experiments, while still demonstrating antimicrobial activity against Enterobacteriaceae. Non-
specific antimicrobial activity from LNPs against anaerobes was only observed when a high dose 
was used (i.e. 30x higher than the usual 2% dose used in the batch culture fermentation), 
suggesting the LNP doses used in batch culture fermentation generally do not interrupt the 
commensal gut microbiota community.  
16S rRNA gene community sequencing indicated that when Enterobacteriaceae was reduced with 
LNPs, bacterial diversity remained similar to the controls, suggesting LNPs did not interrupt other 
bacteria communities while reducing Enterobacteriaceae. From principal coordinates analysis, the 
gut microbiota structure in samples treated with LNPs more closely resembled the controls at 
previous time points, possibly indicating LNPs work by slowing down the dynamic changes in the 
gut microbiota to maintain stability. This was confirmed by metabonomic data showing LNP 
treatment delayed bacterial growth in the batch culture fermentation experiment with a declined 
usage of substrates for metabolic pathways. SLNPs induced shifts in the gut microbiota 
abundance at later time points, suggesting the delivery system could interfere with the gut 
microbiota composition regardless of the selectivity of TFD. 
As other Enterobacteria-targeting antibiotics generally have side effects of decreased bacterial 
cell count, reduced abundance of anaerobes and declined bacterial diversity (Langdon et al. 
2016), this suggests that TFD antimicrobials may be a better alternative to antibiotics as they 
reduced disruption to the gut microbiota and maintained microbiota diversity. 
 
7.1.3 Can TFD antimicrobial activity be demonstrated in vivo? 
After the in vitro antimicrobial assays of LNPs against Enterobacteriaceae were established 
(Chapter 4), we investigated whether the same effects can be observed in an in vivo setting. A 
wild type mouse model was utilised to evaluate the changes to the gut microbiota and the host 
upon LNP treatment, and LNP’s TFD-specific activity against Enterobacteriaceae was again 
observed indicating the antimicrobial response was dose dependant (Chapter 5). The 16S rRNA 
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gene-based community analysis revealed the mouse gut microbiota consisted largely of 
unculturable organisms. The reduction in Enterobacteriaceae was observed despite this group 
making up only a tiny proportion of the total bacterial community. Non-TFD specific changes in 
LNP and SLNP include the reduction of the S24-7 family in the Bacteroidales order, suggesting that 
the delivering NP may adversely affect this community. Decrease of S24-7 has also been observed 
in a pathogen-selective treatment (Yao et al. 2016), indicating S24-7 may be sensitive to other 
changes in the microbiota. The overall diversity remained constant despite TFD activity though 
changes in abundance were seen in some groups of bacteria.   
 
7.1.4 Can LNP be used to target sulphate reducing bacteria?  
Following the validation of TFD selective antimicrobial activity against Enterobacteriaceae using in 
vitro and in vivo systems, it was interesting to investigate whether TFDs can be designed to target 
SRB. After successful targeting of a well defined phylogenetic group we investigated whether TFD 
could be used to target SRB, a phylogenetically diverse group with similar metabolic capabilities.  
Several transcription factors including FUR, nrfR and RNAPσ54 have been identified as crucial for 
SRB survival, and TFDs were designed according to the binding sites in a human gut D. piger strain 
UC15. Other novel strains of SRB were isolated from the human gut and were also used for 
antimicrobial testing, though no TFD-specific activity from LNP was observed compared to ENP 
and SLNP controls. The lack of TFD-specific antimicrobial activity was suspected to be due to 
reduced TFD delivery by the NP delivery system, as was evident in confocal scanning microscopy 
experiment. Batch to batch variation in 12-bis-THA occurred, leading to delayed delivery in E. coli 
positive control and this may have reduced the efficacy of delivery. Viable bacterial counts 
suggested LNP may not have reduced Pseudomonas aeruginosa in batch culture fermentation 
(Chapter 4), as they have different cell wall structure and this may affect LNP delivering TFD. 
Confocal scanning microscopy suggested SRB may also be a more difficult bacterial targets to 
deliver TFD using the current LNP system. A method of SRB quantification using qPCR were also 
established for future SRB detection in a complex human gut community.  More method 
development needs to be performed to fully investigate LNP’s therapeutic potential against SRB, 
including utilising a different formulation e.g. TFD-conjugates in the view to improve TFD delivery.   
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7.2 Future Research 
7.2.1 Extensive LNP dosing range studies  
In this thesis, it has been demonstrated both by viable culturing and non-culturing 16S rRNA gene 
community profiling that TFD can successfully and selectively reduce Enterobacteriaceae levels. 
However, ENP and/or SLNP had some antimicrobial capacity of their own, as was observed in MIC 
experiments (Chapter 3). Though not apparent from viable counts, non-target specific effects on 
the 16S rRNA gene community analysis were observed in the SLNP control in the in vitro (Chapter 
4) and in vivo studies (Chapter 5), indicating the delivery system is not functionally inert and may 
induce shifts in the gut microbiota.  
The effective antimicrobial dose of TFD was established in chapter 4, however, there is still a 
knowledge gap of the minimum LNPs needed to have specific activity without a broad spectrum 
effect on the gut microbiota. The dose dependent response needs to be fine-tuned for effective 
antimicrobial activity.  
We expect the LNP effective dose to be affected by the total number of bacteria. However, it was 
interesting that there was instead a strong link between the LNP effective dose and the starting 
Enterobacteriaceae levels in both dosing range and batch culture fermentation experiments. This 
may suggest that the LNP efficiency is related only to the targeted bacterial group, regardless of 
the total bacterial community, making TFD a desirable tool for fine tuning the reduction of specific 
organisms for microbiome engineering without using excessive amounts of starting materials.  
 
7.2.2 Alternative delivery system for TFD 
It has been established that TFD can exert target-specific antimicrobial activity. However, the 
delivery nanoparticles themselves appeared to cause non-specific changes to the gut microbiota 
when the community structure was explored using 16S rRNA gene sequencing. Batch-to-batch NP 
variation led to difference in stability, along with NP handling difference between individuals, 
could lead to variation in nanoparticles’ efficiency to deliver TFD. As there is a maximum amount 
of TFD that can be loaded, the current formulation of LNPs is limited to ensure proper 
complexation of LNPs; a large excess of 12-bis-THA was used compared to TFD which makes the 
TFD specific response less evident, as it was dampened by the 12-bis-THA side effects. TFD 
therapeutics in the form of LNPs therefore may not be the perfect system, factors that contribute 
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to LNP delivery can be further investigated to better exploit the mechanism to exert the full 
therapeutic potential of TFD antimicrobials. 
To minimise the non-specific effects of 12-bis-THA, TFD-conjugates, which is a single compound 
connecting 12-bis-THA and TFD in 1:1 ratio, can be developed as an alternative system for TFD 
delivery (Zhao et al. 2015), they will allow increase amounts of TFD delivered per 12-bis-THA 
molecule, hence improving the therapeutic potential of TFD and minimising side effects related to 
12-bis-THA. 
 
7.2.3 Improving understanding of TFD mechanisms 
As FNR activity is controlled by the repeated assembly and disassembly of iron-sulfur cluster 
(Khoroshilova et al. 1997), iron is required for the functionality of the gene regulation and survival 
of Enterobacteriaceae. The availability of iron may affect the impact of FNR reduction. It would 
also be interesting to explore how FNR repression affect cellular processes, it may be informative 
to perform batch culture fermentation experiments with and without iron or iron chelators to 
investigate how this affects antimicrobial activity.  
 
7.2.4 Determining which bacteria LNP can transfect in the gut microbiota 
Whether LNPs bind to all bacteria equally or have stronger affinity to certain bacteria remains to 
be tested. It would be interesting to determine which bacteria LNP can penetrate using FACS, to 
establish the range of bacterial interactions and identify other possible bacterial targets for the 
design of new TFDs. It would be useful to gain insight into the process of LNP interacting with 
bacterial cells before becoming internalised and reaching their TFD-specific target, and in turn 
expand our understanding and exploit the mechanisms to improve antimicrobial activity. 
 
7.2.5 Incorporating qPCR for Enterobacteriaceae quantification  
Metagenomic analysis showed that a large proportion of non-culturable bacteria were detected in 
mice gut microbiota in high abundance, while Enterobacteriaceae abundance was low. This meant 
it was difficult to confidently show TFD-specific antimicrobial activity by 16S rRNA gene 
community profiling. The incorporation of quantitative data using qPCR to detect E. coli and 
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anaerobes would be a valuable addition to confirm the decrease in Enterobacteriaceae or other 
communities. 
 
7.2.6 Studying LNPs effect in a disease model  
As a proof of principle, wild type mice were used to assess LNP antimicrobial activity, to establish 
the baseline effect LNPs have on a native gut microbiota and to elucidate possible side effects on 
the host. As the LNP antimicrobial response is quite rapid and exerted this effect within a few 
hours of gavage administration, the faecal samples were collected within short time intervals to 
assess the fast-acting antimicrobial activity, unlike other therapeutic studies which measure the 
effects at least a day after the drug administration (Rebello et al. 2015). It would be important to 
see if the system worked when higher quantities of Enterobacteriaceae were present e.g. in an 
infection scenario, as it was established that TFD may not diminish all Enterobacteriaceae at high 
abundances.  
After establishing the baseline effects LNPs have on a wild type model using the improved TFD-
conjugate delivery system, their effects can be studied on a model with predisposed microbiota 
alterations (Spees et al. 2013), enriched with Enterobacteriaceae (Savkovic et al. 2005, Winter et 
al. 2013) or a DSS-induced colitis (Huang et al. 2015). These studies would provide extra 
information on whether LNPs could help counteract the shifts in gut microbiota and improve 
prognosis of disease phenotypes. A study that monitors the gut microbiota in the mice pre- and 
post- diseased state could also be evaluated and ascertain whether alterations in the gut 
microbiota will recover after a period of time.   
 
7.2.7 Improving understanding of host response upon LNP treatment 
The gut microbiota composition and metabonomic profile between mice were variable within and 
between treatment groups at the start of the experiments, making it difficult to draw definitive 
conclusions on the effects of LNPs.  Evaluation of the host response in the mouse model may have 
been enhanced by investigating the effects on the liver tissues to determine whether systemic 
toxicity is present. Also performing caspase staining on intestinal tissue for the detection of 
apoptosis (Kaushal et al. 2014) may have been useful to confirm any cellular damage in the 
epithelium. 
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7.2.8 Choice of TFD targets 
It is important to choose a robust TFD target. It has to be specific to a selected organism or group 
without largely disrupting the commensal gut microbiota. Using metabolic genes (Matsui et al. 
2013) as TFD targets allow us to target a larger range of organisms that may not necessary be 
phylogenetically related (Korner et al. 2003) but perform similar functions e.g. sulphate reduction 
(Rabus et al. 2015).  
After establishing the improved method of TFD delivery, it would be useful to confirm that SRB 
TFDs are good genomic targets for human gut SRBs. Whole genome analysis can be performed to 
confirm the TFD matching similarity to the transcription binding sites for genes of interest. Also, 
promoter reporter assays could be performed to confirm transcription factor inhibition by TFD. 
H2S levels can be evaluated to quantify sulphite reducing functions in SRB after TFD treatment. 
These may help reinforce TFD’s specificity in targeting human gut SRBs. 
Other new TFD targets to move the technology forward would be to down-regulate virulence 
gene expression instead of killing the bacteria itself. Biological knowledge can be used to identify 
new TFD targets to decrease virulence in pathogens e.g. by preventing them from inducing 
attachment to the intestinal epithelial cell (Sule et al. 2017). 
7.3 Conclusion  
The TFD technology could be a good alternative to antibiotics in improving selectivity in bacterial 
targets and reducing disruption of the diversity of the commensal bacteria in complex microbial 
communities such as the gut microbiome, once side effects on host are understood. This 
technology establishes currently unmet needs, which demonstrates its potential in targeting any 
bespoke bacterial-associated condition that require a target-specific approach.  
TFD reduced the levels of Enterobacteriaceae without major disturbance to the commensal 
bacterial diversity, and antimicrobial activity was also observed in an in vivo mouse model. 
Encountering variations in the degree of antimicrobial activity in different microbiotas highlighted 
the difficulty of targeting a specific organism in a diverse and complex microbiota. Also care has to 
be taken to ensure the dose is sufficient to provide the desired antimicrobial output.  
Some non-selective bacterial shifts in the 16S rRNA gene community were observed in SLNP 
treatment, along with its possible cytotoxic nature to eukaryotic cells, reduction in the 12-bis-
THA: TFD ratio for TFD delivery would be the next step to move forward for future TFD-based 
antimicrobial research to improve the target selectivity and stability of the antimicrobial. 
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The designed TFDs for SRB can be the basis of new product development once TFD delivery is 
achieved. Further optimisation will be needed to transfect SRB to establish TFD’s potential in 
targeting this phylogenetically diverse but functionally analogous bacteria.
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